0000105770-23-000068.txt : 20231026 0000105770-23-000068.hdr.sgml : 20231026 20231026162621 ACCESSION NUMBER: 0000105770-23-000068 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231026 DATE AS OF CHANGE: 20231026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 231350502 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 10-Q 1 wst-20230930.htm 10-Q wst-20230930
0000105770--12-312023Q3false36400001057702023-01-012023-09-3000001057702023-10-16xbrli:shares00001057702023-07-012023-09-30iso4217:USD00001057702022-07-012022-09-3000001057702022-01-012022-09-30iso4217:USDxbrli:shares00001057702023-09-3000001057702022-12-3100001057702021-12-3100001057702022-09-300000105770wst:BiologicsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-30xbrli:pure0000105770wst:BiologicsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000105770wst:BiologicsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000105770wst:BiologicsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000105770wst:GenericsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000105770wst:GenericsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000105770wst:GenericsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000105770wst:GenericsCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2023-07-012023-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2023-01-012023-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2022-01-012022-09-300000105770wst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000105770wst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000105770wst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000105770wst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2023-07-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2022-07-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2023-01-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2022-01-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:StandardPackagingMember2023-07-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:StandardPackagingMember2022-07-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:StandardPackagingMember2023-01-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:StandardPackagingMember2022-01-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AmericasMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AmericasMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AmericasMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AmericasMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-3000001057702013-06-300000105770wst:SmartDoseMember2023-09-3000001057702023-02-280000105770wst:DistributorshipAgreementMember2023-07-012023-09-300000105770wst:DistributorshipAgreementMember2023-01-012023-09-300000105770wst:DistributorshipAgreementMember2022-07-012022-09-300000105770wst:DistributorshipAgreementMember2022-01-012022-09-300000105770srt:AffiliatedEntityMember2023-09-300000105770srt:AffiliatedEntityMember2022-12-310000105770srt:AffiliatedEntityMember2023-07-012023-09-300000105770srt:AffiliatedEntityMember2023-01-012023-09-300000105770srt:AffiliatedEntityMember2022-07-012022-09-300000105770srt:AffiliatedEntityMember2022-01-012022-09-300000105770wst:TermLoanDue2024Member2023-09-300000105770wst:TermLoanDue2024Member2022-12-310000105770wst:SeniorBNotesDue2024Member2023-09-300000105770wst:SeniorBNotesDue2024Member2022-12-310000105770wst:SeniorCNotesDue2027Member2023-09-300000105770wst:SeniorCNotesDue2027Member2022-12-310000105770wst:Revolvingcreditfacilitydue2024Member2023-09-300000105770us-gaap:LetterOfCreditMemberwst:Revolvingcreditfacilitydue2024Member2023-09-300000105770us-gaap:SecuredDebtMemberwst:TermLoanDue2024Member2023-09-300000105770us-gaap:ForwardContractsMembercurrency:SGD2023-09-30iso4217:SGD0000105770us-gaap:ForwardContractsMembercurrency:SGD2022-12-310000105770us-gaap:ForwardContractsMembercurrency:EURus-gaap:NetInvestmentHedgingMember2023-09-30iso4217:EUR0000105770us-gaap:ForwardContractsMembercurrency:SGDus-gaap:NetInvestmentHedgingMember2023-09-300000105770us-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000105770us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:EUR2023-09-300000105770us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:EUR2023-09-300000105770us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:JPY2023-09-30iso4217:JPY0000105770us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:JPY2023-09-300000105770us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:SGD2023-09-300000105770us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMembercurrency:SGD2023-09-300000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USDus-gaap:NetInvestmentHedgingMember2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:JPY2023-09-300000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USDus-gaap:NetInvestmentHedgingMember2023-09-300000105770us-gaap:OptionMember2017-11-012023-09-30utr:bbl0000105770us-gaap:OptionMember2023-01-012023-09-300000105770us-gaap:OptionMember2023-09-30iso4217:USDwst:bbl0000105770us-gaap:ForeignCurrencyGainLossMember2023-07-012023-09-300000105770us-gaap:ForeignCurrencyGainLossMember2022-07-012022-09-300000105770us-gaap:ForeignCurrencyGainLossMember2023-01-012023-09-300000105770us-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-300000105770us-gaap:FairValueHedgingMember2023-07-012023-09-300000105770us-gaap:FairValueHedgingMember2023-01-012023-09-300000105770us-gaap:FairValueHedgingMember2022-07-012022-09-300000105770us-gaap:FairValueHedgingMember2022-01-012022-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:ForeignCurrencyGainLossMember2023-07-012023-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:ForeignCurrencyGainLossMember2022-07-012022-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-07-012023-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-07-012022-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2023-07-012023-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2023-07-012023-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2022-07-012022-09-300000105770us-gaap:CashFlowHedgingMember2023-07-012023-09-300000105770us-gaap:CashFlowHedgingMember2022-07-012022-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2023-07-012023-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2022-07-012022-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-300000105770us-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000105770us-gaap:NetInvestmentHedgingMember2022-07-012022-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:ForeignCurrencyGainLossMember2023-01-012023-09-300000105770us-gaap:FairValueHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-01-012023-09-300000105770wst:NetSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-012022-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2023-01-012023-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2022-01-012022-09-300000105770us-gaap:CashFlowHedgingMember2023-01-012023-09-300000105770us-gaap:CashFlowHedgingMember2022-01-012022-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2023-01-012023-09-300000105770us-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000105770us-gaap:NetInvestmentHedgingMember2022-01-012022-09-300000105770wst:NetSalesMember2023-07-012023-09-300000105770wst:NetSalesMember2022-07-012022-09-300000105770wst:NetSalesMember2023-01-012023-09-300000105770wst:NetSalesMember2022-01-012022-09-300000105770us-gaap:CostOfSalesMember2023-07-012023-09-300000105770us-gaap:CostOfSalesMember2022-07-012022-09-300000105770us-gaap:CostOfSalesMember2023-01-012023-09-300000105770us-gaap:CostOfSalesMember2022-01-012022-09-300000105770us-gaap:InterestExpenseMember2023-07-012023-09-300000105770us-gaap:InterestExpenseMember2022-07-012022-09-300000105770us-gaap:InterestExpenseMember2023-01-012023-09-300000105770us-gaap:InterestExpenseMember2022-01-012022-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2023-07-012023-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2022-07-012022-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2023-01-012023-09-300000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2023-07-012023-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2022-07-012022-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2023-01-012023-09-300000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-300000105770us-gaap:NondesignatedMember2023-07-012023-09-300000105770us-gaap:NondesignatedMember2022-07-012022-09-300000105770us-gaap:NondesignatedMember2023-01-012023-09-300000105770us-gaap:NondesignatedMember2022-01-012022-09-300000105770us-gaap:FairValueInputsLevel1Member2023-09-300000105770us-gaap:FairValueInputsLevel2Member2023-09-300000105770us-gaap:FairValueInputsLevel3Member2023-09-300000105770us-gaap:ForeignExchangeContractMember2023-09-300000105770us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2023-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-09-300000105770us-gaap:CurrencySwapMember2023-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2023-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2023-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2023-09-300000105770us-gaap:FairValueInputsLevel1Member2022-12-310000105770us-gaap:FairValueInputsLevel2Member2022-12-310000105770us-gaap:FairValueInputsLevel3Member2022-12-310000105770us-gaap:ForeignExchangeContractMember2022-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2022-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2022-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2022-12-310000105770us-gaap:CurrencySwapMember2022-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2022-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2022-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMember2023-07-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMember2022-07-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMember2023-01-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:TreasuryLockMember2022-01-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:CommonStockMember2022-12-310000105770us-gaap:AdditionalPaidInCapitalMember2022-12-310000105770us-gaap:TreasuryStockCommonMember2022-12-310000105770us-gaap:RetainedEarningsMember2022-12-310000105770us-gaap:RetainedEarningsMember2023-01-012023-03-3100001057702023-01-012023-03-310000105770us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000105770us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000105770us-gaap:CommonStockMember2023-03-310000105770us-gaap:AdditionalPaidInCapitalMember2023-03-310000105770us-gaap:TreasuryStockCommonMember2023-03-310000105770us-gaap:RetainedEarningsMember2023-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100001057702023-03-310000105770us-gaap:RetainedEarningsMember2023-04-012023-06-3000001057702023-04-012023-06-300000105770us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000105770us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000105770us-gaap:CommonStockMember2023-06-300000105770us-gaap:AdditionalPaidInCapitalMember2023-06-300000105770us-gaap:TreasuryStockCommonMember2023-06-300000105770us-gaap:RetainedEarningsMember2023-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000001057702023-06-300000105770us-gaap:RetainedEarningsMember2023-07-012023-09-300000105770us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000105770us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000105770us-gaap:CommonStockMember2023-09-300000105770us-gaap:AdditionalPaidInCapitalMember2023-09-300000105770us-gaap:TreasuryStockCommonMember2023-09-300000105770us-gaap:RetainedEarningsMember2023-09-300000105770us-gaap:CommonStockMember2021-12-310000105770us-gaap:AdditionalPaidInCapitalMember2021-12-310000105770us-gaap:TreasuryStockCommonMember2021-12-310000105770us-gaap:RetainedEarningsMember2021-12-310000105770us-gaap:RetainedEarningsMember2022-01-012022-03-3100001057702022-01-012022-03-310000105770us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000105770us-gaap:TreasuryStockCommonMember2022-01-012022-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000105770us-gaap:CommonStockMember2022-03-310000105770us-gaap:AdditionalPaidInCapitalMember2022-03-310000105770us-gaap:TreasuryStockCommonMember2022-03-310000105770us-gaap:RetainedEarningsMember2022-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100001057702022-03-310000105770us-gaap:RetainedEarningsMember2022-04-012022-06-3000001057702022-04-012022-06-300000105770us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000105770us-gaap:TreasuryStockCommonMember2022-04-012022-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000105770us-gaap:CommonStockMember2022-06-300000105770us-gaap:AdditionalPaidInCapitalMember2022-06-300000105770us-gaap:TreasuryStockCommonMember2022-06-300000105770us-gaap:RetainedEarningsMember2022-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000001057702022-06-300000105770us-gaap:RetainedEarningsMember2022-07-012022-09-300000105770us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000105770us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:CommonStockMember2022-09-300000105770us-gaap:AdditionalPaidInCapitalMember2022-09-300000105770us-gaap:TreasuryStockCommonMember2022-09-300000105770us-gaap:RetainedEarningsMember2022-09-300000105770us-gaap:PerformanceSharesMember2023-01-012023-09-300000105770srt:MinimumMemberus-gaap:PerformanceSharesMember2023-01-012023-09-300000105770us-gaap:PerformanceSharesMembersrt:MaximumMember2023-01-012023-09-300000105770us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-07-012023-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-07-012022-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2023-07-012023-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2022-07-012022-09-300000105770country:US2023-07-012023-09-300000105770country:US2022-07-012022-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-07-012023-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-07-012023-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:ForeignPlanMember2023-07-012023-09-300000105770us-gaap:ForeignPlanMember2022-07-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-01-012023-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-01-012022-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2023-01-012023-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2022-01-012022-09-300000105770country:US2023-01-012023-09-300000105770country:US2022-01-012022-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:ForeignPlanMember2023-01-012023-09-300000105770us-gaap:ForeignPlanMember2022-01-012022-09-30wst:facility00001057702022-12-012022-12-310000105770srt:MinimumMember2022-12-310000105770srt:MaximumMember2022-12-310000105770srt:MinimumMember2022-12-012022-12-310000105770srt:MaximumMember2022-12-012022-12-310000105770wst:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2022-12-310000105770wst:A2022RestructuringPlanMemberus-gaap:OtherRestructuringMember2022-12-310000105770wst:A2022RestructuringPlanMember2022-12-310000105770wst:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-01-012023-09-300000105770wst:A2022RestructuringPlanMemberus-gaap:OtherRestructuringMember2023-01-012023-09-300000105770wst:A2022RestructuringPlanMember2023-01-012023-09-300000105770wst:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-09-300000105770wst:A2022RestructuringPlanMemberus-gaap:OtherRestructuringMember2023-09-300000105770wst:A2022RestructuringPlanMember2023-09-30wst:segment0000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2023-07-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2022-07-012022-09-300000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2023-01-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2022-01-012022-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2023-07-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2022-07-012022-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2023-01-012023-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2022-01-012022-09-300000105770us-gaap:IntersegmentEliminationMember2023-07-012023-09-300000105770us-gaap:IntersegmentEliminationMember2022-07-012022-09-300000105770us-gaap:IntersegmentEliminationMember2023-01-012023-09-300000105770us-gaap:IntersegmentEliminationMember2022-01-012022-09-300000105770us-gaap:OperatingSegmentsMember2023-07-012023-09-300000105770us-gaap:OperatingSegmentsMember2022-07-012022-09-300000105770us-gaap:OperatingSegmentsMember2023-01-012023-09-300000105770us-gaap:OperatingSegmentsMember2022-01-012022-09-300000105770us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000105770us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000105770us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000105770us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000105770us-gaap:CorporateNonSegmentMemberwst:A2022RestructuringPlanMember2023-07-012023-09-300000105770us-gaap:CorporateNonSegmentMemberwst:A2022RestructuringPlanMember2022-07-012022-09-300000105770us-gaap:CorporateNonSegmentMemberwst:A2022RestructuringPlanMember2023-01-012023-09-300000105770us-gaap:CorporateNonSegmentMemberwst:A2022RestructuringPlanMember2022-01-012022-09-300000105770us-gaap:CorporateNonSegmentMemberwst:A2022RestructuringPlanMemberus-gaap:OtherOperatingIncomeExpenseMember2023-01-012023-09-300000105770wst:EricMGreenMember2023-01-012023-09-300000105770wst:EricMGreenMember2023-07-012023-09-300000105770wst:EricMGreenMember2023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to

Commission File Number 1-8036

WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania23-1210010
 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
530 Herman O. West Drive, Exton, PA
19341-1147
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.          Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                      Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑ Accelerated filer☐
Non-accelerated filer
☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                      ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
As of October 16, 2023, there were 73,989,670 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS
  Page
 
ITEM 1. 
 
 
 
 
 
ITEM 2.
ITEM 3.
ITEM 4.
   
 
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 5.
ITEM 6.
   
   

2
PART I. FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)

 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Net sales$747.4 $686.9 $2,217.8 $2,178.2 
Cost of goods and services sold459.1 418.9 1,366.8 1,304.1 
Gross profit288.3 268.0 851.0 874.1 
Research and development16.4 13.6 50.0 42.6 
Selling, general and administrative expenses89.0 66.3 263.4 231.2 
Other expense (income) (Note 15)5.6 1.9 22.5 (4.0)
Operating profit177.3 186.2 515.1 604.3 
Interest expense2.9 2.2 7.8 6.2 
Interest income(8.8)(1.5)(18.6)(2.2)
Other nonoperating (income) expense(3.8)49.3 (3.9)49.1 
Income before income taxes and equity in net income of affiliated companies187.0 136.2 529.8 551.2 
Income tax expense29.4 20.4 87.8 85.8 
Equity in net income of affiliated companies(3.7)(4.8)(14.4)(17.5)
Net income$161.3 $120.6 $456.4 $482.9 
Net income per share:   
Basic$2.17 $1.62 $6.13 $6.49 
Diluted$2.14 $1.59 $6.05 $6.36 
Weighted average shares outstanding:    
Basic74.3 74.4 74.4 74.4 
Diluted75.3 75.7 75.5 75.9 

See accompanying notes to condensed consolidated financial statements.
3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Net income$161.3 $120.6 $456.4 $482.9 
Other comprehensive (loss) income, net of tax:   
Foreign currency translation adjustments, net of tax of $0.4, $1.1, $1.9 and $3.8, respectively
(40.9)(76.0)(36.9)(162.5)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.0, $14.6, $(0.5), and $15.5, respectively
0.2 13.6 (1.2)16.4 
Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively
— (0.1)(0.1)(0.2)
Net gain (loss) on derivatives, net of tax of $0.8, $0.0, $(0.3) and $(0.8), respectively
1.2 (0.1)(1.8)(2.6)
Other comprehensive (loss) income, net of tax(39.5)(62.6)(40.0)(148.9)
Comprehensive income$121.8 $58.0 $416.4 $334.0 

See accompanying notes to condensed consolidated financial statements.
4
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)September 30,
2023		December 31,
2022
ASSETS  
Current assets:  
Cash and cash equivalents$898.6 $894.3 
Accounts receivable, net519.1 507.4 
Inventories431.8 414.8 
Other current assets122.8 103.0 
Total current assets1,972.3 1,919.5 
Property, plant and equipment2,607.1 2,386.6 
Less: accumulated depreciation and amortization1,295.5 1,228.3 
Property, plant and equipment, net1,311.6 1,158.3 
Operating lease right-of-use assets96.8 104.4 
Investments in affiliated companies195.4 204.9 
Goodwill106.8 107.3 
Intangible assets, net15.7 18.4 
Deferred income taxes17.3 65.6 
Other noncurrent assets38.8 38.4 
Total Assets$3,754.7 $3,616.8 
LIABILITIES AND EQUITY  
Current liabilities:  
Notes payable and other current debt$55.2 $2.2 
Accounts payable219.8 215.4 
Accrued salaries, wages and benefits90.5 76.8 
Income taxes payable15.0 24.8 
Operating lease liabilities16.5 16.0 
Other current liabilities136.5 183.8 
Total current liabilities533.5 519.0 
Long-term debt152.1 206.7 
Deferred income taxes16.5 14.3 
Pension and other postretirement benefits28.4 28.2 
Operating lease liabilities83.0 93.0 
Deferred compensation benefits17.9 19.1 
Other long-term liabilities55.1 51.6 
Total Liabilities886.5 931.9 
Commitments and contingencies (Note 17)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
— — 
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.1 million, respectively
18.8 18.8 
Capital in excess of par value122.6 232.2 
Retained earnings3,415.9 2,987.8 
Accumulated other comprehensive loss(223.0)(183.0)
Treasury stock, at cost (1.3 million and 1.2 million shares, respectively)
(466.1)(370.9)
Total Equity2,868.2 2,684.9 
Total Liabilities and Equity$3,754.7 $3,616.8 
See accompanying notes to condensed consolidated financial statements.
5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Nine Months Ended
September 30,
 20232022
Cash flows from operating activities:  
Net income$456.4 $482.9 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation99.1 86.8 
Amortization2.3 2.7 
Stock-based compensation21.9 17.0 
Loss on disposal of plant11.6 — 
Asset impairments6.9 1.6 
Pension settlement charge— 50.8 
Other non-cash items, net(13.5)(17.9)
Changes in assets and liabilities
(47.3)(130.7)
Net cash provided by operating activities537.4 493.2 
Cash flows from investing activities:  
Capital expenditures(253.3)(189.7)
Other, net(6.6)(3.7)
Net cash used in investing activities(259.9)(193.4)
Cash flows from financing activities:  
Repayments of long-term debt(1.7)(43.7)
Debt issuance costs— (1.3)
Dividend payments(42.2)(40.0)
Proceeds from stock-based compensation awards42.6 17.1 
Employee stock purchase plan contributions5.3 6.1 
Shares purchased under share repurchase programs(261.3)(202.9)
Shares repurchased for employee tax withholdings(12.8)(19.4)
Net cash used in financing activities(270.1)(284.1)
Effect of exchange rates on cash(3.1)(49.3)
Net increase (decrease) in cash and cash equivalents4.3 (33.6)
Cash, including cash equivalents at beginning of period894.3 762.6 
Cash, including cash equivalents at end of period$898.6 $729.0 

See accompanying notes to condensed consolidated financial statements.
6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1:  Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

Note 2:  New Accounting Standards

Recently Adopted Standards

In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023.

7
Note 3:  Revenue

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Biologics
40 %
41 %
37 %
42 %
Generics
 19 %
18 %
20 %
18 %
Pharma
22 %
24 %
24 %
24 %
Contract-Manufactured Products
19 %
17 %
19 %
16 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
High-Value Product Components
50 %
54 %
50 %
56 %
High-Value Product Delivery Devices
11 %
6 %
10 %
5 %
Standard Packaging
20 %
23 %
21 %
23 %
Contract-Manufactured Products
19 %
17 %
19 %
16 %
100 %
100 %
100 %
100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Americas
46 %
53 %
45 %
48 %
Europe, Middle East, Africa
46 %
38 %
46 %
43 %
Asia Pacific
8 %
9 %
9 %
9 %
100 %
100 %
100 %
100 %





8
Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2022$16.3 
Contract assets, September 30, 2023
19.9 
Change in contract assets - increase (decrease)$3.6 
Deferred income, December 31, 2022$(68.2)
Deferred income, September 30, 2023
(50.0)
Change in deferred income - decrease (increase)$18.2 

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2023, $33.2 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2023, there was $2.4 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $1.5 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Note 4:  Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2023202220232022
Net income$161.3 $120.6 $456.4 $482.9 
Weighted average common shares outstanding74.3 74.4 74.4 74.4 
Dilutive effect of equity awards, based on the treasury stock method
1.0 1.3 1.1 1.5 
Weighted average shares assuming dilution75.3 75.7 75.5 75.9 

During the three months ended September 30, 2023 and 2022, there were 0.0 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.1 million antidilutive shares outstanding during the nine months ended September 30, 2023 and 2022, respectively.






9
In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. During the three months ended September 30, 2023, we purchased 77,329 shares of our common stock under the program at a cost of $27.8 million, or an average price of $360.25 per share. During the nine months ended September 30, 2023, we purchased 753,399 shares of our common stock under the program at a cost of $261.3 million, or an average price of $346.86 per share.

In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions was dependent on a variety of factors, including market conditions. This share repurchase program was completed by December 31, 2022. During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the calendar-year 2022 program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the calendar-year 2022 program at a cost of $202.9 million, or an average price of $360.03 per share.

Note 5:  Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2023		December 31,
2022
Raw materials$180.2 $170.7 
Work in process93.8 79.0 
Finished goods157.8 165.1 
 $431.8 $414.8 

Note 6:  Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Operating lease cost$4.3 $3.7 $15.0 $10.4 
Short-term lease cost1.9 0.3 4.4 1.1 
Variable lease cost1.4 2.3 4.4 4.7 
Total lease cost$7.6 $6.3 $23.8 $16.2 

10
Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$4.5 $3.7 $14.4 $10.0 
Right-of-use assets obtained in exchange for new operating lease liabilities$3.1 $14.0 $6.6 $29.5 

As of September 30, 2023 and December 31, 2022, the weighted average remaining lease term for operating leases was 10.1 years and 9.3 years, respectively.

As of September 30, 2023 and December 31, 2022, the weighted average discount rate was 3.46% and 3.25%, respectively.

Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20232022
2023 (remaining period as of)$4.8 $19.0 
202419.1 18.1 
202517.1 16.0 
202614.1 13.4 
20279.8 9.4 
Thereafter50.6 50.8 
115.5 126.7 
Less: imputed lease interest(16.0)(17.7)
Total lease liabilities$99.5 $109.0 

Note 7:  Affiliated Companies

At September 30, 2023 and December 31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $189.7 million and $197.0 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $5.7 million and $7.9 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

Our purchases from, and royalty payments made to, affiliates totaled $34.4 million and $118.5 million for the three and nine months ended September 30, 2023, respectively, as compared to $33.6 million and $131.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the payable balance due to affiliates was $20.6 million and $31.2 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products.



11
Sales to affiliates were $2.5 million and $8.5 million, respectively, for the three and nine months ended September 30, 2023, as compared to $2.6 million and $10.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the receivable balance due from affiliates was $1.3 million and $2.2 million, respectively.

Note 8:  Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023.
($ in millions)September 30,
2023		December 31,
2022
Term Loan, due December 31, 2024 (6.37%)
$81.5 $83.2 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
207.5 209.2 
Less: unamortized debt issuance costs0.2 0.3 
Total debt207.3 208.9 
Less: current portion of long-term debt55.2 2.2 
Long-term debt, net$152.1 $206.7 

Credit Facility

At September 30, 2023, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million.

Term Loan

At September 30, 2023, we had $81.5 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $79.3 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2023, we were in compliance with all of our debt covenants.

Note 9:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

12



Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2023 and December 31, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed in June 2023. As of September 30, 2023, the total amount of these forward exchange contracts was Euro ("EUR") 278.6 million and SGD 94.0 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
EUR20.3 22.3 — 
Yen5,159.3 29.8 9.0 
SGD44.7 15.2 16.8 

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2023, the notional amount of the cross-currency swap is ¥8.9 billion ($81.5 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2023, we purchased several series of call options for a total of 975,206 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.

As of September 30, 2023, we had outstanding contracts to purchase 229,397 barrels of crude oil from September 2023 to March 2025, at a weighted-average strike price of $94.93 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2023 and December 31, 2022.

13
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2023202220232022
Fair Value Hedges:
Hedged item (intercompany loan)
$(1.2)$(14.1)$8.7 $(35.4)Other expense (income)
Derivative designated as hedging instrument
0.7 14.1 (10.0)35.4 Other expense (income)
Amount excluded from effectiveness testing
(1.5)2.2 (0.4)4.4 Other expense (income)
Total$(2.0)$2.2 $(1.7)$4.4 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2023 were $0.2 million and $1.6 million, respectively. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 were $1.1 million and $2.8 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2023202220232022 
Fair Value Hedges:
Foreign currency hedge contracts$(0.3)$(0.4)$2.3 $0.5 Other expense (income)
Total$(0.3)$(0.4)$2.3 $0.5 
Cash Flow Hedges:     
Foreign currency hedge contracts$0.5 $0.7 $0.1 $(0.5)Net sales
Foreign currency hedge contracts(2.5)(1.5)1.1 1.0 Cost of goods and services sold
Forward treasury locks— — — 0.1 Interest expense
Total$(2.0)$(0.8)$1.2 $0.6  
Net Investment Hedges:     
Cross-currency swap$2.9 $4.3 $— $— Other expense (income)
Total$2.9 $4.3 $— $—  
14
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022 
Fair Value Hedges:
Foreign currency hedge contracts$(2.3)$0.3 $4.2 $(0.7)Other expense (income)
Total$(2.3)$0.3 $4.2 $(0.7)
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.4)$1.1 $1.2 $(1.1)Net sales
Foreign currency hedge contracts(6.1)(4.9)1.5 2.5 Cost of goods and services sold
Forward treasury locks— — 0.1 0.2 Interest expense
Total$(6.5)$(3.8)$2.8 $1.6  
Net Investment Hedges:     
Cross-currency swap$10.1 $13.2 $— $— Other expense (income)
Total$10.1 $13.2 $— $—  

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Net sales$0.1 $(0.5)$1.2 $(1.1)
Cost of goods and services sold1.1 1.0 1.5 2.5 
Interest expense— 0.1 0.1 0.2 

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2023202220232022
Commodity call options$0.5 $(1.5)$(0.5)$1.6 Other expense (income)
Currency Forwards— — (0.2)— Other expense (income)
Total$0.5 $(1.5)$(0.7)$1.6 

For the three and nine months ended September 30, 2023 and 2022, there was no material ineffectiveness related to our hedges.
15

Note 10:  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2023		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$9.1 $9.1 $— $— 
Foreign currency contracts2.4 — 2.4 — 
Cross-currency swap22.1 — 22.1 — 
Commodity call options1.4 — 1.4 — 
 $35.0 $9.1 $25.9 $— 
Liabilities:    
Contingent consideration$4.0 $— $— $4.0 
Deferred compensation liabilities9.3 9.3 — — 
Foreign currency contracts12.1 — 12.1 — 
 $25.4 $9.3 $12.1 $4.0 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2022		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.5 $12.5 $— $— 
Foreign currency contracts4.5 — 4.5 — 
Cross-currency swap13.9 — 13.9 — 
Commodity call options1.2 1.2 
 $32.1 $12.5 $19.6 $— 
Liabilities:    
Contingent consideration$4.7 $— $— $4.7 
Deferred compensation liabilities12.7 12.7 — — 
Foreign currency contracts1.4 — 1.4 — 
 $18.8 $12.7 $1.4 $4.7 


16
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.

Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2023, the estimated fair value of long-term debt was $147.2 million compared to a carrying amount of $152.1 million. At December 31, 2022, the estimated fair value of long-term debt was $201.8 million and the carrying amount was $206.7 million.

Note 11:  Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2022$0.2 $1.6 $(9.4)$(175.4)$(183.0)
Other comprehensive (loss) income before reclassifications(8.8)(0.1)(0.1)(36.9)(45.9)
Amounts reclassified out from accumulated other comprehensive (loss) income 7.0 — (1.1)— 5.9 
Other comprehensive (loss) income, net of tax(1.8)(0.1)(1.2)(36.9)(40.0)
Balance, September 30, 2023$(1.6)$1.5 $(10.6)$(212.3)$(223.0)












17
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications(3.5)(0.2)2.9 (162.5)(163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income0.9 — 13.5 — 14.4 
Other comprehensive (loss) income, net of tax(2.6)(0.2)16.4 (162.5)(148.9)
Balance, September 30, 2022$(3.8)$1.3 $(15.4)$(290.6)$(308.5)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2023202220232022
Gains (losses) on derivatives:
Foreign currency contracts$(0.2)$0.5 $(1.5)$1.2 Net sales
Foreign currency contracts(1.4)(1.2)(2.0)(2.9)Cost of goods and services sold
Foreign currency contracts(3.4)(0.7)(6.2)1.1 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.2)(0.3)Interest expense
Total before tax(5.1)(1.5)(9.9)(0.9)
Tax benefit (expense)1.6 0.4 2.9 — 
Net of tax$(3.5)$(1.1)$(7.0)$(0.9)
Amortization of defined benefit pension and other postretirement plans:
Actuarial gains$0.3 $1.1 $1.1 $1.1 (a)
Settlements— (27.6)— (28.8)(a)
Other— — 0.4 (0.4)
Total before tax0.3 (26.5)1.5 (28.1)
Tax (expense) benefit(0.1)14.2 (0.4)14.6 
Net of tax$0.2 $(12.3)$1.1 $(13.5)
Total reclassifications for the period, net of tax$(3.3)$(13.4)$(5.9)$(14.4)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
18
Note 12: Shareholders’ Equity

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202275.3 $18.8 $232.2 1.2 $(370.9)$2,987.8 $(183.0)$2,684.9 
Net income— — — — — 140.0 — 140.0 
Activity related to stock-based compensation— — (50.8)(0.3)61.8 — — 11.0 
Shares purchased under share repurchase program— — — 0.2 (60.1)— — (60.1)
Dividends declared ($0.19 per share)
— — — — — (14.2)— (14.2)
Other comprehensive income, net of tax— — — — — — 14.6 14.6 
Balance, March 31, 202375.3 $18.8 $181.4 1.1 $(369.2)$3,113.6 $(168.4)$2,776.2 
Net income— — — — — 155.1 — 155.1 
Activity related to stock-based compensation— — (23.2)(0.2)41.2 — — 18.0 
Shares purchased under share repurchase program— — — 0.5 (173.4)— — (173.4)
Dividends declared ($0.19 per share)
— — — — — (14.1)— (14.1)
Other comprehensive loss, net of tax— — — — — — (15.1)(15.1)
Balance, June 30, 202375.3 $18.8 $158.2 1.4 $(501.4)$3,254.6 $(183.5)$2,746.7 
Net income— — — — — 161.3 — 161.3 
Activity related to stock-based compensation— — (35.6)(0.2)63.1 — — 27.5 
Shares purchased under share repurchase program— — — 0.1 (27.8)— — (27.8)
Other comprehensive loss, net of tax— — — — — — (39.5)(39.5)
Balance, September 30, 202375.3 $18.8 $122.6 1.3 $(466.1)$3,415.9 $(223.0)$2,868.2 

19
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net income— — — — — 173.8 — 173.8 
Activity related to stock-based compensation— — (29.1)(0.3)29.2 — — 0.1 
Shares purchased under share repurchase program— — — 0.4 (147.1)— — (147.1)
Dividends declared ($0.18 per share)
— — — — — (13.2)— (13.2)
Other comprehensive loss, net of tax— — — — — — (22.8)(22.8)
Balance, March 31, 202275.3 $18.8 $219.9 1.2 $(347.4)$2,617.3 $(182.4)$2,326.2 
Net income— — — — — 188.5 — 188.5 
Activity related to stock-based compensation— — 5.4 — 9.7 — — 15.1 
Shares purchased under share repurchase program— — — 0.1 (28.6)— — (28.6)
Dividends declared ($0.18 per share)
— — — — — (13.3)— (13.3)
Other comprehensive loss, net of tax— — — — — — (63.5)(63.5)
Balance, June 30, 202275.3 $18.8 $225.3 1.3 $(366.3)$2,792.5 $(245.9)$2,424.4 
Net income— — — — — 120.6 — 120.6 
Activity related to stock-based compensation— — 5.3 (0.1)10.3 — — 15.6 
Shares purchased under share repurchase program— — — 0.1 (27.2)— — (27.2)
Other comprehensive loss, net of tax— — — — — — (62.6)(62.6)
Balance, September 30, 202275.3 $18.8 $230.6 1.3 $(383.2)$2,913.1 $(308.5)$2,470.8 

20
Note 13:  Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2023, there were 1,438,454 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2023, we granted 105,640 stock options at a weighted average exercise price of $306.92 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $108.88 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 5.7 years based on prior experience; stock volatility of 29.8% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2023, we granted 37,536 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $306.91 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2023, we granted 4,563 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $310.56 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Stock-based compensation expense was $5.9 million and $21.9 million for the three and nine months ended September 30, 2023, respectively. For the three and nine months ended September 30, 2022, stock-based compensation expense was $6.0 million and $17.0 million, respectively.

21
Note 14:  Benefit Plans

The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
Service cost$0.2 $0.3 $— $— $0.2 $0.3 
Interest cost0.6 0.5 0.1 0.1 0.7 0.6 
Expected return on assets(0.4)(0.8)— — (0.4)(0.8)
Recognized actuarial losses (gains)0.2 0.3 (0.5)(0.4)(0.3)(0.1)
Settlements— 49.6 — — — 49.6 
Net periodic benefit cost$0.6 $49.9 $(0.4)$(0.3)$0.2 $49.6 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
U.S. plans$— $49.6 $(0.4)$(0.3)$(0.4)$49.3 
International plans0.6 0.3 — — 0.6 0.3 
Net periodic benefit cost$0.6 $49.9 $(0.4)$(0.3)$0.2 $49.6 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
Service cost$0.8 $1.0 $— $— $0.8 $1.0 
Interest cost1.8 3.7 0.2 0.1 2.0 3.8 
Expected return on assets(1.0)(5.4)— — (1.0)(5.4)
Recognized actuarial losses (gains)0.5 1.0 (1.6)(1.1)(1.1)(0.1)
Settlements— 50.8 — — — 50.8 
Net periodic benefit cost$2.1 $51.1 $(1.4)$(1.0)$0.7 $50.1 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
U.S. plans$0.3 $50.3 $(1.4)$(1.0)$(1.1)$49.3 
International plans1.8 0.8 — — 1.8 0.8 
Net periodic benefit cost$2.1 $51.1 $(1.4)$(1.0)$0.7 $50.1 

During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating (income) expense, which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan.

22
Note 15:  Other Expense (Income)

Other expense (income) consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Loss on disposal of plant$— $— $11.6 $— 
Asset impairments3.5 1.4 6.9 1.6 
Restructuring and related charges— — (0.8)(1.6)
(Gain) loss on oil hedges(0.5)1.5 0.5 (1.6)
Contingent consideration0.7 1.5 1.5 2.6 
Foreign exchange transaction losses (gains)1.8 (2.2)3.0 (4.6)
Other items0.1 (0.3)(0.2)(0.4)
Total other expense (income)$5.6 $1.9 $22.5 $(4.0)

Loss on Disposal of Plant

During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million, respectively, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

Restructuring and Related Charges

In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $25 million to $27 million, with annualized savings in the range of $22 million to $24 million. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2022$10.1 $15.3 $25.4 
(Credits) Charges(0.8)— (0.8)
Cash payments(3.7)— (3.7)
Non-cash asset write downs— (15.3)(15.3)
Balance, September 30, 2023$5.6 $— $5.6 

Oil Hedges

During the three and nine months ended September 30, 2023, we recorded a gain of $0.5 million and a loss of $0.5 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our hedging activity.

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

23
Note 16:  Income Taxes

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $29.4 million and $20.4 million for the three months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 15.7% and 15.0%, respectively. The increase in the effective tax rate is primarily due to a tax benefit of $20.0 million related to the termination of the U.S. pension plan recorded in the three months ended September 30, 2022 that was not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the three months ended September 30, 2023, as compared to the same period in 2022.

The provision for income taxes was $87.8 million and $85.8 million for the nine months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 16.6% and 15.6%, respectively. The increase in the effective tax rate is primarily due to a tax benefit of $20.3 million related to the termination of the U.S. pension plan recorded in the nine months ended September 30, 2022 and a $5.9 million tax benefit recorded as the result of a state tax valuation allowance reversal in the nine months ended September 30, 2022 that were not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the nine months ended September 30, 2023, as compared to the same period in 2022.

Note 17:  Commitments and Contingencies

From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2022 Annual Report.

Note 18:  Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.

24
The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Net sales:    
Proprietary Products$602.5 $567.0 $1,803.6 $1,822.0 
Contract-Manufactured Products144.9 120.0 414.2 356.5 
Intersegment sales elimination— (0.1)— (0.3)
Consolidated net sales$747.4 $686.9 $2,217.8 $2,178.2 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Operating profit (loss):
Proprietary Products$181.6 $188.6 $546.5 $615.9 
Contract-Manufactured Products21.0 14.7 53.3 48.0 
Total business segment operating profit$202.6 $203.3 $599.8 $663.9 
Corporate and Unallocated
Stock-based compensation expense$(5.9)$(6.0)$(21.9)$(17.0)
Corporate general costs (1)
(15.9)(10.9)(47.2)(43.6)
Unallocated Items:
Loss on disposal of plant (2)
— — (11.6)— 
Cost investment impairment (3)
(3.3)— (3.3)— 
Restructuring and other charges (4)
— — (0.1)1.6 
Amortization of acquisition-related intangible assets (5)
(0.2)(0.2)(0.6)(0.6)
Total Corporate and Unallocated(25.3)(17.1)(84.7)(59.6)
Total consolidated operating profit$177.3 $186.2 $515.1 $604.3 
Interest (income) expense and other nonoperating (income) expense, net(9.7)50.0 (14.7)53.1 
Income before income taxes and equity in net income of affiliated companies$187.0 $136.2 $529.8 $551.2 

25
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.

(4) Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represents the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan. During the nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates.

(5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 15, Other Expense (Income), for further discussion of these items.

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2022 Annual Report. Our historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2022 Annual Report and in Part II, Item 1A of this Form 10-Q.

Throughout this section, references to “Notes” refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.

26
Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Our business operations are organized into two global segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

Macroeconomic Factors

Through the nine months ended September 30, 2023, the war between Russia and Ukraine has not had a material impact on the Company’s business, financial condition or results of operations as we do not have manufacturing operations or significant commercial relationships in either country. However, the continuation of the Russia-Ukraine military conflict and/or an escalation of the conflict beyond its current scope may further weaken the global economy and could result in additional inflationary pressures and supply chain constraints, including the unavailability and cost of energy.

We have operations based in Israel that conduct research and development activities and manufacture certain components for our devices. Our Israel-based facilities continue to substantially operate as they had prior to the conflict in Israel and surrounding area. We will continue to monitor the impact of the conflict in Israel and surrounding areas on our operations and those of our suppliers, the possible expansion of such conflict and potential geopolitical consequences, if any, on our business and operations.



27
Due to the uncertainty that exists relative to the duration and overall impact of the macroeconomic factors discussed above, our future operating performance, particularly in the short-term, may be subject to volatility. The impacts of macroeconomic conditions on our business, results of operations, financial condition and cash flows are dependent on certain factors, including those discussed in Item 1A. Risk Factors and the risk factors described in Part I, Item 1A of our 2022 Annual Report.

2023 Financial Performance Summary

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2023:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2023 GAAP
$177.3 $29.4 $161.3 $2.14 
Unallocated items:
Cost investment impairment (2)
3.3 — 3.3 0.05 
Amortization of acquisition-related intangible assets (4)
0.2 0.1 0.7 0.01 
Legal settlement (5)
— (0.9)(2.9)(0.04)
Three months ended September 30, 2023 adjusted amounts (non-U.S. GAAP)
$180.8 $28.6 $162.4 $2.16 

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2023 GAAP
$515.1 $87.8 $456.4 $6.05 
Unallocated items:
Loss on disposal of plant (1)
11.6 (0.7)12.3 0.16 
Cost investment impairment (2)
3.3 — 3.3 0.05 
Restructuring and other charges (3)
0.1 (0.3)0.4 — 
Amortization of acquisition-related intangible assets (4)
0.6 0.1 2.1 0.03 
Legal settlement (5)
— (0.9)(2.9)(0.04)
Nine months ended September 30, 2023 adjusted amounts (non-U.S. GAAP)
$530.7 $86.0 $471.6 $6.25 

During the three and nine months ended September 30, 2023, we recorded a tax benefit of $12.0 million and $31.3 million, respectively, associated with stock-based compensation.

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2022:

28
($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2022 GAAP
$186.2 $20.4 $120.6 $1.59 
Unallocated items:
Pension settlement (6)
— 20.0 29.6 0.39 
Amortization of acquisition-related intangible assets (4)
0.2 0.1 0.7 0.01 
Tax law changes (7)
— (3.2)3.2 0.04 
Three months ended September 30, 2022 adjusted amounts (non-U.S. GAAP)
$186.4 $37.3 $154.1 $2.03 

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2022 GAAP
$604.3 $85.8 $482.9 $6.36 
Unallocated items:
Restructuring and other charges (3)
(1.6)(0.4)(1.2)(0.01)
Pension settlement (6)
— 20.3 30.5 0.40 
Amortization of acquisition-related intangible assets (4)
0.6 0.1 2.1 0.03 
Tax law changes (7)
— (3.2)3.2 0.04 
Royalty acceleration (8)
— 1.3 (1.3)(0.02)
Nine months ended September 30, 2022 adjusted amounts (non-U.S. GAAP)
$603.3 $103.9 $516.2 $6.80 

During the three and nine months ended September 30, 2022, we recorded a tax benefit of $2.1 million and $12.3 million, respectively, associated with stock-based compensation.

(1)During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(2)During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.

(3)Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represents the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan. During the nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates.

(4)During the three and nine months ended September 30, 2023 and 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2023 and 2022, the Company recorded $0.6 million and $1.6 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.

29
(5)During the three and nine months ended September 30, 2023, the Company recorded a benefit of $3.8 million within other nonoperating (income) expense as a result of a favorable legal settlement related to a matter not included in our normal operations.

(6)During the three and nine months ended September 30, 2022, we recorded a gross pension settlement charge of $49.6 million and $50.8 million, respectively, within other nonoperating (income) expense, that fully settled the U.S. qualified defined benefit plan (the "U.S. pension plan"). Please refer to Note 14, Benefit Plans, for further discussion of these items.

(7)During the three and nine months ended September 30, 2022, the Company incurred additional tax expense of $3.2 million due to the impact of a tax law change in the state of Pennsylvania enacted during the period.

(8)During the nine months ended September 30, 2022, the Company increased its expected tax benefit related to the prepayment of future royalties from one of its subsidiaries by $1.3 million.

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.

Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment, for the three months ended September 30, 2023 and 2022:
Three Months Ended
September 30,		Percentage Change
($ in millions)20232022As-ReportedOrganic
Proprietary Products$602.5 $567.0 6.3 %3.2 %
Contract-Manufactured Products144.9 120.0 20.8 %17.4 %
Intersegment sales elimination— (0.1)— — 
Consolidated net sales$747.4 $686.9 8.8 %5.7 %

Consolidated net sales increased by $60.5 million, or 8.8%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $25.1 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $3.5 million, consolidated net sales for the three months ended September 30, 2023 increased by $38.9 million, or 5.7%, as compared to the same period in 2022, primarily due to sales price increases.

30
Proprietary Products – Proprietary Products net sales increased by $35.5 million, or 6.3%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $21.1 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $3.5 million, net sales for the three months ended September 30, 2023 increased by $17.9 million, or 3.2%, as compared to the same period in 2022, due to growth in our high-value components, primarily FluroTec®, Daikyo® and Envision®, growth in our high-value devices, such as self-injection systems and administration systems, and sales price increases. This was offset by a decline in COVID-related sales of approximately $78 million.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $24.9 million, or 20.8%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $4.0 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2023 increased by $20.9 million, or 17.4%, as compared to the same period in 2022, primarily due to an increase in the volume of sales of components associated with injection-related devices and healthcare diagnostic devices, as well as sales price increases.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table presents net sales, consolidated and by reportable segment, for the nine months ended September 30, 2023 and 2022:
Nine Months Ended
September 30,		Percentage Change
($ in millions)20232022As-ReportedOrganic
Proprietary Products$1,803.6 $1,822.0 (1.0)%(1.0)%
Contract-Manufactured Products414.2 356.5 16.2 %15.4 %
Intersegment sales elimination— (0.3)— — 
Consolidated net sales$2,217.8 $2,178.2 1.8 %1.7 %

Consolidated net sales increased by $39.6 million, or 1.8%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $9.4 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $6.6 million, consolidated net sales for the nine months ended September 30, 2023 increased by $36.8 million, or 1.7%, as compared to the same period in 2022, primarily due to sales price increases, offset by a decline in COVID-related sales.

Proprietary Products – Proprietary Products net sales decreased by $18.4 million, or 1.0%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $6.5 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $6.6 million, net sales for the nine months ended September 30, 2023 decreased by $18.3 million, or 1.0%, as compared to the same period in 2022, primarily due to a decline in COVID-related sales of approximately $272 million, offset by growth in our high-value components, primarily Westar®, FluroTec®, and Daikyo®, as well as growth in high-value devices, such as self-injection systems and administration systems, and sales price increases.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $57.7 million, or 16.2%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $2.9 million. Excluding foreign currency translation effects, net sales for the nine months ended September 30, 2023 increased by $54.8 million, or 15.4%, as compared to the same period in 2022, primarily due to an increase in the volume of sales of components associated with injection-related devices and healthcare diagnostic devices, as well as sales price increases.

31
The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

Gross Profit

The following table presents gross profit and related gross profit margins, consolidated and by reportable segment:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Proprietary Products:  
Gross profit$261.4 $247.3 $780.6 $810.3 
Gross profit margin43.4 %43.6 %43.3 %44.5 %
Contract-Manufactured Products:   
Gross profit$26.9 $20.7 $71.3 $63.8 
Gross profit margin18.6 %17.3 %17.2 %17.9 %
Unallocated items$— $— $(0.9)$— 
Consolidated gross profit$288.3 $268.0 $851.0 $874.1 
Consolidated gross profit margin38.6 %39.0 %38.4 %40.1 %

Consolidated gross profit increased by $20.3 million, or 7.6%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $10.3 million for the three months ended September 30, 2023, as compared to the same period in 2022. Consolidated gross profit margin decreased by 0.4 margin points for the three months ended September 30, 2023, as compared to the same period in 2022.

Consolidated gross profit decreased by $23.1 million, or 2.6% for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $6.0 million for the nine months ended September 30, 2023, as compared to the same period in 2022. Consolidated gross profit margin decreased by 1.7 margin points for the nine months ended September 30, 2023, as compared to the same period in 2022.

Proprietary Products - Proprietary Products gross profit increased by $14.1 million, or 5.7%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $9.5 million. Proprietary Products gross profit margin decreased by 0.2 margin points for the three months ended September 30, 2023, as compared to the same periods in 2022, due to a decline in higher margin COVID-related sales and a decrease of approximately $17 million, net, in fees received from COVID-19 supply agreements. These items were partially offset by increased sales prices.

Proprietary Products gross profit decreased by $29.7 million, or 3.7%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $5.5 million. Proprietary Products gross profit margin decreased by 1.2 margin points for the nine months ended September 30, 2023, as compared to the same period in 2022, due to a decline in higher margin COVID-related sales, a decrease of approximately $21 million, net, in fees received from COVID-19 supply agreements, and inflationary pressures, primarily within compensation costs. These headwinds were partially offset by increased sales prices and production efficiencies.





32
Contract-Manufactured Products - Contract-Manufactured Products gross profit increased by $6.2 million, or 30.0%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $0.8 million. Contract-Manufactured Products gross profit margin increased by 1.3 margin points for the three months ended September 30, 2023, as compared to the same period in 2022, due to the mix of products sold and increased sales prices, offset by inflationary pressures, primarily within compensation costs.

Contract-Manufactured Products gross profit increased by $7.5 million, or 11.8%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $0.5 million. Contract-Manufactured Products gross profit margin decreased by 0.7 margin points for the nine months ended September 30, 2023, as compared to the same period in 2022, due to inflationary pressures, primarily within compensation costs. These headwinds were partially offset by increased sales prices.

Research and Development (“R&D”) Costs

The following table presents consolidated R&D costs:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Consolidated R&D costs$16.4 $13.6 $50.0 $42.6 

Consolidated R&D costs increased by $2.8 million, or 20.6%, and $7.4 million, or 17.4%, for the three and nine months ended September 30, 2023, respectively, as compared to the same period in 2022, due to higher annual incentive compensation and additional research performed to identify new product opportunities. The increases in spend included $0.2 million for the three months ended September 30, 2023 and $2.8 million for the nine months ended September 30, 2023 of research performed on glass systems. Efforts remain focused on the continued investment in elastomeric packaging components, formulation development, drug containment systems, self-injection systems and drug administration consumables.

All of the R&D costs incurred the three and nine months ended September 30, 2023 and 2022 related to Proprietary Products.

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Proprietary Products$61.4 $44.3 $176.8 $155.6 
Contract-Manufactured Products6.0 4.7 18.1 14.4 
Corporate and unallocated items21.6 17.3 68.5 61.2 
Consolidated SG&A costs$89.0 $66.3 $263.4 $231.2 
SG&A as a % of net sales11.9 %9.7 %11.9 %10.6 %

Consolidated SG&A costs increased by $22.7 million, or 34.2%, for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to higher annual incentive compensation, increased costs related to professional services and an unfavorable foreign currency translation impact of $1.2 million.

33
Consolidated SG&A costs increased by $32.2 million, or 13.9%, for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to higher annual incentive compensation, an increase in mark-to-market expense related to stock-based compensation, increased compensation costs and an unfavorable foreign currency translation impact of $0.6 million.

Proprietary Products - Proprietary Products SG&A costs increased by $17.1 million, or 38.6%, for the three months ended September 30, 2023, as compared to the same period in 2022. Proprietary Products SG&A costs increased primarily due to higher annual incentive compensation, an increase in compensation costs and an unfavorable foreign currency translation impact of $1.0 million.

Proprietary Products SG&A costs increased by $21.2 million, or 13.6%, for the nine months ended September 30, 2023, as compared to the same period in 2022. Proprietary Products SG&A costs increased primarily due to higher annual incentive compensation, an increase in compensation costs and an unfavorable foreign currency translation impact of $0.4 million.

Contract-Manufactured Products - Contract-Manufactured Products SG&A costs increased by $1.3 million, or 27.7%, for the three months ended September 30, 2023, as compared to the same period in 2022, and increased by $3.7 million, or 25.7%, for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to a higher allocation of corporate function spend and higher annual incentive compensation.

Corporate and unallocated items - Corporate SG&A costs increased by $4.3 million, or 24.9%, for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to higher annual incentive compensation and an increase in mark-to-market expense related to stock-based compensation.

Corporate SG&A costs increased by $7.3 million, or 11.9%, for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to an increase in mark-to-market expense related to stock-based compensation and higher annual incentive compensation.

Other Expense (Income)

The following table presents other income and expense items, consolidated and by reportable segment, corporate and unallocated items:
(Income) ExpenseThree Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Proprietary Products$2.0 $0.8 $7.3 $(3.8)
Contract-Manufactured Products(0.1)1.3 (0.1)1.4 
Corporate and unallocated3.7 (0.2)15.3 (1.6)
Consolidated other expense (income)$5.6 $1.9 $22.5 $(4.0)

Other expense and income items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, contingent consideration, fixed asset impairments and miscellaneous income and charges.

Consolidated other expense (income) changed by $3.7 million for the three months ended September 30, 2023, as compared to the same period in 2022 and changed by $26.5 million for the nine months ended September 30, 2023, as compared to the same period in 2022, due to the factors described below.





34
Proprietary Products - Proprietary Products other expense (income) changed by $1.2 million for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to a loss on foreign exchange transactions being recorded in the three months ended September 30, 2023, while a gain on foreign exchange transactions was recorded during the same period in 2022. This was offset by a $0.5 million gain related to oil hedges being recorded during the three months ended September 30, 2023, while a loss of $1.5 million was recorded in the same period in 2022. This was further offset by $0.7 million of expense related to contingent consideration being recorded during the three months ended September 30, 2023, while expense of $1.5 million was recorded in the same period in 2022.

Proprietary Products other expense (income) changed by $11.1 million for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to a loss on foreign exchange transactions being recorded in the nine months ended September 30, 2023, while a gain on foreign exchange transactions was recorded during the same period in 2022. Additionally, the Company recorded a loss of $0.5 million related to oil hedges during the nine months ended September 30, 2023, while a gain of $1.6 million was recorded in the same period in 2022. This was offset by $1.5 million of expense related to contingent consideration being recorded during the nine months ended September 30, 2023, while expense of $2.6 million was recorded in the same period in 2022.

Contract-Manufactured Products - Contract-Manufactured Products other expense (income) changed by $1.4 million for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to fixed asset impairments recorded in the three months ended September 30, 2022 that did not recur in 2023.

Contract-Manufactured Products other expense (income) changed by $1.5 million for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to fixed asset impairments recorded in the three months ended September 30, 2022 that did not recur in 2023.

Corporate and unallocated items - Corporate and unallocated items changed by $3.9 million for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to the Company recording expense related to impairment of one of the Company's cost investments of $3.3 million in the three months ended September 30, 2023 that did not occur in the same period in 2022.

Corporate and unallocated items changed by $16.9 million for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to the Company recording expense of $11.6 million as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment and the Company recording expense related to impairment of one of the Company's cost investments of $3.3 million in the nine months ended September 30, 2023. Neither of these items occurred in the same period in 2022.

35
Operating Profit

The following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Proprietary Products$181.6 $188.6 $546.5 $615.9 
Contract-Manufactured Products21.0 14.7 53.3 48.0 
Corporate and unallocated items(25.3)(17.1)(84.7)(59.6)
Consolidated operating profit$177.3 $186.2 $515.1 $604.3 
Consolidated operating profit margin23.7 %27.1 %23.2 %27.7 %
Unallocated items3.5 0.2 15.6 (1.0)
Adjusted consolidated operating profit$180.8 $186.4 $530.7 $603.3 
Adjusted consolidated operating profit margin24.2 %27.1 %23.9 %27.7 %

Consolidated operating profit decreased by $8.9 million, or 4.8%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $8.9 million for the three months ended September 30, 2023, as compared to the same period in 2022.

Consolidated operating profit decreased by $89.2 million, or 14.8%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $5.2 million for the nine months ended September 30, 2023, as compared to the same period in 2022.

Proprietary Products - Proprietary Products operating profit decreased by $7.0 million, or 3.7%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $8.3 million, due to the factors described above, most notably an increase in compensation costs, including the annual incentive compensation, and a decline in higher margin COVID-related sales.

Proprietary Products operating profit decreased by $69.4 million, or 11.3%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $4.9 million, due to the factors described above, most notably the decline in COVID-related sales.

Contract-Manufactured Products - Contract-Manufactured Products operating profit increased by $6.3 million, or 42.9%, for the three months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $0.6 million, due to the factors described above, most notably an increase in sales of components associated with injection-related devices.

Contract-Manufactured Products operating profit increased by $5.3 million, or 11.0%, for the nine months ended September 30, 2023, as compared to the same period in 2022, including a favorable foreign currency translation impact of $0.3 million, due to the factors described above, most notably an increase in sales of components associated with injection-related devices.

Corporate - Excluding the unallocated items, Corporate costs increased by $4.9 million, or 29.0%, for the three months ended September 30, 2023, as compared to the same period in 2022, due to the factors described above.

Excluding the unallocated items, Corporate costs increased by $8.5 million, or 14.0%, for the nine months ended September 30, 2023, as compared to the same period in 2022, due to the factors described above.

Unallocated items – Please refer to the Financial Performance Summary section above for details.

36
Interest Expense, Net and Interest Income

The following table presents interest expense, net, by significant component:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Interest expense$4.4 $2.8 $11.7 $8.4 
Capitalized interest(1.5)(0.6)(3.9)(2.2)
Interest expense, net$2.9 $2.2 $7.8 $6.2 
Interest income$(8.8)$(1.5)$(18.6)$(2.2)
Interest expense, net, increased by $0.7 million, for the three months ended September 30, 2023, as compared to the same period in 2022, and increased by $1.6 million, for the nine months ended September 30, 2023, as compared to the same period in 2022, due to higher interest rates compared to the prior year.

Interest income increased by $7.3 million for the three months ended September 30, 2023, as compared to the same period in 2022, and $16.4 million for the nine months ended September 30, 2023, as compared to the same period in 2022, resulting from higher interest rates compared to the prior year, primarily within the U.S., Europe and South America.

Other Nonoperating (Income) Expense

Other nonoperating (income) expense changed by $53.1 million for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to the recording of a $49.6 million pension settlement charge during the three months ended September 30, 2022, which relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan, while no such amounts were recorded in the same period in 2023. Additionally, the Company recorded a benefit of $3.8 million in the three months ended September 30, 2023 as a result of a favorable legal settlement related to a matter not included in our normal operations. This did not occur in the same period in 2022.

Other nonoperating (income) expense changed by $53.0 million for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to the recording of a $50.8 million pension settlement charge during the nine months ended September 30, 2022, which relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan, while no such amounts were recorded in the same period in 2023. Additionally, the Company recorded a benefit of $3.8 million in the nine months ended September 30, 2023 as a result of a favorable legal settlement related to a matter not included in our normal operations. This did not occur in the same period in 2022.

Please refer to Note 14, Benefit Plans, for further discussion of these items.

Income Tax Expense

The provision for income taxes was $29.4 million and $20.4 million for the three months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 15.7% and 15.0%, respectively. The increase in the effective tax rate is primarily due to a tax benefit of $20.0 million related to the termination of the U.S. pension plan recorded in the three months ended September 30, 2022 that was not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the three months ended September 30, 2023, as compared to the same period in 2022.

37
The provision for income taxes was $87.8 million and $85.8 million for the nine months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 16.6% and 15.6%, respectively. The increase in the effective tax rate is primarily due to a tax benefit of $20.3 million related to the termination of the U.S. pension plan recorded in the nine months ended September 30, 2022 and a $5.9 million tax benefit recorded as the result of a state tax valuation allowance reversal in the nine months ended September 30, 2022 that were not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the nine months ended September 30, 2023, as compared to the same period in 2022.

Equity in Net Income of Affiliated Companies

Equity in net income of affiliated companies decreased by $1.1 million for the three months ended September 30, 2023, as compared to the same period in 2022, due to less favorable operating results at the Mexico affiliates.

Equity in net income of affiliated companies decreased by $3.1 million for the nine months ended September 30, 2023, as compared to the same period in 2022, due to less favorable operating results at Daikyo and the Mexico affiliates.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the nine months ended September 30:
($ in millions)20232022
Net cash provided by operating activities$537.4 $493.2 
Net cash used in investing activities$(259.9)$(193.4)
Net cash used in financing activities$(270.1)$(284.1)

Net Cash Provided by Operating Activities – Net cash provided by operating activities increased by $44.2 million for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to favorable working capital management in the nine months ended September 30, 2023, as compared to the same period in 2022. This was offset by a decline in operating results.

Net Cash Used in Investing Activities – Net cash used in investing activities increased by $66.5 million for the nine months ended September 30, 2023, as compared to the same period in 2022, due to an increase in capital expenditures for additional manufacturing capacity in 2023 to meet customer demand.

Net Cash Used in Financing Activities – Net cash used in financing activities decreased by $14.0 million for the nine months ended September 30, 2023, as compared to the same period in 2022, primarily due to reduced debt repayments and increased proceeds from stock-based compensation awards in 2023, as compared to the same period in 2022. This was offset by increases in purchases under our share repurchase program in 2023, as compared to the same period in 2022.

38
Liquidity and Capital Resources

The table below presents selected liquidity and capital measures:
($ in millions)September 30,
2023		December 31,
2022
Cash and cash equivalents$898.6 $894.3 
Accounts receivable, net$519.1 $507.4 
Inventories$431.8 $414.8 
Accounts payable$219.8 $215.4 
Debt$207.3 $208.9 
Equity$2,868.2 $2,684.9 
Working capital$1,438.8 $1,400.5 

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at September 30, 2023 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at September 30, 2023 included $428.6 million of cash held by subsidiaries within the U.S., and $470.0 million of cash held by subsidiaries outside of the U.S. During the nine months ended September 30, 2023, we purchased 753,399 shares of our common stock under the share repurchase program at a cost of $261.3 million, or an average price of $346.86 per share.

Working capital – Working capital at September 30, 2023 increased by $38.3 million, or 2.7%, as compared to December 31, 2022, which includes an unfavorable foreign currency translation impact of $15.8 million. Excluding the impact of currency exchange rates, cash and cash equivalents, accounts receivable, inventories and total current liabilities increased by $7.4 million, $14.1 million, $21.0 million and $20.4 million, respectively. The increase in cash and cash equivalents was due to cash collections driven by positive operating results, offset by capital expenditures and share repurchases. The increase in accounts receivable was due to increased sales activity during the period. The increase in inventories that occurred in the period was to ensure we have sufficient inventory on hand to support the needs of our customers. The increase in total current liabilities was driven primarily by a portion of long-term debt moving to current based on the stated maturity during the period, offset by a decrease in other current liabilities due to declines in deferred income and dividends payable.

Debt and credit facilities – The $1.6 million decrease in total debt at September 30, 2023, as compared to December 31, 2022, resulted primarily from debt repayments under our Term Loan.

Our sources of liquidity include our Credit Facility. At September 30, 2023, we had no outstanding borrowings under the Credit Facility. At September 30, 2023, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.4 million, was $497.6 million. We do not expect any significant limitations on our ability to access this source of funds.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and not to exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2023, we were in compliance with all of our debt covenants.

We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

39
Commitments and Contractual Obligations

A summary of future material cash payments resulting from commitments and contractual obligations was provided in our 2022 Annual Report. During the three months ended September 30, 2023, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.

OFF-BALANCE SHEET ARRANGEMENTS

At September 30, 2023, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2022 Annual Report.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2022 Annual Report.

NEW ACCOUNTING STANDARDS

There were no new accounting standards adopted during the three months ended September 30, 2023, see Note 2, New Accounting Standards.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “plan,” “expect,” “believe,” “intend,” “will,” “estimate,” “continue” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements:
•sales demand and our ability to meet that demand;
•competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;
•customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;
•interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or
40
unauthorized access to our or our customers’ information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;
•the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;
•whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;
•the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Crystal Zenith prefilled syringes;
•profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;
•maintaining or improving production efficiencies and overhead absorption;
•dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;
•the loss of key personnel or highly-skilled employees;
•the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;
•the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;
•the cost and progress of development, regulatory approval and marketing of new products;
•our ability to obtain and maintain licenses in any jurisdiction in which we do business;
•the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; and
•the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.

This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2022 Annual Report as well as Part II, section 1A of this quarterly report.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2022 Annual Report.

41
ITEM 4.  CONTROLS AND PROCEDURES

Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our CEO and CFO have concluded that, as of September 30, 2023, our disclosure controls and procedures are effective.

Changes in Internal Controls
During the quarter ended September 30, 2023, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.  OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

None.

ITEM 1A.  RISK FACTORS

We are providing the disclosure below and supplementing the risk factors described in Part I, Item 1A of our 2022 Annual Report with the following risk factor. The additional risk factor identified should be read in conjunction with the risk factors described in the 2022 Annual Report and the information under the "Forward Looking Statements" in the 2022 Annual Report.

Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business and financial condition.

The recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure could materially and adversely affect our liquidity, our business and financial condition. Even with our continued effort to mitigate counterparty risk by working with highly liquid, well capitalized counterparties, the failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.

42
ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table shows information with respect to purchases of our common stock made during the three months ended September 30, 2023 by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act:
PeriodTotal number of shares purchased (1)Average price paid per share (1)Total number of shares purchased as part of publicly announced plans or programs (1)Approximate dollar value of shares that may yet be purchased under the plans or programs (1)
July 1 - 31, 202358,770 $359.42 58,770 $745,400,000 
August 1 - 31, 202318,559 362.88 18,559 738,700,000 
September 1 - 30, 2023— — — 738,700,000 
Total77,329 $360.25 77,329 $738,700,000 

(1)In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.

ITEM 5.  OTHER INFORMATION

Rule 10b5-1 Trading Plans

Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors, entered into a prearranged stock trading arrangement on May 5, 2023. Mr. Green’s plan provides for the purchase and sale of an aggregate number of 234,864 shares of the Company's common stock (of which Mr. Green will sell 204,864 shares and retain the rest immediately following the exercise) between August 8, 2023 and August 6, 2024. The trading plan was entered into during an open insider trading window and is intended to satisfy Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding insider transactions.

ITEM 6.  EXHIBITS

Amendments to Amended and Restated Bylaws
On October 23, 2023, the Board of Directors ("Board) of the Company approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”), effective immediately. The amendments include various updates to bring the bylaws in line with the Company’s current governance practices and to reflect changes in practice and applicable law and regulatory developments since the last amendment to our Bylaws on February 23, 2021. Among other items, these changes facilitate and supplement the SEC’s Universal Proxy Card (“UPC”) Rules, modernize our Advance Notice requirements and make clarifications to address provisions in the Pennsylvania Business Corporation Law pursuant to which we are incorporated. The specific changes include:

Article I, Section 1(d)
Clarifies presiding officer’s ability to determine and regulate business in accordance with Pennsylvania law
Article I, Section 3(b)
White proxy card reserved for management and shareholder soliciting proxies must use a different color and clarifies process for granting proxies in accordance with Pennsylvania law
Article I, Section 3(d)
Clarifies shareholder list may not be available if provided to judges of election in accordance with Pennsylvania law
43
Article I, Section 5(a)
Number of shareholder nominees cannot exceed number of directors up for election
Article I, Section 5(a) and Section 6(a)
Proposing shareholders or their qualified representative is required to be present at the meeting and proposing shareholder must own shares through date of the meeting
Article I, Section 5(b)
Requires shareholders to use proxy access or advance notice process for nominations and eliminates simple recommendation process
Article I, Section 5(b) and Section 6(a)
Requires shareholders to update and supplement information as of the record date and prior to meeting
Article I, Section 5(b)(1) and Section 6(a)
Clarifies shareholders are not entitled to make additional or substitute nominations or proposals after deadline
Article I, Section 5(b)(1)
Advance notice of nomination procedures apply to special meetings
Article I, Section 5(c)
Proposed nominees must make themselves available for interviews if requested
Article I, Section 5(b)(2)(c)(xvi)
Nominating shareholders must declare intent to solicit proxies in accordance with UPC Rules and agree it will comply
Article I, Section 5(b)(2)(F) and Section 9
Nominees must consent to being named in the proxy materials and intends to serve for the entire term
Article I, Section 5(d)
Nominations that do not meet the UPC Rules will be disregarded
Article I, Section 6(a)
Shareholder’s proposed business must be proper subject for shareholder action and not expressly reserved for action by the Board
Article I, Section 6(b)
Shareholders must include information required by applicable law, additional information regarding relationships and rationale for why the proposal is in the best interests of the Company
Article I, Section 7(h)(3)
Broadened the scope of related parties in order to more fully analyze the proposal
Article I, Section 7(a)
Nomination or proposal may be omitted if a shareholder or related party takes action contrary to representations or the notice is untrue
Article I, Section 7(g)
Proposing shareholders cannot contain untrue, incorrect or incomplete information and must be updated to be true, accurate and complete
Article II, Section 7
Clarifies Board’s ability to act by unanimous written consent in accordance with Pennsylvania law
Article II, Section 8
Clarifies the Board may fill a vacancy resulting from a future resignation in accordance with Pennsylvania law and aligns proxy access provisions with other changes made due to adoption of the UPC Rules
Article II, Section 11
Clarifies Board’s authority to fix compensation in accordance with Pennsylvania law
Article IV
Aligns indemnification and expense advancement provisions with prevailing market practices
Article VII
Clarifies the authority and function of Board may not be varied by a bylaw adopted by shareholders without approval by the Board also in accordance with applicable Pennsylvania law

The summary herein is qualified in its entirety by reference to the Amended and Restated Bylaws, a copy of which is filed with this Quarterly Report on Form 10-Q as Exhibit 3.2 and is incorporated herein by reference.
44
Exhibit NumberDescription
3.1
3.2
4.1
4.2
4.3
4.4 (1)
Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.
10.1
10.2
10.3
31.1
31.2
32.1*
32.2*
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

* Furnished, not filed.
45
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)




By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer



October 26, 2023
46
 EX-3.2 2 amendedrestatedbylawsoct20.htm EX-3.2 Document
As Amended through October 23, 2023
WEST PHARMACEUTICAL SERVICES, INC.

AMENDED AND RESTATED BYLAWS
ARTICLE I
SHAREHOLDERS
Section 1.Meetings.
(a)Annual Meeting. The annual meeting of the shareholders for the election of directors from the nominees for director at such meeting and for other business as may be properly brought before the meeting, in each case, in accordance with the applicable provisions of these Amended and Restated Bylaws (the “Bylaws”) of West Pharmaceutical Services, Inc. (the “Company”), the Articles of Incorporation of the Company (as amended from time to time, the “Articles of Incorporation”), and applicable law, shall be held at such time as may be fixed by the Board of Directors of the Company (the “Board of Directors”).
(b)Special Meetings. Special meetings of the shareholders may be called at any time by the Chair of the Board (as defined below), the President, or a majority of the entire Board of Directors. Only business within the purpose or purposes specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors may be conducted at a special meeting of the shareholders. No shareholder shall have the power to require that a meeting of the shareholders be held or that any matter be voted on by the shareholders at any special meeting, except as required by applicable law.
(c)Place. Meetings of the shareholders shall be held (1) at such place, within or without the Commonwealth of Pennsylvania, as may be fixed by the Board of Directors or, in the case of a special meeting, by the Chair of the Board, the President, or a majority of the entire Board of Directors or, (2) if so determined by the Board of Directors or, in the case of a special meeting, by the Chair of the Board, the President or a majority of the entire board, by means of the internet or other electronic technology in a manner that satisfies the requirements of the Pennsylvania Business Corporation Law of 1988, as may be amended or replaced from time to time (the “PBCL”), in each case, from time to time.
(d)Conduct of Meeting of Shareholders. There shall be a presiding officer at all meetings of the shareholders. The presiding officer shall be the Chair of the Board or, in the case of vacancy of office or absence of the Chair of the Board, the presiding officer shall be designated by the Board of Directors. Unless otherwise determined by the Board of Directors prior to the meeting, the presiding officer shall, except as otherwise required by applicable law (including Section 1765 of the PBCL), determine the order of business and shall have the authority to establish rules for the conduct of the meeting and to regulate the conduct of the meeting, including, without limitation, by: (1) imposing restrictions on the persons (other than shareholders of the Company or their duly appointed proxy holders) that may attend the meeting; (2) ascertaining whether any shareholder or his or her proxy holder may be excluded from the meeting based upon any determination by the presiding officer, in his or her sole discretion, that any such person has disrupted the proceedings thereat; (3) determining the circumstances in which any person may make a statement or ask questions at the meeting; (4) ruling on all procedural questions that may arise during or in connection with the meeting; (5) determining whether any nomination or business proposed to be brought before the meeting has been


properly brought before the meeting; and (6) determining the time or times at which the polls for voting at the meeting will be opened and closed. The presiding officer shall announce at the meeting when the polls close for each matter voted upon. If no announcement is made, the polls shall be deemed to have closed upon the final adjournment of the meeting. After the polls close, no ballots, proxies or votes, nor any revocations or changes thereto, may be accepted. Any regular or special meeting of the shareholders, including one at which directors are to be elected, may be adjourned for such period or periods as the presiding officer shall direct. If the presiding officer for a meeting of shareholders that is to be held exclusively by means of electronic technology decides in his or her reasonable judgment on the day of the meeting that the meeting cannot be convened because of a reason outside the control of the Company, the presiding officer may postpone the meeting to a specified time later that day or the following day. Notice of the postponed meeting may be given by means solely of a publicly available filing with the Securities and Exchange Commission (“SEC”).
(e)Attendance by Electronic Means. A shareholder or a shareholder’s proxy’s presence or participation, including voting and taking other action, at a meeting of shareholders or the expression of consent or dissent to corporate action by a shareholder or a shareholder’s proxy by telephone or other electronic means, including, without limitation, the internet, shall constitute the presence of, or vote or action by, or consent or dissent of the shareholder or a shareholder’s proxy for all purposes.
Section 2.Notice.
(a)Valid Notice. Written notice of the date, time and place, if any, of all meetings of shareholders and of the purpose of each special meeting of shareholders shall be given to each shareholder of record entitled to vote thereat at least five days before the date of the meeting, unless a greater period of notice is required by applicable law in a particular case. Such notice may be given to the shareholder by either of the following methods:
(1) by first class or express mail, postage prepaid, or courier service, charges prepaid, to the postal address of the person appearing on the books of the Company, which notice shall be deemed to have been given to the shareholder when deposited in the United States mail or with a courier service for delivery to that person; or
(2) by facsimile transmission, e-mail or other electronic communication to the facsimile number or address for e-mail or other electronic communications supplied by the person to the Company for the purpose of notice, which notice shall be deemed to have been given to the person entitled thereto when sent.
If the Company has given a shareholder notice of the internet availability of proxy materials in a manner conforming with the rules of the SEC, the Company may give notice of the meeting to the shareholder by posting the notice on the internet website to which the proxy materials are posted.
(b)Waivers of Notice. No notice of any meeting of shareholders need be given to any shareholder entitled to notice who files an executed waiver of notice in record form with the Secretary of the Company, whether before or after the meeting. Neither the business to be transacted at, nor the purpose of, any meeting of the shareholders need be specified in a
2

waiver of notice. The attendance of any shareholder at a meeting of shareholders shall constitute a waiver of notice of such meeting, except when the shareholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business on the ground that the meeting is not lawfully called or convened.
(c)Notice of Adjournment. When a meeting of shareholders is adjourned, it shall not be necessary to give any notice of the adjourned meeting or of the business to be transacted at an adjourned meeting, other than by announcement at the meeting at which the adjournment is taken, unless the Board of Directors fixes a new record date for the adjourned meeting or required by applicable law.
Section 3.Voting.
(a)Votes. Except as otherwise provided in these Bylaws, in the Articles of Incorporation, or by applicable law, every shareholder shall have the right at every shareholders’ meeting to one vote for every share standing in his name on the books of the Company which is entitled to vote at such meeting. Every shareholder may vote either in person or by proxy. No shareholder shall be entitled to be present or participate, including voting and taking other action, in any meeting of shareholders by means of conference telephone or other electronic technology, unless provided by action of the Board of Directors.
(b)Proxies. Every shareholder entitled to vote at a meeting of shareholders or to express consent or dissent to corporate action without a meeting may authorize another person to act for him or her by proxy. Every proxy will be executed or authenticated in a manner permitted by Section 1759 of the PBCL (or any successor provision). Unless a proxy is a proxy coupled with an interest (as defined for purposes of Section 1759 of the PBCL (or any successor provision), a proxy shall be revocable at will notwithstanding any other agreement or any provision in the proxy to the contrary, but the revocation of a proxy shall not be effective until notice thereof has been given to the Secretary of the Company or its designated agent in writing or by electronic transmission. An unrevoked proxy shall not be valid after three years from the date of its execution, authentication or transmission unless a longer time is expressly provided therein. A proxy shall not be revoked by the death or incapacity of the maker unless, before the vote is counted or the authority is exercised, notice in record form of the death or incapacity is given to the Secretary of the Company or its designated agent. A shareholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or by filing another duly executed proxy bearing a later date with the Secretary of the Company.
(c)Proxy Card. Any shareholder directly or indirectly soliciting proxies from other shareholders must use a proxy card color other than white, which shall be reserved for the exclusive use of the Board of Directors.
(d)Voting List. The Company shall make a complete list of the shareholders entitled to vote at any meeting of shareholders, arranged in alphabetical order, with the address of and the number of shares held by each. The Company shall not be required to include electronic mail addresses or other electronic contact information of the shareholders on such list. The list shall be produced and kept open at the date, time and place, if any, of the meeting and shall be subject to the inspection of any shareholder during the whole time of the meeting for the purposes thereof except that the Company shall not be required to produce the list at a meeting of
3

shareholders for which a judge or judges of election are appointed but instead shall furnish the list to the judge or judges of election. Failure to comply with the requirements of this section shall not affect the validity of any action taken at a meeting prior to a demand at the meeting by any shareholder entitled to vote thereat to examine the list. The original share register, or a duplicate thereof kept in the Commonwealth of Pennsylvania, shall be prima facie evidence as to who are the shareholders entitled to examine the list or share register or to vote at any meeting of shareholders. If a meeting of shareholders is not held at a place, the Company shall make the list of shareholders available in a reasonably accessible manner.
Section 4.Quorum and Required Vote. Except as otherwise provided in these Bylaws, in the Articles of Incorporation, or by applicable law, the presence, in person or by proxy, of the holders of a majority of the outstanding shares of stock of the Company entitled to vote at a meeting shall constitute a quorum. If a quorum is not present, no business shall be transacted except to adjourn to a future time. In all matters other than the election of directors, the affirmative vote of the majority of shares [present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the shareholders]. Subject to the Articles of Incorporation, at each meeting of the shareholders for the election of directors at which a quorum is present, the persons receiving a majority of the votes cast at such election shall be elected; provided, however, that at any meeting of the shareholders for which the Secretary of the Company determines that the number of nominees for director exceeds the number of directors to be elected, directors shall be elected by a plurality of the votes of the shares represented in person or represented by proxy at such meeting and entitled to vote on the election of directors. For purposes of this Section 4, a majority of the votes cast means that the number of shares voted “for” a director must exceed the number of votes cast “against” that director. Votes cast shall include votes “for” and “against” a nominee but shall exclude “abstentions” and “broker non-votes” with respect to that nominee’s election. If a director is not elected, the director shall tender his or her resignation to the Board of Directors. The Board of Directors will publicly disclose its decision with respect to whether to accept or reject the resignation, or whether other action should be taken, and the rationale behind such decision within ninety (90) days from the date of the certification of the election results.
Section 5.Nomination of Directors.
(a)Notice Required. Nominations for election of directors at a meeting of shareholders may be made only (1) by or at the direction of the Board of Directors, (2) at an annual meeting or at a special meeting where the Board of Directors has determined that directors shall be elected at such meeting in accordance with Section 1(b) of Article I by a shareholder of record who (A) has complied with all applicable requirements of this Section 5 and Section 7 of Article I in relation to such nomination, (B) was a shareholder of record at the time of the giving of notice required by this Section 5, on the record date(s) for the determination of shareholders entitled to notice of and to vote at the meeting and is a shareholder of record at the time of the meeting, (C) is entitled to vote at the meeting and is present in person (as defined below) at such meeting and (D) has nominated a number of nominees that does not exceed the number of directors that will be elected at such meeting or (3) by a shareholder or group of shareholders of record in compliance with Section 8 of Article I. This Section 5, Section 7 and Section 8 of Article I of these Bylaws shall be the exclusive means for a shareholder to make nominations before a meeting of shareholders. If a shareholder is not present in person to present its nomination, such nomination shall be disregarded (notwithstanding that proxies or votes in respect of such proposal may have been solicited, obtained or delivered). For the avoidance of
4

doubt, a shareholder is not entitled to have its nomination included in the Company proxy materials solely as a result of such shareholder’s compliance with the provisions of this Section 5, except to the extent required by applicable law if such nominees are submitted in accordance and in compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”), and any other requirements of applicable state and federal law. For nominations to be properly brought before a meeting by a shareholder pursuant to this Section 5(a) such nominations must be made by such a shareholder by timely notice in proper written form (the “Nomination Notice”) of the shareholder’s intent to nominate a director at the meeting.
(b)Timely Notice; Proper Written Form.
(1)To be timely, the Nomination Notice shall be delivered to and received by the Secretary of the Company (A) in the case of an annual meeting, not less than [one hundred and twenty (120) days nor more than one hundred and fifty (150) days of the anniversary] of the date the Company commenced delivery of its proxy materials (as stated in such proxy materials) in connection with the most recent annual meeting of shareholders and (B) in the case of a special meeting, not later than the close of business on the later of the date that is sixty (60) days prior to such special meeting and the 10th calendar day following the day on which public disclosure of the date of such meeting is first made; provided, however, in the case of clause (A) or clause (B) of this Section 5(b)(1), that in the event less than 21 days’ notice or prior public disclosure of the date of the meeting is given to shareholders or made, the Nomination Notice shall be delivered to the Secretary of the Company not later than the earlier of (i) the seventh day following the day on which notice of the date of the meeting was first mailed to shareholders or such public disclosure was made, whichever occurs first, or (ii) the fourth day prior to the meeting. In no event shall the recess, adjournment or postponement of a meeting (or public disclosure thereof) commence a new time period (or extend any time period) for the giving of a Nomination Notice as described above. For the avoidance of doubt, a shareholder shall not be entitled to make additional or substitute nominations following the expiration of the time periods set forth in this Section 5(b)(1).
(2)To be in proper form, the Nomination Notice shall be in writing and shall contain or be accompanied by:
(A)the name and address (including, if applicable, the name and address as they appear on the Company’s books) of each Proposing Person;
(B)a representation and warranty that the shareholder delivering the Nomination Notice is a holder of record of the Company’s shares, intends to continue to hold such shares through the conclusion of such shareholders meeting and intends to appear in person at the meeting to nominate the person or persons specified in the Nomination Notice;
(C)as to each Proposing Person: (i) the number and class of the Company’s securities which are, directly or indirectly, owned beneficially or of record, by such Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or
5

series as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future, (ii) any “derivative security” (as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a “call equivalent position” (as such term is defined in Rule 16a-1(b) under the Exchange Act) and that is, directly or indirectly, held or maintained by such Proposing Person with respect to any shares of any class or series of shares of the Company, including, without limitation, any option, warrant, convertible security, stock appreciation right, or similar right or interest (including any derivative securities (as such term is defined in Rule 16a-1(c) under the Exchange Act) or other synthetic arrangement having the characteristics of a long position) which, assuming for purposes of these Bylaws, are presently exercisable, with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of the Company’s securities or with a value derived in whole or in part from the price, value, dividend or amount of dividend or volatility of any class or series of the Company’s securities, whether or not such instrument or right is subject to settlement, in whole or in part, in the underlying class or series of the Company’s securities or otherwise directly or indirectly held of record or owned beneficially by such Proposing Person and whether or not such Proposing Person may have entered into transactions that hedge or mitigate the economic effects of such security or instrument and any other direct or indirect opportunity, right or interest that may enable such Proposing Person to profit or share in any profit derived from, or to manage the risk or benefit from, any increase or decrease in the price, value, dividend or amount of dividend or volatility of the Company’s securities, in each case, regardless of whether (x) such right or interest conveys any voting rights in such security to such Proposing Person, (y) such right or interest is required to be, or is capable of being, settled through delivery of such security, or (z) such Proposing Person may have entered into other transactions that hedge the economic effect of any such right or interest (any such right or interest referred to in this clause (ii) being a “Derivative Instrument”); provided, however, that for the purpose of the term “Derivative Instrument,” the term “derivative security” shall also include any security or instrument that would not otherwise constitute a “derivative security” (as such term is defined in Rule 16a-1(c) under the Exchange Act) as a result of any feature that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination, or otherwise include rights with an exercise or conversion privilege that is not fixed; provided, further, that any shareholder satisfying the requirements of Rule 13d-1(b)(1) under the Exchange Act (other than a shareholder that so satisfies Rule 13d-1(b)(1) under the Exchange Act solely by reason of Rule 13d-1(b)(1)(ii)(e) under the Exchange Act) shall not be required to disclose a Derivative Instrument held by such shareholder as a hedge with respect to a bona fide
6

derivatives trade or position of such shareholder arising in the ordinary course of such shareholder’s business as a derivatives dealer, (iii) any proxy, contract, arrangement, understanding, or relationship pursuant to which any Proposing Person has a right to vote any shares of any security of the Company or which has the effect of increasing or decreasing the voting power of such person, (iv) any contract, agreement, arrangement, understanding or relationship, including any repurchase or similar so-called “stock borrowing” agreement or arrangement, including, without limitation, any short position or any borrowing or lending of shares of stock, the purpose or effect of which is to mitigate loss, reduce economic risk (of ownership or otherwise) or increase or decrease voting power with respect to any capital stock of the Company or which provides any party, directly or indirectly, the opportunity to profit or share in any profit derived from any decrease in the price or value of the capital stock of the Company, including, without limitation, any “put equivalent position” (as such term is defined in Rule 16a-1(h) under the Exchange Act) related to any shares of any class or series of shares of the Company (any of the foregoing, a ”Short Interest”), (v) any rights to dividends on the Company’s securities owned, directly or indirectly, beneficially or of record by such Proposing Person that are separated or separable from the underlying securities of the Company, (vi) any proportionate interest in the Company’s securities or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such Proposing Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, (vii) any performance-related fees (other than an asset-based fee) that such Proposing Person may be entitled to based on any increase or decrease in the value of the Company’s securities, Derivative Instruments or Short Interests, if any, as of the date of such notice, including without limitation any such interests held by members of such Proposing Person’s affiliate or immediate family sharing the same household, (viii) any material pending or threatened legal proceeding in which such Proposing Person or its affiliates is a party, material participant or has an interest (other than an interest that is substantially the same as all shareholders) involving the Company or its affiliates or its or their directors or officers, (ix) any direct or indirect interest (including a Derivative Instrument or Short Interest) of such Proposing Person in any contract or agreement with the Company, any affiliate of the Company or any significant competitor of the Company (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement) (provided that, solely for purposes of this clause (ix), references to the words “the Company” within the definitions of “Derivative Instrument” and “Short Interest” shall be replaced with the words “such affiliate” when such definitions pertain to “any affiliate of the Company” and “such competitor” when such definitions pertain to “any significant competitor of the Company”), (x) any other material relationship with such Proposing Person, on the one hand, and the Company, any affiliate of the Company or any significant competitor of the Company, on the other hand, (xi) any other information relating to such Proposing Person that would be required to be disclosed in a proxy
7

statement or other filings required to be made in connection with solicitations of proxies for the election of directors in a contested election pursuant to Section 14 of the Exchange Act, (xii) any other information that would be required to be set forth in a Schedule 13D filed pursuant to Rule 13d-1(a) under the Exchange Act or an amendment pursuant to Rule 13d-2(a) under the Exchange Act if such a statement were required to be filed under the Exchange Act by such Proposing Person, (xiii) a representation and warranty as to whether the shareholder(s) is a holder of record of the shares of the Company entitled to vote at such meeting, intends to continue to hold such shares through the conclusion of such shareholders meeting, and intends to be present in person at the meeting to propose such nomination, (xiv) a representation and warranty as to whether such Proposing Person intends or is part of a group which intends to (A) deliver a proxy statement and/or any form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to elect the nominee (and if so, the identity of such Proposing Person) and/or (B) otherwise engage in or be a participant in a “solicitation” (within the meaning of Rule 14a-1(l) under the Exchange Act) of proxies in support of such nomination (and if so, the identity of each participant (as such term is defined for purposes of Item 4 of Schedule 14A under the Exchange Act) in such solicitation); (xv) a representation and warranty regarding whether a Proposing Person or any other person with whom the Proposing Person is acting in concert intends to or will submit, or is part of a group that intends to or will submit, any other proposal at the meeting, and (xvi) a representation and warranty regarding whether the Proposing Person intends, or is part of a group that intends, to solicit proxies in support of director nominees other than the Company’s nominees in accordance with Rule 14a-19 under the Exchange Act, and, in the event that a Proposing Person so intends, or is part of a group that so intends, a written agreement (in the form provided by the Secretary of the Company upon written request), on behalf of such Proposing Person and any group of which it is a member, in which such Proposing Person acknowledges and agrees (w) that it, or the group of which it is a part, intends to solicit the holders of shares representing at least 67% of the voting power of the Company’s shares entitled to vote on the election of directors in support of such director nominees other than the Company’s nominees in accordance with Rule 14a-19(a)(3) under the Exchange Act, (x) that it shall notify the Secretary promptly if any change occurs with respect to the intent of such Proposing Person or the group of which such Proposing Person is a part to solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of directors in support of director nominees other than the Company’s nominees or with respect to the names of such Proposing Person’s nominees, (y) that if such Proposing Person or the group of which it is a part (1) provides notice pursuant to Rule 14a-19(a)(1) under the Exchange Act and (2) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) and Rule 14a-19(a)(3) under the Exchange Act (with respect to special meetings, if applicable), then the Company shall disregard any proxies or votes solicited for such Proposing Person’s nominees, and (z) that, upon request by the Company,
8

if such Proposing Person or the group of which it is a part provides notice pursuant to Rule 14a-19(a)(1) under the Exchange Act, such Proposing Person shall deliver to the Company, no later than 5 business days prior to the applicable meeting, reasonable documentary evidence (as determined by the Company or one of its representatives, acting in good faith) that it has met the requirements of Rule 14a-19(a)(3) under the Exchange Act;
(D)as to each proposed nominee (each, a “Prospective Nominee”): (i) his or her name, age, business address and, if known, residence address, (ii) his or her principal occupation or employment, (iii) information necessary to determine if such nominee is an “Independent Director” meeting the requirements of Section 10 of Article II of these Bylaws, (iv) all information with respect to such Prospective Nominee that would be required to be set forth in a Nomination Notice pursuant to Section 5(b)(2)(C) of Article I if the term “Prospective Nominee” were substituted for the term “Proposing Person” where it appears in such paragraph, (v) such other information regarding such nominee as would have been required to be included in a proxy statement filed pursuant to Regulation 14A of the Securities and Exchange Commission under the Exchange Act and Rule 14a-11 thereunder, had proxies been solicited with respect to such nominee by the management or Board of Directors of the Company, and (vi) a reasonably detailed description of all direct and indirect compensation, reimbursement, indemnification, benefits or and other agreements, arrangements and understandings (whether written or oral, formal or informal, or monetary or non-monetary) during the past three years, and any other material relationships, between or among any Proposing Person(s), on the one hand, and any of such Prospective Nominee, his or her respective affiliates or associates, or others acting in concert therewith, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 of Regulation S-K under the Exchange Act if the Proposing Person were the “registrant” for purposes of such rule and the Prospective Nominee were a director or executive officer of such registrant;
(E)a description of all arrangements or understandings among a Proposing Person and each Prospective Nominee and any other person or persons (naming such person or persons) pursuant to which the recommendation or recommendations or nomination or nominations are to be made by the Proposing Person;
(F)the consent of each Prospective Nominee to being named in proxy materials as a nominee and to serve as a director of the Company if so elected; and
(G)a completed and executed questionnaire, representation and agreement required by Section 9 of Article I.
9

The Company may require any Prospective Nominee to furnish such other information as may reasonably be required by the Company to determine the eligibility and qualifications of the nominee to serve as a director.
(c)Interviews. Upon written request by the Secretary of the Company, the Board of Directors or any duly authorized committee thereof, each Prospective Nominee shall, and such shareholder shall cause such Prospective Nominee to, make himself or herself available for interviews with the Board of Directors and any duly authorized committee thereof within five (5) business days of delivery of such request (or such other period as may be specified in such request).
(d)14a-19 Compliance. Without limiting the other provisions and requirements of this Section 5, unless otherwise required by applicable law, if any shareholder (A) provides notice pursuant to Rule 14a-19(a)(1) under the Exchange Act and (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) and Rule 14a-19(a)(3) under the Exchange Act (with respect to special meetings, if applicable), then the Company shall disregard any proxies or votes solicited for such shareholder’s nominees. Upon request by the Company, if any shareholder provides notice pursuant to Rule 14a-19(a)(1) under the Exchange Act, such shareholder shall deliver to the Company, no later than five (5) business days prior to the applicable meeting, reasonable documentary evidence (as determined by the Company or one of its representatives, acting in good faith) that it has met the requirements of Rule 14a-19(a)(3) under the Exchange Act.
Section 6.Notice of Business at Annual Meetings.
(a)Notice Required. At an annual meeting of shareholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be (1) (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (B) otherwise properly brought before the annual meeting by or at the direction of the Board of Directors or (C) properly brought before the annual meeting by a shareholder of record who (i) has complied with all applicable requirements of this Section 6 and Section 7 of Article I in relation to such business, (ii) was a shareholder of record at the time of the giving of notice required by this Section 6, on the record date(s) for the determination of shareholders entitled to notice of and to vote at the annual meeting and is a shareholder of record at the time of the annual meeting, (iii) is entitled to vote at the annual meeting and is present in person at such meeting, (iv) has given timely notice in proper written form (the “Business Notice”) of the shareholder’s intent to propose business at an annual meeting to the Secretary of the Company in accordance with this Section 6 and (2) (A) a proper matter for shareholder action under these Bylaws, the Articles of Incorporation and applicable law and (B) a matter not expressly reserved for action by the Board of Directors under these Bylaws, the Articles of Incorporation or applicable law. This Section 6 shall be the exclusive means for a shareholder to submit other business before an annual meeting of shareholders (other than matters properly brought under Rule 14a-8 of the Exchange Act and included in the notice of annual meeting (or any supplement thereto) given by or at the direction of the Board of Directors). If a shareholder is not present in person to present its proposal, such proposal shall be disregarded (notwithstanding that proxies or votes in respect of such proposal may have been solicited, obtained or delivered). For the avoidance of doubt, a shareholder is not entitled to have its proposal included in the Company
10

proxy materials solely as a result of such shareholder’s compliance with the provisions of this Section 6.
(b)Timely Notice; Proper Written Form
(1)To be timely, the Business Notice shall be delivered to the Secretary of the Company not less than one hundred and twenty (120) days nor more than one hundred and fifty (150) days prior to the anniversary of the date the Company commenced delivery of its proxy materials (as stated in such proxy materials) in connection with the most recent annual meeting of shareholders; provided, however, that in the event that less than 21 days’ notice or prior public disclosure of the date of the annual meeting is given to shareholders or made, the Business Notice shall be delivered to the Secretary of the Company not later than the earlier of (i) the seventh day following the day on which such notice of the date of the annual meeting was first mailed to shareholders or such public disclosure was made, whichever occurs first, or (ii) the fourth day prior to the annual meeting. In no event shall the recess, adjournment or postponement of an annual meeting (or public disclosure thereof) commence a new time period (or extend any time period) for the giving of a Business Notice as described above. For the avoidance of doubt, a shareholder shall not be entitled to make additional or substitute proposals following the expiration of the time periods set forth in this Section 6(b)(1).
(2)To be in proper form, the Business Notice shall be in writing and shall contain or be accompanied by the following as to each matter the shareholder proposes to bring before the annual meeting:
(A)a description in reasonable detail of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting;
(B)the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these Bylaws, the language of the proposed amendment);
(C)a description in reasonable detail of the reasons why such shareholder or any Proposing Person believes that the taking of the action proposed to be taken would be in the best interests of the Company;
(D)the name and address (including, if applicable, the name and address as they appear on the Company’s books) of each Proposing Person;
(E)a representation and warranty that the shareholder delivering the Business Notice is a holder of record of the Company’s shares, intends to continue to hold such shares through the conclusion of such annual meeting and intends to appear in person at the meeting to propose the business specified in the Business Notice;
11

(F)a description of any material direct or indirect interest (including a Derivative Instrument or Short Interest) of each Proposing Person, including any anticipated benefit to the shareholder or any other Proposing Person therefrom, in the business specified in the Business Notice and a description in reasonable detail of all agreements, arrangements and understanding between any Proposing Person and any other persons (including their names) in connection with the proposal of the business set forth in the Business Notice;
(G)as to each Proposing Person: (i) the number and class of the Company’s securities which are, directly or indirectly, owned beneficially or of record, by such Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future, (ii) any Derivative Instrument, (iii) any proxy, contract, arrangement, understanding, or relationship pursuant to which any Proposing Person has a right to vote any shares of any security of the Company or which has the effect of increasing or decreasing the voting power of such person, (iv) any Short Interest, (v) any rights to dividends on the Company’s securities owned, directly or indirectly, beneficially or of record by such Proposing Person that are separated or separable from the underlying securities of the Company, (vi) any proportionate interest in the Company’s securities or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such Proposing Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, (vii) any performance-related fees (other than an asset-based fee) that such Proposing Person may be entitled to based on any increase or decrease in the value of the Company’s securities, Derivative Instruments or Short Interests, if any, as of the date of such notice, including without limitation any such interests held by members of such Proposing Person’s affiliate or immediate family sharing the same household, (viii) any material pending or threatened legal proceeding in which such Proposing Person or its affiliates is a party, material participant or has an interest (other than an interest that is substantially the same as all shareholders) involving the Company its affiliates or its or their directors or officers, (ix) any direct or indirect interest (including a Derivative Instrument or Short Interest) of such Proposing Person in any contract or agreement with the Company, any affiliate of the Company or any significant competitor of the Company (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement) (provided that, solely for purposes of this clause (ix), references to the words “the Company” within the definitions of “Derivative Instrument” and “Short Interest” shall be replaced with the words “such affiliate” when such definitions pertain to “any affiliate of the Company” and “such competitor” when such definitions pertain to “any significant competitor of the Company”), (x) any other material relationship with such Proposing Person, on the one hand, and the Company, any affiliate of the Company or any significant competitor of the Company, on the other hand, (xi) any
12

other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the proposal, (xii) any other information that would be required to be set forth in a Schedule 13D filed pursuant to Rule 13d-1(a) under the Exchange Act or an amendment pursuant to Rule 13d-2(a) under the Exchange Act if such a statement were required to be filed under the Exchange Act by such Proposing Person, (xiii) a representation and warranty as to whether such Proposing Person is a holder of record of the shares of the Company entitled to vote at the annual meeting, intends to continue to hold such shares through the conclusion of such shareholders meeting, and intends to be present in person at the meeting to propose such business, (xiv) a representation and warranty as to whether such Proposing Person intends or is part of a group which intends to (A) deliver a proxy statement and/or any form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to approval the proposed business (and if so, the identity of such Proposing Person) and/or (B) otherwise engage in or be a participant in a “solicitation” (within the meaning of Rule 14a-1(l) under the Exchange Act) of proxies in support of such business (and if so, the identity of such participant (as such term is defined for purposes of Item 4 of Schedule 14A under the Exchange Act) in such solicitation); and (xv) a representation and warranty regarding whether a Proposing Person or any other person with whom the Proposing Person is acting in concert intends to or will submit, or is part of a group that intends to or will submit, any other proposal at the annual meeting.
Section 7.General Provisions Applying to Nomination of Directors and Notice of Business at Annual Meetings.
(a)Determination of Compliance. Only such persons who are nominated in accordance with the procedures set forth in Section 5 of Article I shall be eligible to be elected at a meeting of shareholders to serve as directors and only such business shall be conducted at an annual meeting of shareholders as shall have been brought before the annual meeting in accordance with Section 6 of Article I. Except as otherwise provided in these Bylaws, in the Articles of Incorporation or by applicable law, if a judge or judges of election shall not have been appointed pursuant to these Bylaws, the presiding officer of the meeting may, if the facts warrant, determine and declare to the meeting that any nomination made at the meeting or business brought before the meeting was not made in accordance with the procedures set forth in Section 5 of Article I or Section 6 of Article I, as applicable, and, in such event, the nomination or business shall be disregarded. Any decision by the judge or judges of election or the presiding officer of the meeting, as applicable, shall be conclusive and binding upon all shareholders of the Company for any purpose. In addition, a nomination or business proposed to be brought before a meeting by a shareholder pursuant to Section 5 or Section 6 of Article I, as applicable, may not be brought before a meeting if such shareholder or any Proposing Person takes action contrary to the representations and warranties made in the shareholder notice applicable to such nomination or business or if the applicable shareholder notice contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading, or if after being submitted to the Company, the shareholder notice was not updated in accordance with
13

these Bylaws to cause the information provided therein to be true, correct and complete in all respects.
(b)Required Updates. In addition, to be timely, a shareholder shall update and supplement its Nomination Notice or Business Notice to the Company, if necessary and as applicable, so that the information provided or required to be provided in such notice (including any information regarding any Proposing Person or Prospective Nominee) shall be true, correct and complete as of the record date(s) for the determination of persons entitled to receive notice of and to vote at the meeting and as of the date that is five (5) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to and received by the Secretary of the Company at the principal executive offices of the Company no later than two (2) business days after the record date(s) for the meeting in the case of the update and supplement required to be made as of the record date(s), and not later than two (2) business days prior to the date for the meeting, any adjournment or postponement thereof in the case of the update and supplement required to be made as of five (5) business days prior to the meeting or any adjournment or postponement thereof, and not later than two (2) business days after the occurrence of any event or development that would cause the information provided to be not true, correct and complete in all material respects. For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other section of these Bylaws shall not cure or limit the Company’s rights with respect to any deficiencies in any notice provided by a shareholder, extend any applicable deadlines hereunder or under any other provision of these Bylaws or enable or be deemed to permit a shareholder who has previously submitted notice hereunder, or under any other provision of these Bylaws, to amend or update any nomination or proposal or to submit any new proposal or nomination, including, without limitation, by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of shareholders. If a shareholder fails to provide such update and supplement within such period, the information as to which a written supplement was requested may be deemed not to have been provided in accordance with the requirements of these Bylaws.
(c)Requested Supplement. Upon written request by the Secretary of the Company, the Board of Directors or any duly authorized committee thereof, a shareholder submitting a Nomination Notice or Business Notice pursuant to Section 5 or Section 6 of Article I, respectively, proposing business or a nomination to be brought before a meeting shall provide, within five (5) business days of delivery of such request (or such other period as may be specified in such request), a written supplement, satisfactory in the reasonable discretion of the Board of Directors, to any duly authorized committee thereof or any duly authorized officer of the Company, to update the information (including any information submitted regarding any Proposing Person or Prospective Nominee) contained in any previously submitted notice and provide the disclosures required by Section 5 and Section 6 of Article I, as applicable, such that they are current and true, correct and complete as of the date that such supplement is submitted to the Secretary of the Company. If a shareholder fails to provide such written supplement within such period, the information as to which a written supplement was requested may be deemed not to have been provided in accordance with the requirements of these Bylaws.
(d)Verification of Information. Upon written request by the Secretary of the Company, the Board of Directors or any duly authorized committee thereof, a shareholder submitting a Nomination Notice or Business Notice pursuant to Section 5 or Section 6 of Article I, respectively, proposing business or a nomination to be brought before a meeting shall provide, within five (5) business days of delivery of such request (or such other period as may be
14

specified in such request), (A) written verification, satisfactory in the reasonable discretion of the Board of Directors, to any duly authorized committee thereof or any duly authorized officer of the Company to demonstrate the accuracy of any information submitted by the shareholder (including any information submitted regarding any Proposing Person or any Prospective Nominee) in the notice delivered pursuant to the requirements of these Bylaws (including, if requested, written confirmation by such shareholder that it continues to intend to recommend or bring the nomination proposed in the notice before the meeting) and (B) such other information reasonably required by the Secretary of the Company, the Board of Directors or any duly authorized committee thereof, acting in good faith, to determine compliance with these Bylaws by each Proposing Person or Prospective Nominee or the accuracy and completeness of any notice or solicitation given or made on behalf of a Proposing Person. If a shareholder fails to provide such written verification or other information within such period, the information as to which written verification or other information was requested may be deemed not to have been provided in accordance with the requirements of these Bylaws.
(e)Cross References. For a Nomination Notice or Business Notice pursuant to Section 5 or Section 6 of Article I to comply with the requirements of Section 5 or Section 6 of Article I, respectively, each of the requirements of Section 5 or Section 6 of Article I shall be directly and expressly responded to in a manner that clearly indicates and expressly references to which provisions of Section 5 or Section 6 of Article I the information disclosed is intended to be responsive. Information disclosed in one section of the notice in response to one provision of these Bylaws shall not be deemed responsive to any other provision of these Bylaws unless it is expressly cross-referenced to such other provision and it is clearly apparent on its face how the information included in one section of the notice is directly and expressly responsive to the information required to be included in another section of the notice pursuant to Section 5 or Section 6 of Article I, as applicable. For the avoidance of doubt, statements purporting to provide global cross-references that purport to provide that all information provided shall be deemed to be responsive to all requirements of Section 5 or Section 6 of Article I, as applicable, shall be disregarded and shall not satisfy the applicable requirements.
(f)Incorporation by Reference. For a Nomination Notice or Business Notice pursuant to Section 5 or Section 6 of Article I to comply with the requirements of Section 5 or Section 6 of Article I, respectively, it must set forth in writing directly within the body of the notice (as opposed to being incorporated by reference from any other document or writing not prepared solely in response to the requirements of these Bylaws) all the information required to be included therein as set forth in Section 5 or Section 6 of Article I. A notice shall not be deemed to be in compliance with Section 5 or Section 6 of Article I, as applicable, if it attempts to include the required information by incorporating by reference into the body of the notice any other document, writing or part thereof, including, but not limited to, any documents publicly filed with SEC not prepared solely in response to the requirements of these Bylaws. For the further avoidance of doubt, the body of the notice shall not include any documents that are not prepared solely in response to the requirements of these Bylaws.
(g)Representation Regarding Information. A shareholder submitting a Nomination Notice or Business Notice pursuant to Section 5, Section 6 or this Section 7 of Article I, by its delivery to the Company, represents and warrants to the Company that all information contained therein (including any information regarding any Proposing Person or Prospective Nominee), as of the deadline for submitting the notice, is true, correct and complete in all respects, contains no false or misleading statements and such shareholder acknowledges
15

that it intends for the Company and the Board of Directors to rely on such information as (A) being true, correct and complete in all respects and (B) not containing any false or misleading statements. If the information submitted pursuant to Section 5, Section 6 or this Section 7 of Article I, by any shareholder proposing a nomination or business to be brought before a meeting shall not be true, correct and complete in all respects prior to the deadline for submitting the notice, such information may be deemed not to have been provided in accordance with Section 5 or Section 6 of Article I, as applicable, and this Section 7 of Article I.
(h)Certain Defined Terms. For purposes of these Bylaws:
(1)“acting in concert” means a person who knowingly acts (whether or not pursuant to an express agreement, arrangement or understanding) in concert with, or towards a common goal relating to management, governance or control of the Company in parallel with, another person where each person is conscious of the other person’s conduct or intent and this awareness is an element in their decision-making processes and at least one additional factor suggests that such persons intend to act in concert or in parallel, which such additional factors may include, without limitation, exchanging information (whether publicly or privately), attending meetings, conducting discussions or making or soliciting invitations to act in concert or in parallel; provided, however, that a person shall not be deemed to be acting in concert with any other person solely as a result of the solicitation or receipt of revocable proxies from such other person in response to a solicitation made pursuant to and in accordance with Section 14(a) of the Exchange Act by way of a proxy statement filed on Schedule 14A; provided further, that a person deemed to be acting in concert with another person shall be deemed to be acting in concert with any third party who is also acting in concert with such other person;
(2)“present in person” means, for purposes of Section 5, Section 6 and this Section 7 of Article I only, that the shareholder of record proposing that the nomination or business, as applicable, be brought before the meeting or, if the proposing shareholder is not an individual, a qualified representative of such shareholder, appear at such meeting;
(3)“Proposing Person” means (A) the shareholder delivering a Nomination Notice or Access Nomination Notice (as defined below), as applicable, or a Business Notice, (B) the beneficial owner(s), if any, on whose behalf such notice is delivered, (C) any “Affiliate” or “Associate” (in each case, within the meaning of Rule 12b-2 under the Exchange Act) of such beneficial owner or shareholder, (D) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A of the Exchange Act or any successor instructions) with such shareholder or beneficial owner in the solicitation of proxies in respect of such proposed nomination or business and (E) any other person with whom such shareholder or beneficial owner (or any of their respective Affiliates or Associates) is acting in concert;
(4)“public disclosure” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Company with the SEC pursuant to Section 13, 14 or 15(d) of the Exchange Act; and
16

(5)“qualified representative” means a person who is a duly authorized officer, manager or partner of the proposing shareholder or authorized by a writing executed by such shareholder (or a reliable reproduction or electronic transmission of the writing) delivered to the Company prior to the meeting and stating that such person is authorized to act for such shareholder as proxy at the meeting.
(i)Other Requirements. Notwithstanding the foregoing provisions of Section 5, Section 6 and Section 7 of Article I, a shareholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder (including Rule 14a-19) and the PBCL with respect to the matters set forth in Section 5, Section 6 and Section 7 of Article I. Nothing in Section 5, Section 6 or Section 7 of Article I shall be deemed to affect any rights of a shareholder to request inclusion of proposals in the Company’s proxy statement pursuant to Rule 14a-8 under the Exchange Act. Subject to Rule 14a-8 under the Exchange Act, nothing in these Bylaws shall be construed to permit any shareholder, or give any shareholder the right, to include or have disseminated or described in the Company’s proxy statement any nomination of director or directors or any other business proposal.
Section 8.Proxy Access.
(a)Whenever the Board of Directors solicits proxies with respect to the election of directors of the Company at an annual meeting of shareholders, the Company shall include in the proxy statement distributed on behalf of the Board of Directors for such annual meeting the information specified below (the “Required Information”) with respect to (i) the Access Eligible Shareholder (as defined below) proposing to make a nomination for a director of the Company and who expressly elects at the time of providing the notice required by this Section 8 (the “Access Nomination Notice”) to have its nominee included in the Company’s proxy materials pursuant to this Section 8, (ii) and the nominee to be nominated (an “Access Nominee”); provided that the Access Nomination Notice complies with the other requirements of the Articles of Incorporation, these Bylaws and all applicable laws or regulations. The Required Information shall be (w) the name of the Access Nominee (which shall also be included on the Company’s form of proxy and ballot), (x) all information concerning the Access Nominee and the Access Eligible Shareholder required to be disclosed in the Company’s proxy statement under the rules and regulations of the Exchange Act, these Bylaws, the Articles of Incorporation and applicable law, (y) if the Access Eligible Shareholder so elects, a statement (the “Statement”) of not more than 500 words in support of the nomination that shall comply with Section 14 of the Exchange Act and (z) any other information that the Company or the Board of Directors determines, in their sole discretion, to include in the proxy statement relating to the nomination of the Access Nominee, including, without limitation, any statement in opposition to the nomination and any of the information provided to the Company pursuant to this Section 8.
(b)The Company shall not be required to provide access to the Company’s proxy materials with respect to any annual meeting of shareholders for more than the Maximum Number (as defined below) of Access Nominees. Any Access Eligible Shareholder submitting more than one Access Nominee for inclusion in the Company’s proxy materials pursuant to this Section 8 shall rank such Access Nominees based on the order that the Access Eligible Shareholder desires such Access Nominees to be selected for inclusion in the Company’s proxy statement in the event that the total number of Access Nominees submitted by Access Eligible Shareholders pursuant to this Section 8 exceeds the Maximum Number. If there are more than the Maximum Number of nominations for which access to the Company’s proxy materials has
17

been sought in compliance with this Section 8, the highest ranking Access Nominee who meets the requirements of this Section 8 from each Access Eligible Shareholder will be selected for inclusion in the Company’s proxy materials until the Maximum Number is reached, going in order of the amount (largest to smallest) of shares of the Company each Access Eligible Shareholder disclosed as Owned in its respective Access Nomination Notice submitted to the Company. If the Maximum Number is not reached after the highest ranking Access Nominee who meets the requirements of this Section 8 from each Access Eligible Shareholder has been selected, this selection process will continue with the next highest ranked nominees as many times as necessary, following the same order each time, until the Maximum Number is reached. Following such determination, if any Access Nominee who satisfies the eligibility requirements in this Section 8 (i) thereafter withdraws from the election (or his or her nomination is withdrawn by the applicable Access Eligible Shareholder) or (ii) is thereafter not submitted for director election for any reason (including the failure to comply with this Section 8) other than due to a failure by the Company to include such Access Nominee in the proxy materials in violation of this Section 8, no other nominee or nominees (other than any Access Nominee already determined to be included in the Company’s proxy materials who continues to satisfy the eligibility requirements of this Section 8) shall be included in the Company’s proxy materials or otherwise submitted for director election pursuant to this Section 8.
(c)The Company shall not be required to provide access to the Company’s proxy materials with respect to any annual meeting of shareholders if it receives timely notice pursuant to Section 5(b)(1) of Article I that any Proposing Person proposes (or multiple Proposing Persons propose) to nominate (i) a Prospective Nominee for election with respect to which such access is not being requested or (ii) if another person is engaging in a “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act or any successor rule against a nominee of the Board of Directors.
(d)In order for the Access Nominee to be eligible for election at the annual meeting and the Required Information about such nominee of an Access Eligible Shareholder to be included in the Company’s proxy materials, the following requirements must be satisfied:
(1)The nomination must be made pursuant to a timely Access Nomination Notice to the Secretary of the Company. For such Access Nomination Notice to be deemed timely given, an Access Eligible Shareholder must first notify the Company that such Access Eligible Shareholder intends to nominate an Access Nominee, and all of the information required by this Section 8 as well as Section 5(b)(2) of Article I must be received by the Secretary of the Company at the Company’s principal executive offices not less than one hundred and twenty (120) days nor more than one hundred and fifty (150) days prior to the anniversary of the date the Company commenced mailing of its proxy materials (as stated in such proxy materials) in connection with the most recent annual meeting of shareholders. In no event shall the recess, adjournment or postponement of an annual meeting (or public disclosure thereof) commence a new time period (or extend any time period) for the giving of an Access Nomination Notice as described above.
(2)The Access Nomination Notice shall contain or be accompanied by the following, which shall be received by the Secretary of the Company within the time period specified in this Section 8 for providing the Access Nomination Notice: (i) the name and address of the Access Eligible Shareholder and, if applicable, each member of
18

a group of persons constituting an Access Eligible Shareholder, and an express election to have its Access Nominee included in the Company’s proxy materials pursuant to this Section 8; (ii) clauses (w) – (y) of the Required Information; (iii) a statement certifying the number of shares the Access Eligible Shareholder (and each member of a group of persons constituting the Access Eligible Shareholder) is deemed to Own and has Owned continuously for the three year period prior to the Submission Date (as defined below) of the Access Nomination Notice for the purposes of this Section 8, which statement shall also be included in the Schedule 14N filed with the SEC; (iv) to the extent that an Access Eligible Shareholder (or any member of a group of persons constituting an Access Eligible Shareholder) is not or has not been continuously the holder of record of the shares of the Company that are being used to satisfy the requisite Minimum Ownership (as defined below) and Minimum Holding Period (as defined below) requirements to establish its or their status as an Access Eligible Shareholder, (A) one or more written statements from the holder of record of the shares (and from each intermediary through which each such person derives, or during the Minimum Holding Period has derived, Ownership of such shares) verifying that, as of a date within seven (7) calendar days preceding the Submission Date, each such person Owns such shares and has Owned at least Minimum Ownership continuously for at least the Minimum Holding Period, and (B) an agreement to provide, within five (5) business days after the record date for determining shareholders entitled to vote at the annual meeting of shareholders, written statements from the holder of record and intermediaries verifying the continuous ownership of the Access Eligible Shareholder (including each member of a group of persons constituting an Access Eligible Shareholder) of such shares through and including such record date; (v) a representation and undertaking by the Access Eligible Shareholder (including each member of a group of persons constituting an Access Eligible Shareholder) that it, its Access Nominee and each of its and its Access Nominee’s affiliates and associates: (A) intends to continue to Own the shares satisfying the Minimum Ownership through the conclusion of the annual meeting of shareholders; (B) has not nominated and will not nominate for election to the Board of Directors at the annual meeting of shareholders any individual other than its Access Nominee(s); (C) has not engaged and will not engage in, and has not and will not be a “participant” (within the meaning of Instruction 3 to Item 4 of Schedule 14A under the Exchange Act or any successor rule) in, a “solicitation” (within the meaning of Rule 14a-1(l) under the Exchange Act or any successor rule, without reference to the exception in Section14a-1(l)(2)(iv)) in support of the election of any individual as a director at the annual meeting of shareholders other than its named Access Nominee or a nominee of the Board of Directors; and (D) will not distribute to any shareholder any form of proxy for the annual meeting of shareholders other than the form distributed by the Company; (vi) a representation and undertaking by the Access Eligible Shareholder (including each member of a group of persons constituting an Access Eligible Shareholder) that it acquired the shares Owned, including the requisite number of shares qualifying the Access Eligible Shareholder to submit an Access Nominee, in the ordinary course of business and that (x) as of the Submission Date and (y) at all times until the election of directors at the annual meeting of shareholders, in each case neither it nor the Access Nominee nor any affiliates and associates of it or its Access Nominee Owns or shall Own, as applicable, any securities of the Company for the purpose, or with the effect, of changing or influencing the control of the Company, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction referred to in Rule 13d-3(b) under the Exchange Act or any successor rule, other than
19

solely by reason of seeking the election as a director of its named Access Nominee; (vii) a representation and undertaking by the Access Eligible Shareholder (including each member of a group of persons constituting an Access Eligible Shareholder) that: (A) the Access Eligible Shareholder agrees to comply with all applicable laws and regulations with respect to any solicitation in connection with the annual meeting of shareholders or applicable to the filing and use, if any, of soliciting material; (B) it will provide facts, statements and other information in all communications with the Company and its shareholders that are and will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading, and will promptly provide any other information reasonably requested by the Company, including, without limitation, to evidence or support any such facts, statements or other information; and (C) it will file with the SEC any solicitation or other communication with any of the Company’s shareholders relating to the annual meeting of shareholders at which the Access Nominee will be nominated, regardless of whether any such filing is required under Regulation 14A of the Exchange Act or whether any exemption from filing is available thereunder; (viii) an undertaking by the Access Eligible Shareholder (including each member of a group of persons constituting an Access Eligible Shareholder) acknowledging its responsibility for the Required Information, all other information submitted to the Company pursuant to this Section 8 and all of its and its Access Nominee’s communications to shareholders in connection with the election of directors at the annual meeting of shareholders. In such undertaking, the Access Eligible Shareholder (including each member of a group of persons constituting an Access Eligible Shareholder) shall: (A) expressly assume all liability to which the Company or any of its affiliates, or any director, officer, employee or representative thereof, may be subject as a result of any legal or regulatory violation arising out of any such information or communication made available by or on behalf of the Access Eligible Shareholder or any of its affiliates or its Access Nominee to the Company or to any shareholder of the Company in connection with the election of directors at the annual meeting of shareholders; and (B) agree to indemnify and hold harmless the Company and any of its affiliates, and any director, officer, employee or representative thereof, individually against any liability, loss or damage in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against any such person arising out of or based upon any nomination, solicitation or other activity by the Access Eligible Shareholder in connection with its efforts to elect the Access Nominee pursuant to this Section 8; (ix) if the Access Nomination Notice is submitted by a group of persons that together constitute an Access Eligible Shareholder, an agreement executed by all members of such group (A) designating one group member that is authorized to act on behalf of all members of the group with respect to the nomination and any and all matters related thereto, including withdrawal of the nomination; and (B) acknowledging and agreeing that the undertaking, as well as the assumption of liability and indemnification obligations set forth in paragraph (d) (2) (viii) of this Section 8 shall apply to each member of such group on a joint and several basis; (x) a statement of whether or not the Access Eligible Shareholder (including each member of any group of persons constituting an Access Eligible Shareholder) intends to maintain the Minimum Ownership for at least one year following the annual meeting (subject to any mandatory fund rebalancing required by such person’s preexisting governing instruments or written investment policies); (xi) a copy of the Schedule 14N (or any successor form thereto) that has been filed with the SEC as required by Rule 14a-18 under the Exchange Act or any successor
20

rule; (xii) consent of the Access Nominee to being named in the proxy materials and as a nominee, and to serving as a director and acting as a representative of all shareholders if elected, and all information, agreements and undertakings by each Access Nominee that would be required to be provided by a Prospective Nominee who is nominated pursuant to Section 5 of Article I (other than that required by Section 5(b)(2)(C)(xvi) of Article I of these Bylaws and representations to be made relating to the requirements of Rule 14a-19 under the Exchange Act), and any other information reasonably requested by the Company, including, without limitation, to evidence or support any facts, statements or other information; (xiii) a representation and undertaking by the Access Nominee that such nominee (A) is and will continue to be Independent (as defined below), (B) is not a Disqualified Repeat Nominee (as defined below), (C) is not, and continues not to be, a Disqualified Person (as defined below), (D) is and will continue to be in compliance with the Company’s Corporate Governance Principles to the extent applicable to directors and director nominees and (E) is not and will not become a party to any agreement, arrangement, or understanding with any person other than the Company with respect to any direct or indirect compensation, reimbursement, or indemnification in connection with service or action as a director; (xiv) the details of any position of the Access Nominee as an officer or director of any competitor (that is, any entity that produces products or provides services that compete with are alternatives to the products produced or services provided by the Company or its affiliates) that does not result in such Access Nominee to become a Disqualified Person or significant supplier, customer or counterparty of the Company within the three years preceding the Submission Date; (xv) any other information, representations and agreements that are the same as those that would be required to be set forth in a Nomination Notice pursuant to Section 5 of Article I (including, without limitation a completed and executed questionnaire, representation and agreement required by Section 8 of Article I) and (xvi) the Statement.
(3)The Access Nominee shall meet and shall continue to meet the criteria set forth in Section 8(d) (2) (xiii) of Article I.
(4)Neither the Access Nominee nor the applicable Access Eligible Shareholder (including none of the members of any group of persons constituting an Access Eligible Shareholder) shall have provided information to the Company in respect to such nomination that was untrue in any material respect or omitted to state a material fact necessary in order to make the statement made, in light of the circumstances under which they were made, not misleading, as determined by the Board of Directors or any committee thereof.
(5)Each of the Access Nominee and the applicable Access Eligible Shareholder (including each of the members of any group of persons constituting an Access Eligible Shareholder) shall not have failed to comply with its agreements, representations, undertakings and other obligations pursuant to these Bylaws, including, but not limited to, this Section 8.
(6)The information and documents required by this Section 8(d) shall be (i) provided with respect to and executed by each Access Eligible Shareholder or, in the case of an Access Eligible Shareholder comprised of a group of persons, each member in that group; and (ii) provided with respect to the persons specified in Instruction 1 to Items 6(c) and (d) of Schedule 14N (or any successor item) in the case of
21

an Access Eligible Shareholder or, in the case of an Access Eligible Shareholder comprised of a group of persons, each member in that group. A breach of any obligation, agreement or representation in or pursuant to this Section 8 by any member of such group or any Access Nominee shall be deemed a breach by the Access Eligible Shareholder. The Access Nomination Notice shall be deemed submitted on the date on which all the information and documents referred to in this Section 8(d) (other than such notices, confirmations, information and documents contemplated to be provided after the date the Access Nomination Notice is provided) have been delivered to or, if sent by mail, received by the Secretary of the Company (the “Submission Date”).
(e)Notwithstanding anything to the contrary herein, the Company may omit from its proxy materials any information or statement (including the Statement) that it, in good faith, believes (1) is untrue in any material respect (or omits to state a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading), (2) would violate or cause the Company to violate these Bylaws, the Articles of Incorporation or any applicable law, regulation or listing standard, or (3) directly or indirectly impugns the character, integrity or personal reputation of, or directly or indirectly makes charges concerning improper, illegal or immoral conduct or associations, without factual foundation, with respect to any person.
(f)The Access Eligible Shareholder and its Access Nominee shall each provide to the Company prompt written notice of:
(1)any material error recognized by the Access Eligible Shareholder or its Access Nominee in, or any change in circumstances that makes incorrect or misleading in any material respect (collectively, an “error”), the information previously provided by the Access Eligible Shareholder or its nominee in the Access Nomination Notice or otherwise provided to the Company or to its shareholders in connection with the nomination, and the information that is required to correct any such error (it being understood that providing any such notification shall not be deemed to cure any such error or limit the remedies (including, without limitation, under these Bylaws) available to the Company relating to any such error); or
(2)any material change in its Ownership of shares of the Company occurring since the Submission Date and before the election of directors at the annual meeting; provided, without limiting the generality of the foregoing, that any failure to satisfy the Minimum Ownership requirement shall constitute a material change.
(g)If the Board of Directors nominates an Access Nominee as part of the Board of Directors’ slate of nominees, the notice provided pursuant to this Section 8 will be deemed withdrawn and the former Access Nominee shall be presented to the shareholders at the annual meeting in the same manner as any other nominee of the Board of Directors, except that the Access Nominee shall be considered a director for whom access to the Company’s proxy materials was provided for all purposes of these Bylaws, including the determination of the Maximum Number of Access Nominees.
(h)If, after the deadline for submitting an Access Nomination Notice as set forth in Section 8(d)(1) of Article I, (i) an the Board of Directors (acting in good faith) determines or the Company is notified the Access Eligible Shareholder becomes ineligible to
22

nominate a director for inclusion in the Company’s proxy materials pursuant to this Section 8, any of the representations and warranties made in the Access Nomination Notice ceases to be true and accurate in all material respects (or omits a material fact necessary to make the statement not misleading), any material violation or breach occurs of the obligations, agreements, representations or warranties of the Access Eligible Shareholder or the Access Nominee under this Section 8, or withdraws such nomination, (ii) an Access Nominee withdraws from or becomes unwilling, ineligible or unavailable for election at the meeting or to serve on the Board of Directors for any reason or to be named in the Company’s proxy materials pursuant to this Section 8, (iii) the Company receives a notice pursuant to Section 5 of Article I that a shareholder has nominated or intends to nominate a candidate for director at the annual meeting or (iv) the Access Eligible Shareholder or the designated lead group member, as applicable, or any qualified representative thereof, does not appear at the meeting of shareholders to present the nomination submitted pursuant to this Section 8, in each case whether before or after the mailing of a definitive proxy statement, including for the failure to comply with any provision of these Bylaws (provided that in no event shall any such ineligibility, withdrawal, unwillingness or unavailability commence a new time period (or extend any time period) for the giving of an Access Nomination Notice), then the nomination of any Access Nominee by a person described in clause (i) of this paragraph, and of any Access Nominee described in clause (ii) of this paragraph, shall be disregarded, and the Company (x) shall not be required to include in its proxy statement or on any ballot or form of proxy the disregarded Access Nominee or any successor or replacement nominee and (y) may otherwise communicate to shareholders, including by amending or supplementing its proxy statement or ballot or form of proxy, that any such Access Nominee will not be included as a nominee in the proxy statement or on any ballot or form of proxy and will not be voted on at the annual meeting. No other nominee may be substituted by the Access Eligible Shareholder that nominated any such Access Nominee.
(i)Except as otherwise provided by law, the Articles of Incorporation or these Bylaws, if a judge or judges of election shall not have been appointed pursuant to these Bylaws, the presiding officer of the meeting shall, if the facts warrant, determine and declare that (i) a nomination was not made in accordance with the procedures prescribed by this Section 8, (ii) an Access Nominee is ineligible to be named in the Company’s proxy materials pursuant to this Section 8 or to be considered for election at the meeting, or (iii) an Access Nominee and/or the applicable Access Eligible Shareholder shall have breached its or their representations, undertakings, agreements or obligations under or pursuant to this Section 8, and in each such case, the judge or judges of election or the presiding officer of the meeting, as applicable, shall so declare at the meeting and the nomination shall be disregarded notwithstanding that proxies in respect of the nomination of the relevant Access Nominee may have been received by the Company. Any decision by the judge or judges of election or the presiding officer of the meeting, as applicable, shall be conclusive and binding upon all shareholders of the Company for any purpose.
(j)This Section 8 shall be the exclusive method for shareholders or Access Eligible Shareholders to include nominees for director in the Company’s proxy materials (other than inclusion in the Company’s form of proxy pursuant to Rule 14a-19 of the Exchange Act). Nothing in Section 8 shall be deemed to affect any rights of a nominee to be included in the Company’s form of proxy pursuant to and in accordance with Rule 14a-19 under the Exchange Act. Notwithstanding anything to the contrary contained in this Section 8, the Company may solicit against, and include in the proxy statement and any supplemental proxy materials its own statements relating to, any Access Nominee.
23

(k)For purposes of these Bylaws, the following definitions shall apply:
(1)An “Access Eligible Shareholder” shall mean a person (or a group of not more than twenty (20) persons formed for the purpose of seeking access pursuant to this Section 8; provided that a group of funds that are (i) under common management and investment control, or (ii) under common management and funded primarily by the same employer, or (iii) a “group of investment companies,” as such term is defined in Section 12(d) (1) (G) (ii) of the Investment Company Act of 1940, as amended, shall be treated as one person for this purpose if the Access Eligible Shareholder provides, no later than the deadline for submitting the Access Nomination Notice pursuant to Section 8(d)(1) of Article I, documentation reasonably satisfactory to the Company to evidence the same) who or which has continuously Owned 3% or more of the outstanding shares of the Company as of the most recent date for which such number is disclosed by the Company in any filing by the Company with the SEC prior to submission of the Access Nomination Notice (the “Minimum Ownership”) continuously for a minimum of three full years prior to and as of the Submission Date (the “Minimum Holding Period”) and continue(s) to Own at least the same amount of securities so owned by such person or group of persons through the record date for the annual meeting of shareholders and the date of the annual meeting of shareholders.
For purposes of this Section 8, persons who jointly nominate an individual for election as a director shall be considered an Access Eligible Shareholder only if they have agreed in writing to so act, are so identified in the Access Nomination Notice and the information and the undertakings required by this Section 8 for an Access Eligible Shareholder are provided by and with respect to each such person. For the avoidance of doubt, for purposes of determining if persons who claim jointly to satisfy the Minimum Ownership and Minimum Holding Period requirements for an Access Eligible Shareholder, only the common shares of the Company Owned by any member of a group continuously for at least three full years shall be aggregated with the common shares Owned continuously for three years by each other person acting jointly to constitute an Access Eligible Shareholder. A record holder acting on behalf of a beneficial owner will not be counted separately as a shareholder with respect to the shares owned by beneficial owners on whose behalf such record holder has been directed in writing to act, but each such beneficial owner will be counted separately as a member of such group, subject to the other provisions of this Section 8. No person may be a member of more than one group of persons constituting an Access Eligible Shareholder with respect to any annual meeting of shareholders and if any person appears as a member of more than one group, then it shall be deemed to be a member of the group that has the largest amount of shares of the Company disclosed as owned in the Access Nomination Notice.
(2)A “Disqualified Person” means a nominee (i) whose election as a member of the Board of Directors, or inclusion of such nominee in the Company’s proxy materials, would cause the Company to be in violation of these Bylaws, the Articles of Incorporation, the rules and listing standards of the principal U. S. exchange upon which the shares of the Company are traded, or any applicable state or federal law, rule or regulation; (ii) who is or has been, within the past three (3) years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914; (iii) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past ten
24

(10) years; or (iv) who is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933, as amended, or any successor rule;
(3)A “Disqualified Repeat Nominee” in respect of an annual meeting of shareholders shall mean an individual as to whom access to the Company’s proxy materials was provided pursuant to this Section 8 for either of the two most recent annual meetings of shareholders and (i) who withdrew from or became unwilling, ineligible or unavailable for election at the meeting or to serve on the Board of Directors for any reason or (ii) received at such meeting votes in favor of his or her election representing less than 25% of the total votes cast with respect to his or her election. For the avoidance of doubt, neither this Section 8(k)(3) nor Section 8(d)(2)(iii) of Article I shall prevent any shareholder from nominating any person to the Board of Directors pursuant to and in accordance with Section 5 of Article I.
(4)“Independent” with respect to an Access Nominee shall mean that the nominee would be considered an independent director in accordance with the listing standards of the principal U. S. exchange upon which the shares of the Company trade, any applicable rules of the SEC and any additional publicly disclosed standards used by the Board of Directors or a duly authorized committee thereof in determining and disclosing the independence of the Company’s directors in accordance with the rules of the Securities and Exchange Commission, such principal U. S. exchange or otherwise.
(5)The “Maximum Number” of Access Nominees for an annual meeting of shareholders shall be that number of directors constituting the greater of (x) two or (y) 20% of the total number of directors in office as of the deadline for submitting an Access Nomination Notice as set forth in Section 8(d)(1) of Article I (rounded down to the nearest whole number). In the event that one or more vacancies for any reason occurs after such date but before the date of the annual meeting of shareholders and the size of the Board of Directors is reduced in connection therewith, the Maximum Number shall be calculated based on the number of directors in office as so reduced. The Maximum Number shall be reduced by any of the following, whether occurring before or after the deadline for submitting an Access Nomination Notice: (i) any person who is or will be nominated by the Board of Directors pursuant to Section 8(g) of Article I; (ii) the number of directors in office on such date who were nominated at any of the three most recent annual meetings of shareholders pursuant to this Section 8 (including by the Board of Directors pursuant to Section 8(g) of Article I) or pursuant to Section 5 of Article I, other than such directors whose term of office will expire at such annual meeting of shareholders and who is not seeking (or agreeing) to be nominated at such meeting for another term of office; (iii) any person who is nominated by an Access Eligible Shareholder pursuant to this Section 8 but whose nomination is subsequently withdrawn or who becomes unwilling, ineligible or unavailable for election at the meeting, to serve as a director for any reason or to be named in the Company’s proxy materials pursuant to this Section 8; or (iv) any person who is or will be nominated by the Board of Directors pursuant to an agreement, understanding or arrangement with one or more shareholders or group of shareholders (other than any agreement, understanding or arrangement entered into in connection with an acquisition of shares of the Company, by such shareholder or group of shareholders, from the Company).
25

(6)“Ownership” (and its correlative terms “Owned,” “Owning” and other variations of the word “Own”), when used to describe the nature of a person’s ownership of shares of the Company, shall mean those outstanding shares of common stock of the Company (“common shares”) as to which the person in question possesses (i) the full unhedged power to vote or direct the voting of such shares, (ii) the full unhedged economic incidents of ownership of such shares (including the full right to profits and the full risk of loss), and (iii) the full unhedged power to dispose of or direct the disposition of such shares; provided that the number of shares calculated in accordance with clauses (i), (ii) and (iii) shall not include any shares (x) sold by such person or any of its affiliates in any transaction that has not been settled or closed, including any short sale, or purchased by such person or any of its affiliates but the purchase has not settled or closed, (y) borrowed by such person or any of its affiliates for any purposes or purchased by such person or any of its affiliates pursuant to an agreement to resell or subject to any other obligation to resell to another person, or (z) subject to any option, warrant, forward contract, swap, contract of sale, other derivative or other agreement or understanding entered into by such person or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding common shares of the Company, in any such case which instrument or agreement has, or is intended to have, or if exercised would have, the purpose or effect of (A) reducing in any manner, to any extent or at any time in the future, such person’s or affiliates’ full rights to vote or direct the voting and full rights to dispose or direct the disposition of any of such shares, and/or (B) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of such shares by such person or affiliate. A person shall “Own” shares held in the name of a nominee or other intermediary so long as the person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. A person’s Ownership of shares shall be deemed to continue during any period in which the person has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement which is revocable at any time by the person. A person’s Ownership of shares shall be deemed to continue during any period in which the person has loaned such shares, provided, that the person has the power to recall such loaned shares on five (5) business days’ notice, and recalls such shares promptly upon being notified by the Company that the applicable Access Nominee will be included in the proxy materials.
Section 9.Submission of Questionnaire, Representation and Agreement. To be eligible to be a nominee for election or reelection as a director of the Company, a person must deliver (in accordance with the time periods prescribed for delivery of notice pursuant to Sections 5 or 8 of Article I, as applicable) to the Secretary of the Company at the principal executive offices of the Company a completed and executed written questionnaire (the form of which questionnaire shall be provided by the Secretary upon written request) with respect to the background and qualification of such person and the background of any Proposing Person on whose behalf, directly or indirectly, the nomination is being made, and an executed written representation and agreement (the form of which shall be provided by the Secretary upon written request) that such person (a) is qualified and if elected intends to serve as a director of the Company for the entire term for which such nominee is standing for election, (b) is not, at the time of election will not be, and during his or her service as a director of the Company will not become, a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director
26

of the Company, will act or vote on any issue or question (1) that has not been disclosed to the Company or (2) that could limit or interfere with such person’s ability to comply, if elected as a director of the Company, with such person’s fiduciary duties under applicable law, (c) is not, at the time of election will not be, and during his or her service as a director of the Company will not become, a party to any agreement, arrangement or understanding with any person or entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein, (d) has disclosed to the Company any and all potential and actual conflicts of interest with the Company, and (e) if elected as a director of the Company, would be in compliance with, and at all times during his or her service as a director will remain in compliance with, in such person’s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and stock trading policies and guidelines of the Company.
ARTICLE II
DIRECTORS
Section 1.Number and Term. Subject to the provisions of the Articles of Incorporation and of applicable law, (a) the Board of Directors shall have the exclusive authority by action of the Board of Directors to determine the number of directors to constitute the board, and (b) the directors shall be elected to hold office until the next annual meeting of shareholders of the Company, or until the earlier of his or her death, resignation, disqualification or removal from office.
Section 2.Powers. The business of the Company shall be managed by the Board of Directors, which shall have all powers conferred by applicable law and these Bylaws. The Board of Directors shall elect, remove or suspend officers, determine their duties and compensations, and require security in such amounts as it may deem proper.
Section 3.Chair of the Board. The Board of Directors shall elect one of its members to be the Chair of the board (“Chair of the Board”) for such term of office as the Board of Directors shall determine, but no longer than a one-year term. [The Chair of the Board may not be elected to serve more than four annual terms in succession, unless he or she is an employee of the Company or as otherwise determined by Board of Directors.] The Chair of the Board may be removed at any time with or without cause by the affirmative vote of a majority of the entire Board of Directors. The Chair of the Board may be an Independent Director (as defined below) and shall not be deemed to be an officer of the Company unless he or she is an employee of the Company. The Chair of the Board shall preside at all meetings of the Board of Directors and act as the presiding officer at all meetings of the shareholders, in each case, at which he or she is present and shall have such other powers and duties as may from time to time be assigned by the Board of Directors. The Chair of the Board shall make reports to the Board of Directors and the shareholders and shall see that all orders and actions of the board and any committees thereof are carried into effect. In the absence of the Chair of the Board, a director selected by a majority of the Board of Directors shall discharge the duties of the Chair of the Board.
Section 4.Committees. The Board of Directors shall establish and maintain a Compensation Committee, a Nominating and Governance Committee and an Audit Committee
27

and may establish such other committees as it shall deem appropriate. Each such committee shall consist of one or more directors and shall have such powers and duties as the Board of Directors shall determine. Any committee, to the extent provided in an action by the Board of Directors, shall have and may exercise all of the powers and authority of the Board of Directors, subject to applicable law and Article VII of these Bylaws.
Section 5.Meetings.
(a)Regular Meetings. Regular meetings shall be held at such times as the board shall designate by action of the Board of Directors. Notice of regular meetings need not be given.
(b)Special Meetings. Special meetings of the board may be called at any time by the Chair of the Board or the President and shall be called by him or her upon the written request of one-third of the entire Board of Directors. Notice of the time and place of each special meeting shall be given to each director at least 24 hours (in the case of notice by telephone) or at least two days (in the case of notice by other means) before such meeting in a manner permitted by Section 1702 of the PBCL (or any successor provision).
(c)Place. Meetings of the Board of Directors shall be held at such place, within or without the Commonwealth of Pennsylvania, as the board may designate or as may be designated in the notice calling the meeting.
(d)Participation. One or more directors may participate in a meeting of the board or a committee of the board by means of conference telephone or other electronic technology by means of which all persons participating in the meeting can hear each other. Participation in a meeting pursuant to this Section 5(d) shall constitute presence at the meeting.
(e)Rules. The Board of Directors may adopt rules and regulations for the conduct of meetings and the oversight and management of the affairs of the Company.
Section 6.Quorum and Required Vote. A majority of all the directors in office shall constitute a quorum for the transaction of business at any meeting and the acts of a majority of the directors present at any meeting at which a quorum is present shall be the acts of the Board of Directors.
Section 7.Action by Written Consent. Any action required or permitted to be taken at a meeting of the directors may be taken without a meeting by a consent or consents thereto in record form executed before, on or after the effective time by all of the directors in office at the effective time. Such consent may provide, or a person executing a consent, whether or not then a director, may instruct in record form that the consent will be effective at a future time, including a time determined upon the happening of an event. In the case of a consent executed by a person not a director at the time of execution, the consent is effective at the stated effective time if the person who executed the consent is a director at the effective time and did not revoke the consent in record form prior to the effective time. A consent is effective at the stated effective time even if one or more signatory is no longer directors at the effective time unless the consent has been revoked by a signatory who is a director at the effective time. A signatory of a consent may revoke the signatory’s consent in record form until the consent becomes effective.
28

Section 8.Vacancies. Vacancies on the Board of Directors, including vacancies resulting from an increase in the number of directors, shall be filled only by a majority of the directors then in office, though less than a quorum, and each person so elected shall be a director to serve for the balance of the unexpired term and until his successor is duly elected and qualified. When one or more directors resign from the Board of Directors effective at a future date, the directors then in office, including those who have so resigned, shall have power by the applicable vote to fill the vacancies, the vote thereon to take effect when the resignations become effective.
Section 9.Resignation. Any director may resign at any time upon notice in record form to the Company. The resignation shall be effective upon receipt thereof by the Company or at such subsequent time as shall be specified in the notice of resignation.
Section 10.Independent Directors.
(a)Definition of Independent Director. For purposes of these Bylaws, the term “Independent Director” shall mean a director who qualifies as independent in accordance with the Independence tests set forth in Section 303A.02 of the New York Stock Exchange’s Listed Company Manual, as amended. Notwithstanding the foregoing, the ownership of equity or debt securities of the Company, or derivatives thereof, shall not by itself disqualify any person from being classified as an Independent Director.
(b)Interpretation and Application of This Bylaw. The Board of Directors shall have the exclusive right and power to interpret and apply provisions of this Section 10, including, without limitation, the definitions of terms used in and guidelines for the application of this Section 10. In the case of any such interpretation or application to a specific person which results in such person being classified as an Independent Director, the Board of Directors shall have determined that such person is independent of management and free from any relationship that, in the opinion of the Board of Directors, would interfere with such person’s exercise of independent judgment as a board member. Each director has a duty to disclose all circumstances that may have a bearing on his or her classification as an Independent Director.
(c)Duties of Independent Directors. Independent Directors shall have the following special duties and responsibilities:
(1)to evaluate, periodically and at least annually, the performance of the chief executive officer of the Company, including, among other things, a determination of the manner in which he or she is fulfilling responsibilities to directors, shareholders, employees, customers and other constituencies.
(2)to assure that the chief executive officer has appropriate leadership succession plans for the Company; and
(3)to review and monitor achievement of the chief executive officer’s long-range strategic plans for the Company.
(d)Lead Independent Director. The Board of Directors may, in its discretion, elect from the Independent Directors one director to be the lead independent director, whose term shall be annual[, but who may not be elected to serve more than four annual terms in succession].
29

The lead independent director, if any, shall preside at all meetings of Independent Directors and, in addition, shall have such other duties and responsibilities as may be assigned to him or her from time to time by the Board of Directors.
Section 11.Compensation. The Board of Directors has the authority to fix the compensation of the directors for their services as directors, regardless of the personal interests of the directors, and if the Board of Directors establishes the compensation of directors pursuant to this Section 11 that action is presumed to be fair to the Company. A director may be a salaried officer of the Company. Directors will be reimbursed for their expenses of attendance at any meeting of the Board of Directors or any committee thereof.
Section 12.Limitation on Liability. A director shall not be personally liable for monetary damages for any action taken on or after January 27, 1987, or for the failure to take any action on or after the date, unless (i) the director has breached or failed to perform the duties of his office under Section 8363 of the Pennsylvania Directors’ Liability Act (Act 145 of 1986, P. L. 1458), relating to standard of care and justifiable reliance, and (ii) the breach or failure to perform constitutes self-dealing, willful misconduct or recklessness. The provisions of this Section 8 shall not apply to (i) the responsibility or liability of a director pursuant to any criminal statute, or (ii) the liability of a director for the payment of taxes pursuant to local, state or federal law. Any repeal or modification of any provision of this Section 8 of Article II shall be prospective only and shall not affect, to the detriment of any director, any limitation on the personal liability of a director of the Company existing at the time of such repeal or modification.
ARTICLE III
OFFICERS
Section 1.Election. At its first meeting after each annual meeting of shareholders, the Board of Directors shall elect a president, a treasurer, a secretary, a controller and such other officers as it deems advisable. Any two or more offices may be held by the same person.
Section 2.Removal. Any officer or other agent of the Company may be removed by the Board of Directors with or without cause. The removal shall be without prejudice to the contract rights, if any, of any person so removed. Election or appointment of an officer or agent shall not, of itself, create contract rights.
Section 3.Vacancies. A vacancy in any office because of the death, resignation, removal, disqualification or any other cause shall be filled by the Board of Directors or by the officer or committee to which the power to fill such office has been delegated.
Section 4.President. Except as the Board of Directors may otherwise prescribe by action of the Board of Directors, the president shall be the chief executive officer of the Company and shall have general supervision over the business and operations of the Company and may perform any act and execute any instrument or other papers for the conduct of such business and operations, and shall have all the other powers and duties as are usually related to the chief executive officer of a corporation and such other powers and duties as may be from time to time assigned by the Board of Directors.
30

Section 5.Other Officers. The duties and powers of the other officers shall be those usually related to their offices or as may be designated by the president, except as otherwise prescribed by action of the Board of Directors.
Section 6.General. In the absence of the president or any other officer or officers designated by the board shall exercise the powers and perform the duties of the president. The president, or any officer or employee authorized by him or her, may appoint, remove or suspend agents or employees of the Company, other than officers appointed by the board, and may determine their duties and compensation.
ARTICLE IV
INDEMNIFICATION
Section 1.Right to Indemnification. The Company shall indemnify to the fullest extent permitted by applicable law (as the same exists or may hereafter be amended, but in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than such applicable law permitted the Company to provide prior to such amendment), any person (such person, an “Indemnitee”) who was or is a party (which shall include for purposes of this Article IV the giving of testimony or similar involvement), is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, investigative, including any and all appeals, by reason of the fact that he or she is or was a director or officer of the Company or while serving as a director or officer of the Company is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including an employee benefit plan, or by reason of any action alleged to have been taken or omitted by such Indemnitee in any such capacity or in any other capacity while serving as a director, officer, employee or agent, from and against any loss and liability suffered and penalty, damages, excise tax assessed with respect to an employee benefit plan, costs, expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action, suit or proceeding, including any appeals, whether or not the indemnified liability arises or arose from any threatened, pending or completed action by or in the right of the Company. The Board of Directors may, and on request of any Indemnitee shall be required to, determine in each case whether indemnification is proper under applicable law, or such determination shall be made by independent legal counsel selected by the board if the board so directs or if the board is not empowered by law to make such determination. If there has been a change in control (as such term is used in Item 6(a) of Schedule 14A promulgated by the Securities and Exchange Commission under the Exchange Act) of the Company between (1) the time of the action or failure to act giving rise to the claim for indemnification and (2) the time such claim is made, at the option of the Indemnitee seeking indemnification the permissibility of indemnification shall be determined by independent legal counsel selected jointly by the Company and the Indemnitee seeking indemnification. The fees and expenses of such counsel shall be paid by the Company. The obligations of the Company to indemnify an Indemnitee under this Article IV, including the duty to advance expenses, shall be a contract between the Company and such person, and no modification or repeal of any provision of this Article IV shall affect, to the detriment of the director, officer, employee or agent such obligations of the Company in connection with a claim based on any act or failure to act occurring before such modification or repeal.
31

Section 2.Advancement of Expenses. In addition to the right to indemnification pursuant to Section 1 of Article IV, an Indemnitee shall also have the right, to the fullest extent permitted by applicable law (as the same exists or may hereafter be amended) to be paid by the Company expenses (including attorney’s fees, costs and expenses) incurred by the Indemnitee in appearing at, participating in and defending, or otherwise arising out of or related to, an action, suit or proceeding for which such Indemnitee may be entitled to indemnification under this Article IV in advance of the final disposition of such action, suit or proceeding subject, if required by applicable law, to receipt of an undertaking by or on behalf of the indemnified person to repay such amount if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such person is not entitled to be indemnified by the Company as authorized in this Article IV or otherwise or found that such Indemnitee is not entitled to be indemnified by the Company as authorized in this Article IV or otherwise pursuant to applicable law. With respect to any indemnifiable proceeding for which an Indemnitee requests advancement of expenses under this Section 2, the Company shall be entitled, in its sole discretion, to assume the defense of such action, suit or proceeding, with counsel reasonably acceptable to the Indemnitee, upon the delivery to indemnitee of prior written notice of its election to do so.
Section 3.Indemnification Not Exclusive. The indemnification and advancement of expenses provided by this Article IV shall not be deemed exclusive of any other right to which one indemnified may be entitled under any agreement, vote of shareholders or otherwise, both as to action in his official capacity and as to action in another capacity while holding that office, and shall inure to the benefit of the heirs, executors and administrators of any such person.
Section 4.Insurance, Security and Other Indemnification. The Board of Directors shall have the power to (a) authorize the Company to purchase and maintain, at the Company’s expense, insurance on behalf of the Company and others to the extent that power to do so has not been restricted by applicable law, (b) create any fund of any nature, whether or not under the control of a trustee, or otherwise secure in any manner any of its indemnification obligations and (c) give other indemnification to the extent not prohibited by applicable law.
Section 5.Indemnification of Employees and Agents. The Company may provide indemnification and advancement of expenses to any employee or agent of the Company to the full extent of this Article IV.
ARTICLE V
CERTIFICATES OF STOCK
Section 1.Share Certificates. Any or all classes and series of shares of the Company, or any part thereof, may be represented by uncertificated shares to the extent determined by the Board of Directors, except as otherwise required by applicable law or the Articles of Incorporation. To the extent a shareholder of record holds any shares not represented by uncertificated shares, such shareholder shall be entitled to a share certificate representing such shares held by him or her. To the extent that share certificates for the Company are issued, each such share certificate shall bear the corporate seal and the signature (which may be a facsimile signature) of the Chair of the Board, president or a vice president and the Secretary of the Company or an assistant secretary or treasurer of the Company.
32

Section 2.Transfers. Shares of stock of the Company shall be transferable on the books of the Company only upon written instructions to the Company (or through its duly authorized transfer agent) by the registered holder or by such register holder’s duly authorized attorney, and, with respect to certificated shares of stock, only upon surrender of such share certificate(s), properly endorsed by the registered holder or by such register holder’s duly authorized attorney.
Section 3.Record Holder. The Company shall be entitled to treat the person in whose name any share or shares of the Company stand on the books of the Company as the absolute owner thereof, and shall not be bound to recognize any equitable or other claim to, or interest in, such share or shares on the part of any other person.
Section 4.Lost, Destroyed or Mutilated Certificates. The holder of any shares of the Company shall immediately notify the Company of any loss, destruction or mutilation of the certificate therefor, and the Board of Directors may, in its discretion, cause a new certificate or certificates to be issued to the holder, in case of mutilation of the certificate, upon the surrender of the mutilated certificate or, in case of loss or destruction of the certificate, upon satisfactory proof of the loss or destruction and, if the Board of Directors shall so determine, the deposit of a bond in such form and in such sum, and with such surety or sureties, as it may direct.
ARTICLE VI
CERTAIN MATTERS RELATING TO
PENNSYLVANIA ACT NO. 36 OF 1990
In accordance with the provisions of Section 2571(b) (2) (I) of the Pennsylvania Associations Code, as amended, Subchapter H, Disgorgement by Certain Controlling Shareholders Following Attempts to Acquire Control, of Chapter 25 of the Pennsylvania Associations Code shall not be applicable to the Company.
ARTICLE VII
AMENDMENTS
Except as restricted by applicable law, the authority to adopt, amend and repeal the Bylaws of the Company is expressly vested in the Board of Directors, subject to the power of the shareholders to change such action. These Bylaws may be changed at any regular or special meeting of the Board of Directors by the vote of a majority of all the directors in office. The authority, powers and functions of the Board of Directors may not be varied, and a committee of the Board of Directors may not be established, by a Bylaw adopted by the shareholders unless such Bylaw has been adopted with the approval of the Board of Directors.
33
 EX-31.1 3 ex311q32023.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION

I, Eric M. Green, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer, Chair of the Board of Directors

Date: October 26, 2023

EX-31.2 4 ex312q32023.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION

I, Bernard J. Birkett, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer

Date: October 26, 2023

EX-32.1 5 ex321q32023.htm EX-32.1 Document

EXHIBIT 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer, Chair of the Board of Directors

Date: October 26, 2023

 EX-32.2 6 ex322q32023.htm EX-32.2 Document

EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President, Chief Financial and Operations Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer

Date: October 26, 2023


 EX-101.SCH 7 wst-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Other Expense (Income) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Other Expense (Income) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Revenue - Contracts and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Net Income Per Share - Schedule of Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Net Income Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Lease Weighted Average (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Affiliated Companies (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Other Expense (Income) - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Other Expense (Income) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 wst-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 wst-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 wst-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Debt Debt Disclosure [Text Block] Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Share Unit (PSUs) Performance Shares [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Derivative Instruments Not Designated as Hedges Derivatives Not Designated as Hedging Instruments [Table Text Block] Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Interest (income) expense and other nonoperating (income) expense, net Nonoperating Income (Expense) Commitments and contingencies (Note 17) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Year five Lessee, Operating Lease, Liability, to be Paid, Year Five Target award percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Shareholders' Equity Equity [Text Block] Pension settlement charge Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Inventory write-down Inventory Write-down Change in deferred income - decrease (increase) Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Geographical [Axis] Geographical [Axis] Tax benefit from termination of pension plans Effective Income Tax Rate Reconciliation Termination Of Pension Plan Amount Effective Income Tax Rate Reconciliation Termination Of Pension Plan Amount International plans Foreign Plan [Member] Income Taxes Income Tax Disclosure [Text Block] Dividend yield (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Effective income tax rate reconciliation tax benefit Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding Preferred Stock, Value, Issued Intersegment sales elimination Intersegment Eliminations [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Dividend payments Payments of Ordinary Dividends, Common Stock Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted (in dollars per share) Earnings Per Share, Diluted Series C notes, due July 5, 2027 (4.02%) Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Foreign currency contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock, at cost (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stock options, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Stock options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Long-term debt, fair value Long-Term Debt, Fair Value Net loss on equity affiliate accumulated other comprehensive income, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract Type [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] All Currencies [Domain] All Currencies [Domain] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Amounts reclassified out from accumulated other comprehensive (loss) income Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Deferred income, December 31, 2022 Deferred income, September 30, 2023 Deferred income Contract with Customer, Liability Cash flow hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Derivative, nonmonetary notional amount, volume Derivative, Nonmonetary Notional Amount, Volume Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Schedule of Reconciliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of goods and services sold Cost of goods and services sold Cost of Goods and Services Sold Service cost Defined Benefit Plan, Service Cost Executive Category: Executive Category [Axis] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Foreign currency hedge contracts Foreign currency contracts Foreign Exchange Contract [Member] Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Defined benefit pension and other postretirement plan adjustments, net of tax of $0.0, $14.6, $(0.5), and $15.5, respectively Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Name Forgone Recovery, Individual Name Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Shares available for issuance under the 2016 Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Amount excluded from effectiveness testing Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Generics Generics Customers [Member] Generics Customers [Member] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Restructuring and related charges (Credits) Charges Restructuring and Related Cost, Incurred Cost Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Derivative, notional amount Derivative, Notional Amount Operating lease liabilities Operating Lease, Liability, Noncurrent Retirement Plan Type [Domain] Retirement Plan Type [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Debt issuance costs Payments of Debt Issuance Costs Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Pension and other postretirement benefits Liability, Defined Benefit Plan, Noncurrent Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Foreign Exchange Forward Foreign Exchange Forward [Member] Net sales Revenues Income taxes payable Accrued Income Taxes, Current Product and Service [Domain] Product and Service [Domain] Repayments of long-term debt Repayments of Other Long-Term Debt Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Lease Expense Lease, Cost [Table Text Block] Domestic Plan Domestic Plan [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Balance, December 31, 2022 Balance, September 30, 2023 Restructuring Reserve Award Type [Axis] Award Type [Axis] Recognized in earnings, pre-tax, for forward point Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest expense Interest Expense Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Property, plant and equipment Property, Plant and Equipment, Gross Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Fair value and net investment hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Trading Arrangement: Trading Arrangement [Axis] Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Contributions by employer Defined Benefit Plan, Plan Assets, Contributions by Employer PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Expected return on assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Non-cash asset write downs Restructuring Reserve, Settled without Cash Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Operating lease liabilities Operating Lease, Liability, Current Derivative contract term Derivative, Term of Contract Change in equity affiliate investment AOCI AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Amortization of acquisition-related intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Year three Lessee, Operating Lease, Liability, to be Paid, Year Three Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent SGD Singapore, Dollars New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Other Operating Income (Expense) Other Operating Income (Expense) [Member] Stock repurchase program, average price per share (in dollars per share) Shares Acquired, Average Cost Per Share Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Year two Lessee, Operating Lease, Liability, to be Paid, Year Two Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Weighted average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Gross profit Gross Profit Benefit within other expense (income) for revised severance estimates Severance Costs Deferred income, current Contract with Customer, Liability, Current Treasury stock, at cost (1.3 million and 1.2 million shares, respectively) Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total assets at fair value Assets, Fair Value Disclosure Total debt Long-Term Debt Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Settlements Settlements Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Geographic Concentration Risk Geographic Concentration Risk [Member] Tabular List, Table Tabular List [Table Text Block] Short-term lease cost Short-Term Lease, Cost Cross-currency swap Currency Swap [Member] Europe, Middle East, Africa EMEA [Member] Entity Address, Address Line One Entity Address, Address Line One Stock purchase program, cost of shares purchased Shares purchased under share repurchase program Treasury Stock, Value, Acquired, Cost Method Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items, net Other Noncash Income (Expense) High-Value Product Delivery Devices Standard Packaging [Member] Standard Packaging [Member] Derivative [Table] Derivative [Table] Customer Concentration Risk Customer Concentration Risk [Member] Other current liabilities Amount due to affiliates Other Liabilities, Current Change in contract assets - increase (decrease) Contract With Customer, Asset, Increase (Decrease) Contract With Customer, Asset, Increase (Decrease) Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Title of each class Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Actuarial gains Recognized actuarial losses (gains) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Restructuring and related activities, period of implementation Restructuring and Related Activities, Period of Implementation Restructuring and Related Activities, Period of Implementation Related Party, Type [Domain] Related Party, Type [Domain] Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Activity related to stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other current assets Amount receivable from affiliates Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Other expense (income) Foreign Currency Gain (Loss) [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Carrying amount, equity-method investments Equity Method Investments Inventories Total inventories Inventory, Net Total lease cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Number of loss on disposal manufacturing facility Number of Manufacturing Facilities Sold Number of Manufacturing Facilities Sold Contract-Manufactured Products Contract Manufactured Products [Member] Contract Manufactured Products [Member] Contract-Manufactured Products Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Total Shareholder Return Amount Total Shareholder Return Amount Shares purchased under share repurchase programs Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Effect on future earnings, amount Effect on Future Earnings, Amount Yen Japan, Yen Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Segment [Domain] Segments [Domain] Deferred compensation assets Deferred Compensation Plan Assets Notes payable and other current debt Notes Payable and Other Debt, Current Notes Payable and Other Debt, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Short Short [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Operating cash flows from operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Commodity call options Commodity Option [Member] Interest cost Defined Benefit Plan, Interest Cost Gain (loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] PEO PEO [Member] Benefit Plans Retirement Benefits [Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustments, net of tax of $0.4, $1.1, $1.9 and $3.8, respectively Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Reclassification Out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Net gain (loss) on derivatives, net of tax of $0.8, $0.0, $(0.3) and $(0.8), respectively Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Total lease liabilities Operating Lease, Liability Credit Facility [Axis] Credit Facility [Axis] Total Liabilities Liabilities Stock volatility (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Deferred income, noncurrent Contract with Customer, Liability, Noncurrent Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Defined benefit pension and other postretirement plans Amortization of defined benefit pension and other postretirement plans: Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Schedule of Other Expense (Income) Schedule Of Other Income And Expense, By Component [Table Text Block] Schedule Of Other Income And Expense, By Component Related Party Transaction [Domain] Related Party Transaction [Domain] Number of reportable segments Number of Reportable Segments Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Hedged item (intercompany loan) Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Affiliated Entity Affiliated Entity [Member] Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.1 million, respectively Common Stock, Value, Issued Forward treasury locks Treasury Lock [Member] Corporate general costs General and Administrative Expense Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] USD United States of America, Dollars Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Interest income Investment Income, Net Investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Asset impairments Asset Impairment Charges Contingent consideration Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Amortization Amortization Other nonoperating (income) expense Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Current Fiscal Year End Date Current Fiscal Year End Date New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Derivative designated as hedging instrument Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments PEO Name PEO Name Percentage of net sales Concentration Risk, Percentage Asia Pacific Asia Pacific [Member] Schedule of Components of Accumulated Other Comprehensive Income ("AOCI") (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Other retirement benefits Other Postretirement Benefits Plan [Member] Employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Currency Forwards Forward Contracts [Member] Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Term Loan, due December 31, 2024 (6.37%) Term Loan Due 2024 [Member] Term Loan Due 2024 Other expense (income) Other Income Corporate and Unallocated Corporate, Non-Segment [Member] Product Concentration Risk Product Concentration Risk [Member] Changes in assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Other items Other Operating Income (Expense), Net EUR Euro Member Countries, Euro Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Total Equity Beginning balance Ending balance Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other Defined Benefit Plan, Other Cost (Credit) Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] High-Value Product Components High-Value Components [Member] High-Value Components [Member] (Losses) gains on derivatives Gains (losses) on derivatives: Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Eric M. Green [Member] Eric M. Green Other Expense (Income) Other Income and Other Expense Disclosure [Text Block] Carrying amount, investments not accounted for under the equity method Equity Securities without Readily Determinable Fair Value, Amount Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Pharma Pharma Customers [Member] Pharma Customers [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Net Investment Hedges: Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Year one Lessee, Operating Lease, Liability, to be Paid, Year One Line of credit facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Year four Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Stock-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Position [Domain] Position [Domain] Common Stock Common Stock [Member] Stock options, granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Individual: Individual [Axis] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Net Income Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total Gain (Loss) on Fair Value Hedges Recognized in Earnings Minimum Minimum [Member] Property, plant and equipment, net Property, Plant and Equipment, Net Exercise Price Award Exercise Price Gain (loss) on oil hedges (Gain) loss on oil hedges Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Net sales Net Sales [Member] Net sales member Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Dividends declared Dividends, Common Stock, Cash ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Total liabilities at fair value Liabilities, Fair Value Disclosure Foreign exchange transaction losses (gains) Gain (Loss), Foreign Currency Transaction, before Tax Derivative, average price risk option strike price Derivative, Average Price Risk Option Strike Price Shares repurchased for employee tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred income taxes Deferred Income Tax Assets, Net Retirement Plan Type [Axis] Retirement Plan Type [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Other, net Payments for (Proceeds from) Other Investing Activities Retained earnings Retained Earnings [Member] Less: current portion of long-term debt Long-Term Debt, Current Maturities Revolving credit facility, Due 2024 Revolving credit facility, due 2024 [Member] Revolving credit facility, due 2024 [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] 2022 Restructuring Plan 2022 Restructuring Plan [Member] 2022 Restructuring Plan Schedule of Segment Information Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total Liabilities and Equity Liabilities and Equity Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Foreign currency translation adjustments, tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Currency [Axis] Currency [Axis] Remainder of fiscal year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Restructuring and related cost, expected cost Restructuring and Related Cost, Expected Cost Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] SmartDose SmartDose [Member] SmartDose [Member] Restructuring and other charges Restructuring Charges Accrued salaries, wages and benefits Accrued Salaries, Wages, and Benefits, Current Accrued Salaries, Wages, and Benefits, Current Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest expense Interest Expense [Member] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Americas Americas [Member] Contract-Manufactured Products Delivery Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Standard Packaging Delivery Devices [Member] Delivery Devices [Member] Commodity call options Other Assets, Fair Value Disclosure Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Long-Term Debt, Gross Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other expense (income) (Note 15) Total other expense (income) Other Income (Expense) The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. All Adjustments to Compensation All Adjustments to Compensation [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Capital in excess of par value Additional Paid in Capital Restructuring Plan [Axis] Restructuring Plan [Axis] Proceeds from stock-based compensation awards Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Cost investment impairment Cost Investment Impairment Cost Investment Impairment Long-term debt, current Debt, Current Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Related Party, Type [Axis] Related Party, Type [Axis] Activity related to stock -based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive effect of equity awards, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Options Held Options Held [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Cost of goods and services sold Cost of Sales [Member] Severance and benefits Employee Severance [Member] Cash payments Payments for Restructuring Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Loss on disposal of plant Loss on disposal of plant Gain (Loss) on Disposition of Property Plant Equipment Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Tax (expense) benefit Provision for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument Designated as Hedging Instrument [Member] Deferred compensation benefits Deferred Compensation Liability, Classified, Noncurrent Fair Value Measurements Fair Value Disclosures [Text Block] Other charges Other Restructuring [Member] Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Other comprehensive (loss) income, net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Series B notes, due July 5, 2024 (3.82%) Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Equity: Equity [Abstract] Inventories Inventory Disclosure [Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Net sales Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Distributorship Agreement Distributorship Agreement [Member] Distributorship Agreement Amendment Flag Amendment Flag Fair Value Hedges: Fair Value Hedging [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Assets: Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Share purchased under share repurchase program (in shares) Treasury Stock, Shares, Acquired Defined benefit pension and other postretirement plan adjustments, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt Long-term debt, net Long-Term Debt, Excluding Current Maturities Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Schedule of Change in Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Net gain (loss) on derivatives, tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Revenue Revenue from Contract with Customer [Text Block] Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Capital in Excess of Par Value Additional Paid-in Capital [Member] Total Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Deferred compensation liabilities Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent Equity in net income of affiliated companies Income (Loss) from Equity Method Investments Cover [Abstract] Position [Axis] Position [Axis] U.S. plans UNITED STATES Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Operating leases liabilities payments due Lessee, Operating Lease, Liability, to be Paid Related party transaction, purchases from related party Related Party Transaction, Purchases from Related Party Pension benefits Pension Plan [Member] Cash Flow Hedges: Cash Flow Hedging [Member] Segment Information Segment Reporting Disclosure [Text Block] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Income before income taxes and equity in net income of affiliated companies Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Proprietary Products Packaging Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Contract assets, December 31, 2022 Contract assets, September 30, 2023 Contract with Customer, Asset, after Allowance for Credit Loss Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Less: unamortized debt issuance costs Unamortized Debt Issuance Expense Operating profit Operating profit Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Long Long [Member] Biologics Biologics Customers [Member] Biologics Customers [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Schedule of Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Long-term Debt Obligations, Net of Unamortized Debt Issuance Costs and Current Maturities Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Long-term line of credit Long-Term Line of Credit Schedule of Supplemental Cash Flow Information Related to Leases Lessee, Lease Cash Flow And Supplemental Information [Table Text Block] Lessee, Lease Cash Flow And Supplemental Information Type of Restructuring [Domain] Type of Restructuring [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Stock repurchase program, shares authorized (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased EX-101.PRE 11 wst-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2023
Oct. 16, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 1-8036  
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 23-1210010  
Entity Address, Address Line One 530 Herman O. West Drive  
Entity Address, City or Town Exton  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19341-1147  
City Area Code 610  
Local Phone Number 594-2900  
Title of each class Common Stock, par value $0.25 per share  
Trading Symbol WST  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   73,989,670
Entity Central Index Key 0000105770  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Net sales $ 747.4 $ 686.9 $ 2,217.8 $ 2,178.2
Cost of goods and services sold 459.1 418.9 1,366.8 1,304.1
Gross profit 288.3 268.0 851.0 874.1
Research and development 16.4 13.6 50.0 42.6
Selling, general and administrative expenses 89.0 66.3 263.4 231.2
Other expense (income) (Note 15) 5.6 1.9 22.5 (4.0)
Operating profit 177.3 186.2 515.1 604.3
Interest expense 2.9 2.2 7.8 6.2
Interest income (8.8) (1.5) (18.6) (2.2)
Other nonoperating (income) expense (3.8) 49.3 (3.9) 49.1
Income before income taxes and equity in net income of affiliated companies 187.0 136.2 529.8 551.2
Income tax expense 29.4 20.4 87.8 85.8
Equity in net income of affiliated companies (3.7) (4.8) (14.4) (17.5)
Net income $ 161.3 $ 120.6 $ 456.4 $ 482.9
Net income per share:        
Basic (in dollars per share) $ 2.17 $ 1.62 $ 6.13 $ 6.49
Diluted (in dollars per share) $ 2.14 $ 1.59 $ 6.05 $ 6.36
Weighted average shares outstanding:        
Basic (in shares) 74.3 74.4 74.4 74.4
Diluted (in shares) 75.3 75.7 75.5 75.9
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net income $ 161.3 $ 120.6 $ 456.4 $ 482.9
Other comprehensive (loss) income, net of tax:        
Foreign currency translation adjustments, net of tax of $0.4, $1.1, $1.9 and $3.8, respectively (40.9) (76.0) (36.9) (162.5)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.0, $14.6, $(0.5), and $15.5, respectively 0.2 13.6 (1.2) 16.4
Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively 0.0 (0.1) (0.1) (0.2)
Net gain (loss) on derivatives, net of tax of $0.8, $0.0, $(0.3) and $(0.8), respectively 1.2 (0.1) (1.8) (2.6)
Other comprehensive (loss) income, net of tax (39.5) (62.6) (40.0) (148.9)
Comprehensive income $ 121.8 $ 58.0 $ 416.4 $ 334.0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Foreign currency translation adjustments, tax $ 0.4 $ 1.1 $ 1.9 $ 3.8
Defined benefit pension and other postretirement plan adjustments, tax 0.0 14.6 (0.5) 15.5
Net loss on equity affiliate accumulated other comprehensive income, tax 0.0 0.0 0.0 0.0
Net gain (loss) on derivatives, tax $ 0.8 $ 0.0 $ (0.3) $ (0.8)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 898.6 $ 894.3
Accounts receivable, net 519.1 507.4
Inventories 431.8 414.8
Other current assets 122.8 103.0
Total current assets 1,972.3 1,919.5
Property, plant and equipment 2,607.1 2,386.6
Less: accumulated depreciation and amortization 1,295.5 1,228.3
Property, plant and equipment, net 1,311.6 1,158.3
Operating lease right-of-use assets 96.8 104.4
Investments in affiliated companies 195.4 204.9
Goodwill 106.8 107.3
Intangible assets, net 15.7 18.4
Deferred income taxes 17.3 65.6
Other noncurrent assets 38.8 38.4
Total Assets 3,754.7 3,616.8
Current liabilities:    
Notes payable and other current debt 55.2 2.2
Accounts payable 219.8 215.4
Accrued salaries, wages and benefits 90.5 76.8
Income taxes payable 15.0 24.8
Operating lease liabilities 16.5 16.0
Other current liabilities 136.5 183.8
Total current liabilities 533.5 519.0
Long-term debt 152.1 206.7
Deferred income taxes 16.5 14.3
Pension and other postretirement benefits 28.4 28.2
Operating lease liabilities 83.0 93.0
Deferred compensation benefits 17.9 19.1
Other long-term liabilities 55.1 51.6
Total Liabilities 886.5 931.9
Commitments and contingencies (Note 17)
Equity:    
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding 0.0 0.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.1 million, respectively 18.8 18.8
Capital in excess of par value 122.6 232.2
Retained earnings 3,415.9 2,987.8
Accumulated other comprehensive loss (223.0) (183.0)
Treasury stock, at cost (1.3 million and 1.2 million shares, respectively) (466.1) (370.9)
Total Equity 2,868.2 2,684.9
Total Liabilities and Equity $ 3,754.7 $ 3,616.8
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized (in shares) 3,000,000 3,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.25 $ 0.25
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 75,300,000 75,300,000
Common stock, shares outstanding (in shares) 74,000,000 74,100,000
Treasury stock, at cost (in shares) 1,300,000 1,200,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income $ 456.4 $ 482.9
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 99.1 86.8
Amortization 2.3 2.7
Stock-based compensation 21.9 17.0
Loss on disposal of plant 11.6 0.0
Asset impairments 6.9 1.6
Pension settlement charge 0.0 50.8
Other non-cash items, net (13.5) (17.9)
Changes in assets and liabilities (47.3) (130.7)
Net cash provided by operating activities 537.4 493.2
Cash flows from investing activities:    
Capital expenditures (253.3) (189.7)
Other, net (6.6) (3.7)
Net cash used in investing activities (259.9) (193.4)
Cash flows from financing activities:    
Repayments of long-term debt (1.7) (43.7)
Debt issuance costs 0.0 (1.3)
Dividend payments (42.2) (40.0)
Proceeds from stock-based compensation awards 42.6 17.1
Employee stock purchase plan contributions 5.3 6.1
Shares purchased under share repurchase programs (261.3) (202.9)
Shares repurchased for employee tax withholdings (12.8) (19.4)
Net cash used in financing activities (270.1) (284.1)
Effect of exchange rates on cash (3.1) (49.3)
Net increase (decrease) in cash and cash equivalents 4.3 (33.6)
Cash, including cash equivalents at beginning of period 894.3 762.6
Cash, including cash equivalents at end of period $ 898.6 $ 729.0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting PoliciesBasis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
New Accounting Standards
 9 Months Ended
Sep. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards New Accounting Standards
Recently Adopted Standards

In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Biologics
40 %
41 %
37 %
42 %
Generics
 19 %
18 %
20 %
18 %
Pharma
22 %
24 %
24 %
24 %
Contract-Manufactured Products
19 %
17 %
19 %
16 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
High-Value Product Components
50 %
54 %
50 %
56 %
High-Value Product Delivery Devices
11 %
6 %
10 %
5 %
Standard Packaging
20 %
23 %
21 %
23 %
Contract-Manufactured Products
19 %
17 %
19 %
16 %
100 %
100 %
100 %
100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Americas
46 %
53 %
45 %
48 %
Europe, Middle East, Africa
46 %
38 %
46 %
43 %
Asia Pacific
8 %
9 %
9 %
9 %
100 %
100 %
100 %
100 %
Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2022$16.3 
Contract assets, September 30, 2023
19.9 
Change in contract assets - increase (decrease)$3.6 
Deferred income, December 31, 2022$(68.2)
Deferred income, September 30, 2023
(50.0)
Change in deferred income - decrease (increase)$18.2 

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2023, $33.2 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2023, there was $2.4 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $1.5 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Net Income Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2023202220232022
Net income$161.3 $120.6 $456.4 $482.9 
Weighted average common shares outstanding74.3 74.4 74.4 74.4 
Dilutive effect of equity awards, based on the treasury stock method
1.0 1.3 1.1 1.5 
Weighted average shares assuming dilution75.3 75.7 75.5 75.9 

During the three months ended September 30, 2023 and 2022, there were 0.0 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.1 million antidilutive shares outstanding during the nine months ended September 30, 2023 and 2022, respectively.
In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. During the three months ended September 30, 2023, we purchased 77,329 shares of our common stock under the program at a cost of $27.8 million, or an average price of $360.25 per share. During the nine months ended September 30, 2023, we purchased 753,399 shares of our common stock under the program at a cost of $261.3 million, or an average price of $346.86 per share.

In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions was dependent on a variety of factors, including market conditions. This share repurchase program was completed by December 31, 2022. During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the calendar-year 2022 program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the calendar-year 2022 program at a cost of $202.9 million, or an average price of $360.03 per share.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2023		December 31,
2022
Raw materials$180.2 $170.7 
Work in process93.8 79.0 
Finished goods157.8 165.1 
 $431.8 $414.8 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases Leases
A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Operating lease cost$4.3 $3.7 $15.0 $10.4 
Short-term lease cost1.9 0.3 4.4 1.1 
Variable lease cost1.4 2.3 4.4 4.7 
Total lease cost$7.6 $6.3 $23.8 $16.2 
Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$4.5 $3.7 $14.4 $10.0 
Right-of-use assets obtained in exchange for new operating lease liabilities$3.1 $14.0 $6.6 $29.5 

As of September 30, 2023 and December 31, 2022, the weighted average remaining lease term for operating leases was 10.1 years and 9.3 years, respectively.

As of September 30, 2023 and December 31, 2022, the weighted average discount rate was 3.46% and 3.25%, respectively.

Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20232022
2023 (remaining period as of)$4.8 $19.0 
202419.1 18.1 
202517.1 16.0 
202614.1 13.4 
20279.8 9.4 
Thereafter50.6 50.8 
115.5 126.7 
Less: imputed lease interest(16.0)(17.7)
Total lease liabilities$99.5 $109.0 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Affiliated Companies
 9 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Affiliated Companies Affiliated Companies
At September 30, 2023 and December 31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $189.7 million and $197.0 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $5.7 million and $7.9 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

Our purchases from, and royalty payments made to, affiliates totaled $34.4 million and $118.5 million for the three and nine months ended September 30, 2023, respectively, as compared to $33.6 million and $131.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the payable balance due to affiliates was $20.6 million and $31.2 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products.
Sales to affiliates were $2.5 million and $8.5 million, respectively, for the three and nine months ended September 30, 2023, as compared to $2.6 million and $10.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the receivable balance due from affiliates was $1.3 million and $2.2 million, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Debt
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Debt Debt
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023.
($ in millions)September 30,
2023		December 31,
2022
Term Loan, due December 31, 2024 (6.37%)
$81.5 $83.2 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
207.5 209.2 
Less: unamortized debt issuance costs0.2 0.3 
Total debt207.3 208.9 
Less: current portion of long-term debt55.2 2.2 
Long-term debt, net$152.1 $206.7 

Credit Facility

At September 30, 2023, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million.

Term Loan

At September 30, 2023, we had $81.5 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $79.3 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2023, we were in compliance with all of our debt covenants.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Financial Instruments
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial InstrumentsOur ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.
Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2023 and December 31, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed in June 2023. As of September 30, 2023, the total amount of these forward exchange contracts was Euro ("EUR") 278.6 million and SGD 94.0 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
EUR20.3 22.3 — 
Yen5,159.3 29.8 9.0 
SGD44.7 15.2 16.8 

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2023, the notional amount of the cross-currency swap is ¥8.9 billion ($81.5 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2023, we purchased several series of call options for a total of 975,206 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.

As of September 30, 2023, we had outstanding contracts to purchase 229,397 barrels of crude oil from September 2023 to March 2025, at a weighted-average strike price of $94.93 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2023 and December 31, 2022.
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2023202220232022
Fair Value Hedges:
Hedged item (intercompany loan)
$(1.2)$(14.1)$8.7 $(35.4)Other expense (income)
Derivative designated as hedging instrument
0.7 14.1 (10.0)35.4 Other expense (income)
Amount excluded from effectiveness testing
(1.5)2.2 (0.4)4.4 Other expense (income)
Total$(2.0)$2.2 $(1.7)$4.4 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2023 were $0.2 million and $1.6 million, respectively. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 were $1.1 million and $2.8 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2023202220232022 
Fair Value Hedges:
Foreign currency hedge contracts$(0.3)$(0.4)$2.3 $0.5 Other expense (income)
Total$(0.3)$(0.4)$2.3 $0.5 
Cash Flow Hedges:     
Foreign currency hedge contracts$0.5 $0.7 $0.1 $(0.5)Net sales
Foreign currency hedge contracts(2.5)(1.5)1.1 1.0 Cost of goods and services sold
Forward treasury locks— — — 0.1 Interest expense
Total$(2.0)$(0.8)$1.2 $0.6  
Net Investment Hedges:     
Cross-currency swap$2.9 $4.3 $— $— Other expense (income)
Total$2.9 $4.3 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022 
Fair Value Hedges:
Foreign currency hedge contracts$(2.3)$0.3 $4.2 $(0.7)Other expense (income)
Total$(2.3)$0.3 $4.2 $(0.7)
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.4)$1.1 $1.2 $(1.1)Net sales
Foreign currency hedge contracts(6.1)(4.9)1.5 2.5 Cost of goods and services sold
Forward treasury locks— — 0.1 0.2 Interest expense
Total$(6.5)$(3.8)$2.8 $1.6  
Net Investment Hedges:     
Cross-currency swap$10.1 $13.2 $— $— Other expense (income)
Total$10.1 $13.2 $— $—  

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Net sales$0.1 $(0.5)$1.2 $(1.1)
Cost of goods and services sold1.1 1.0 1.5 2.5 
Interest expense— 0.1 0.1 0.2 

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2023202220232022
Commodity call options$0.5 $(1.5)$(0.5)$1.6 Other expense (income)
Currency Forwards— — (0.2)— Other expense (income)
Total$0.5 $(1.5)$(0.7)$1.6 

For the three and nine months ended September 30, 2023 and 2022, there was no material ineffectiveness related to our hedges.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2023		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$9.1 $9.1 $— $— 
Foreign currency contracts2.4 — 2.4 — 
Cross-currency swap22.1 — 22.1 — 
Commodity call options1.4 — 1.4 — 
 $35.0 $9.1 $25.9 $— 
Liabilities:    
Contingent consideration$4.0 $— $— $4.0 
Deferred compensation liabilities9.3 9.3 — — 
Foreign currency contracts12.1 — 12.1 — 
 $25.4 $9.3 $12.1 $4.0 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2022		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.5 $12.5 $— $— 
Foreign currency contracts4.5 — 4.5 — 
Cross-currency swap13.9 — 13.9 — 
Commodity call options1.2 1.2 
 $32.1 $12.5 $19.6 $— 
Liabilities:    
Contingent consideration$4.7 $— $— $4.7 
Deferred compensation liabilities12.7 12.7 — — 
Foreign currency contracts1.4 — 1.4 — 
 $18.8 $12.7 $1.4 $4.7 
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.

Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2023, the estimated fair value of long-term debt was $147.2 million compared to a carrying amount of $152.1 million. At December 31, 2022, the estimated fair value of long-term debt was $201.8 million and the carrying amount was $206.7 million.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Loss
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2022$0.2 $1.6 $(9.4)$(175.4)$(183.0)
Other comprehensive (loss) income before reclassifications(8.8)(0.1)(0.1)(36.9)(45.9)
Amounts reclassified out from accumulated other comprehensive (loss) income 7.0 — (1.1)— 5.9 
Other comprehensive (loss) income, net of tax(1.8)(0.1)(1.2)(36.9)(40.0)
Balance, September 30, 2023$(1.6)$1.5 $(10.6)$(212.3)$(223.0)
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications(3.5)(0.2)2.9 (162.5)(163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income0.9 — 13.5 — 14.4 
Other comprehensive (loss) income, net of tax(2.6)(0.2)16.4 (162.5)(148.9)
Balance, September 30, 2022$(3.8)$1.3 $(15.4)$(290.6)$(308.5)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2023202220232022
Gains (losses) on derivatives:
Foreign currency contracts$(0.2)$0.5 $(1.5)$1.2 Net sales
Foreign currency contracts(1.4)(1.2)(2.0)(2.9)Cost of goods and services sold
Foreign currency contracts(3.4)(0.7)(6.2)1.1 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.2)(0.3)Interest expense
Total before tax(5.1)(1.5)(9.9)(0.9)
Tax benefit (expense)1.6 0.4 2.9 — 
Net of tax$(3.5)$(1.1)$(7.0)$(0.9)
Amortization of defined benefit pension and other postretirement plans:
Actuarial gains$0.3 $1.1 $1.1 $1.1 (a)
Settlements— (27.6)— (28.8)(a)
Other— — 0.4 (0.4)
Total before tax0.3 (26.5)1.5 (28.1)
Tax (expense) benefit(0.1)14.2 (0.4)14.6 
Net of tax$0.2 $(12.3)$1.1 $(13.5)
Total reclassifications for the period, net of tax$(3.3)$(13.4)$(5.9)$(14.4)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202275.3 $18.8 $232.2 1.2 $(370.9)$2,987.8 $(183.0)$2,684.9 
Net income— — — — — 140.0 — 140.0 
Activity related to stock-based compensation— — (50.8)(0.3)61.8 — — 11.0 
Shares purchased under share repurchase program— — — 0.2 (60.1)— — (60.1)
Dividends declared ($0.19 per share)
— — — — — (14.2)— (14.2)
Other comprehensive income, net of tax— — — — — — 14.6 14.6 
Balance, March 31, 202375.3 $18.8 $181.4 1.1 $(369.2)$3,113.6 $(168.4)$2,776.2 
Net income— — — — — 155.1 — 155.1 
Activity related to stock-based compensation— — (23.2)(0.2)41.2 — — 18.0 
Shares purchased under share repurchase program— — — 0.5 (173.4)— — (173.4)
Dividends declared ($0.19 per share)
— — — — — (14.1)— (14.1)
Other comprehensive loss, net of tax— — — — — — (15.1)(15.1)
Balance, June 30, 202375.3 $18.8 $158.2 1.4 $(501.4)$3,254.6 $(183.5)$2,746.7 
Net income— — — — — 161.3 — 161.3 
Activity related to stock-based compensation— — (35.6)(0.2)63.1 — — 27.5 
Shares purchased under share repurchase program— — — 0.1 (27.8)— — (27.8)
Other comprehensive loss, net of tax— — — — — — (39.5)(39.5)
Balance, September 30, 202375.3 $18.8 $122.6 1.3 $(466.1)$3,415.9 $(223.0)$2,868.2 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net income— — — — — 173.8 — 173.8 
Activity related to stock-based compensation— — (29.1)(0.3)29.2 — — 0.1 
Shares purchased under share repurchase program— — — 0.4 (147.1)— — (147.1)
Dividends declared ($0.18 per share)
— — — — — (13.2)— (13.2)
Other comprehensive loss, net of tax— — — — — — (22.8)(22.8)
Balance, March 31, 202275.3 $18.8 $219.9 1.2 $(347.4)$2,617.3 $(182.4)$2,326.2 
Net income— — — — — 188.5 — 188.5 
Activity related to stock-based compensation— — 5.4 — 9.7 — — 15.1 
Shares purchased under share repurchase program— — — 0.1 (28.6)— — (28.6)
Dividends declared ($0.18 per share)
— — — — — (13.3)— (13.3)
Other comprehensive loss, net of tax— — — — — — (63.5)(63.5)
Balance, June 30, 202275.3 $18.8 $225.3 1.3 $(366.3)$2,792.5 $(245.9)$2,424.4 
Net income— — — — — 120.6 — 120.6 
Activity related to stock-based compensation— — 5.3 (0.1)10.3 — — 15.6 
Shares purchased under share repurchase program— — — 0.1 (27.2)— — (27.2)
Other comprehensive loss, net of tax— — — — — — (62.6)(62.6)
Balance, September 30, 202275.3 $18.8 $230.6 1.3 $(383.2)$2,913.1 $(308.5)$2,470.8 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2023, there were 1,438,454 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2023, we granted 105,640 stock options at a weighted average exercise price of $306.92 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $108.88 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 5.7 years based on prior experience; stock volatility of 29.8% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2023, we granted 37,536 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $306.91 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2023, we granted 4,563 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $310.56 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.
Stock-based compensation expense was $5.9 million and $21.9 million for the three and nine months ended September 30, 2023, respectively. For the three and nine months ended September 30, 2022, stock-based compensation expense was $6.0 million and $17.0 million, respectively.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Benefit Plans
 9 Months Ended
Sep. 30, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Benefit Plans Benefit Plans
The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
Service cost$0.2 $0.3 $— $— $0.2 $0.3 
Interest cost0.6 0.5 0.1 0.1 0.7 0.6 
Expected return on assets(0.4)(0.8)— — (0.4)(0.8)
Recognized actuarial losses (gains)0.2 0.3 (0.5)(0.4)(0.3)(0.1)
Settlements— 49.6 — — — 49.6 
Net periodic benefit cost$0.6 $49.9 $(0.4)$(0.3)$0.2 $49.6 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
U.S. plans$— $49.6 $(0.4)$(0.3)$(0.4)$49.3 
International plans0.6 0.3 — — 0.6 0.3 
Net periodic benefit cost$0.6 $49.9 $(0.4)$(0.3)$0.2 $49.6 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
Service cost$0.8 $1.0 $— $— $0.8 $1.0 
Interest cost1.8 3.7 0.2 0.1 2.0 3.8 
Expected return on assets(1.0)(5.4)— — (1.0)(5.4)
Recognized actuarial losses (gains)0.5 1.0 (1.6)(1.1)(1.1)(0.1)
Settlements— 50.8 — — — 50.8 
Net periodic benefit cost$2.1 $51.1 $(1.4)$(1.0)$0.7 $50.1 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
U.S. plans$0.3 $50.3 $(1.4)$(1.0)$(1.1)$49.3 
International plans1.8 0.8 — — 1.8 0.8 
Net periodic benefit cost$2.1 $51.1 $(1.4)$(1.0)$0.7 $50.1 

During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating (income) expense, which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Other Expense (Income)
 9 Months Ended
Sep. 30, 2023
Other Income and Expenses [Abstract]  
Other Expense (Income) Other Expense (Income)
Other expense (income) consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Loss on disposal of plant$— $— $11.6 $— 
Asset impairments3.5 1.4 6.9 1.6 
Restructuring and related charges— — (0.8)(1.6)
(Gain) loss on oil hedges(0.5)1.5 0.5 (1.6)
Contingent consideration0.7 1.5 1.5 2.6 
Foreign exchange transaction losses (gains)1.8 (2.2)3.0 (4.6)
Other items0.1 (0.3)(0.2)(0.4)
Total other expense (income)$5.6 $1.9 $22.5 $(4.0)

Loss on Disposal of Plant

During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million, respectively, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

Restructuring and Related Charges

In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $25 million to $27 million, with annualized savings in the range of $22 million to $24 million. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2022$10.1 $15.3 $25.4 
(Credits) Charges(0.8)— (0.8)
Cash payments(3.7)— (3.7)
Non-cash asset write downs— (15.3)(15.3)
Balance, September 30, 2023$5.6 $— $5.6 

Oil Hedges

During the three and nine months ended September 30, 2023, we recorded a gain of $0.5 million and a loss of $0.5 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our hedging activity.

Contingent Consideration
Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $29.4 million and $20.4 million for the three months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 15.7% and 15.0%, respectively. The increase in the effective tax rate is primarily due to a tax benefit of $20.0 million related to the termination of the U.S. pension plan recorded in the three months ended September 30, 2022 that was not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the three months ended September 30, 2023, as compared to the same period in 2022.

The provision for income taxes was $87.8 million and $85.8 million for the nine months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 16.6% and 15.6%, respectively. The increase in the effective tax rate is primarily due to a tax benefit of $20.3 million related to the termination of the U.S. pension plan recorded in the nine months ended September 30, 2022 and a $5.9 million tax benefit recorded as the result of a state tax valuation allowance reversal in the nine months ended September 30, 2022 that were not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the nine months ended September 30, 2023, as compared to the same period in 2022.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2022 Annual Report.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.
The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Net sales:    
Proprietary Products$602.5 $567.0 $1,803.6 $1,822.0 
Contract-Manufactured Products144.9 120.0 414.2 356.5 
Intersegment sales elimination— (0.1)— (0.3)
Consolidated net sales$747.4 $686.9 $2,217.8 $2,178.2 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Operating profit (loss):
Proprietary Products$181.6 $188.6 $546.5 $615.9 
Contract-Manufactured Products21.0 14.7 53.3 48.0 
Total business segment operating profit$202.6 $203.3 $599.8 $663.9 
Corporate and Unallocated
Stock-based compensation expense$(5.9)$(6.0)$(21.9)$(17.0)
Corporate general costs (1)
(15.9)(10.9)(47.2)(43.6)
Unallocated Items:
Loss on disposal of plant (2)
— — (11.6)— 
Cost investment impairment (3)
(3.3)— (3.3)— 
Restructuring and other charges (4)
— — (0.1)1.6 
Amortization of acquisition-related intangible assets (5)
(0.2)(0.2)(0.6)(0.6)
Total Corporate and Unallocated(25.3)(17.1)(84.7)(59.6)
Total consolidated operating profit$177.3 $186.2 $515.1 $604.3 
Interest (income) expense and other nonoperating (income) expense, net(9.7)50.0 (14.7)53.1 
Income before income taxes and equity in net income of affiliated companies$187.0 $136.2 $529.8 $551.2 
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.

(4) Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represents the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan. During the nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates.

(5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 15, Other Expense (Income), for further discussion of these items.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure                
Net income $ 161.3 $ 155.1 $ 140.0 $ 120.6 $ 188.5 $ 173.8 $ 456.4 $ 482.9
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2023
shares
Sep. 30, 2023
shares
Trading Arrangements, by Individual    
Rule 10b5-1 Arrangement Adopted false  
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Eric M. Green [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors, entered into a prearranged stock trading arrangement on May 5, 2023. Mr. Green’s plan provides for the purchase and sale of an aggregate number of 234,864 shares of the Company's common stock (of which Mr. Green will sell 204,864 shares and retain the rest immediately following the exercise) between August 8, 2023 and August 6, 2024. The trading plan was entered into during an open insider trading window and is intended to satisfy Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding insider transactions.
Name Eric M. Green  
Title President and Chief Executive Officer, Chair of the Board of Directors  
Adoption Date May 5, 2023  
Arrangement Duration 364 days  
Aggregate Available 234,864 234,864
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.
New Accounting Standards New Accounting Standards
Recently Adopted Standards

In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Biologics
40 %
41 %
37 %
42 %
Generics
 19 %
18 %
20 %
18 %
Pharma
22 %
24 %
24 %
24 %
Contract-Manufactured Products
19 %
17 %
19 %
16 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
High-Value Product Components
50 %
54 %
50 %
56 %
High-Value Product Delivery Devices
11 %
6 %
10 %
5 %
Standard Packaging
20 %
23 %
21 %
23 %
Contract-Manufactured Products
19 %
17 %
19 %
16 %
100 %
100 %
100 %
100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Americas
46 %
53 %
45 %
48 %
Europe, Middle East, Africa
46 %
38 %
46 %
43 %
Asia Pacific
8 %
9 %
9 %
9 %
100 %
100 %
100 %
100 %
Schedule of Change in Contract with Customer, Asset and Liability The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2022$16.3 
Contract assets, September 30, 2023
19.9 
Change in contract assets - increase (decrease)$3.6 
Deferred income, December 31, 2022$(68.2)
Deferred income, September 30, 2023
(50.0)
Change in deferred income - decrease (increase)$18.2 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Net Income Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic to Diluted Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2023202220232022
Net income$161.3 $120.6 $456.4 $482.9 
Weighted average common shares outstanding74.3 74.4 74.4 74.4 
Dilutive effect of equity awards, based on the treasury stock method
1.0 1.3 1.1 1.5 
Weighted average shares assuming dilution75.3 75.7 75.5 75.9 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2023		December 31,
2022
Raw materials$180.2 $170.7 
Work in process93.8 79.0 
Finished goods157.8 165.1 
 $431.8 $414.8 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Schedule of Lease Expense The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Operating lease cost$4.3 $3.7 $15.0 $10.4 
Short-term lease cost1.9 0.3 4.4 1.1 
Variable lease cost1.4 2.3 4.4 4.7 
Total lease cost$7.6 $6.3 $23.8 $16.2 
Schedule of Supplemental Cash Flow Information Related to Leases Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$4.5 $3.7 $14.4 $10.0 
Right-of-use assets obtained in exchange for new operating lease liabilities$3.1 $14.0 $6.6 $29.5 
Schedule of Maturities of Operating Lease Liabilities Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20232022
2023 (remaining period as of)$4.8 $19.0 
202419.1 18.1 
202517.1 16.0 
202614.1 13.4 
20279.8 9.4 
Thereafter50.6 50.8 
115.5 126.7 
Less: imputed lease interest(16.0)(17.7)
Total lease liabilities$99.5 $109.0 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Obligations, Net of Unamortized Debt Issuance Costs and Current Maturities
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023.
($ in millions)September 30,
2023		December 31,
2022
Term Loan, due December 31, 2024 (6.37%)
$81.5 $83.2 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
207.5 209.2 
Less: unamortized debt issuance costs0.2 0.3 
Total debt207.3 208.9 
Less: current portion of long-term debt55.2 2.2 
Long-term debt, net$152.1 $206.7 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Foreign Currency Contracts As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEuro
EUR20.3 22.3 — 
Yen5,159.3 29.8 9.0 
SGD44.7 15.2 16.8 
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2023202220232022
Fair Value Hedges:
Hedged item (intercompany loan)
$(1.2)$(14.1)$8.7 $(35.4)Other expense (income)
Derivative designated as hedging instrument
0.7 14.1 (10.0)35.4 Other expense (income)
Amount excluded from effectiveness testing
(1.5)2.2 (0.4)4.4 Other expense (income)
Total$(2.0)$2.2 $(1.7)$4.4 
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2023202220232022 
Fair Value Hedges:
Foreign currency hedge contracts$(0.3)$(0.4)$2.3 $0.5 Other expense (income)
Total$(0.3)$(0.4)$2.3 $0.5 
Cash Flow Hedges:     
Foreign currency hedge contracts$0.5 $0.7 $0.1 $(0.5)Net sales
Foreign currency hedge contracts(2.5)(1.5)1.1 1.0 Cost of goods and services sold
Forward treasury locks— — — 0.1 Interest expense
Total$(2.0)$(0.8)$1.2 $0.6  
Net Investment Hedges:     
Cross-currency swap$2.9 $4.3 $— $— Other expense (income)
Total$2.9 $4.3 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022 
Fair Value Hedges:
Foreign currency hedge contracts$(2.3)$0.3 $4.2 $(0.7)Other expense (income)
Total$(2.3)$0.3 $4.2 $(0.7)
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.4)$1.1 $1.2 $(1.1)Net sales
Foreign currency hedge contracts(6.1)(4.9)1.5 2.5 Cost of goods and services sold
Forward treasury locks— — 0.1 0.2 Interest expense
Total$(6.5)$(3.8)$2.8 $1.6  
Net Investment Hedges:     
Cross-currency swap$10.1 $13.2 $— $— Other expense (income)
Total$10.1 $13.2 $— $—  

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Net sales$0.1 $(0.5)$1.2 $(1.1)
Cost of goods and services sold1.1 1.0 1.5 2.5 
Interest expense— 0.1 0.1 0.2 
Schedule of Derivative Instruments Not Designated as Hedges The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2023202220232022
Commodity call options$0.5 $(1.5)$(0.5)$1.6 Other expense (income)
Currency Forwards— — (0.2)— Other expense (income)
Total$0.5 $(1.5)$(0.7)$1.6 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2023		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$9.1 $9.1 $— $— 
Foreign currency contracts2.4 — 2.4 — 
Cross-currency swap22.1 — 22.1 — 
Commodity call options1.4 — 1.4 — 
 $35.0 $9.1 $25.9 $— 
Liabilities:    
Contingent consideration$4.0 $— $— $4.0 
Deferred compensation liabilities9.3 9.3 — — 
Foreign currency contracts12.1 — 12.1 — 
 $25.4 $9.3 $12.1 $4.0 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2022		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.5 $12.5 $— $— 
Foreign currency contracts4.5 — 4.5 — 
Cross-currency swap13.9 — 13.9 — 
Commodity call options1.2 1.2 
 $32.1 $12.5 $19.6 $— 
Liabilities:    
Contingent consideration$4.7 $— $— $4.7 
Deferred compensation liabilities12.7 12.7 — — 
Foreign currency contracts1.4 — 1.4 — 
 $18.8 $12.7 $1.4 $4.7 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Loss (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive Income ("AOCI") (Loss)
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2022$0.2 $1.6 $(9.4)$(175.4)$(183.0)
Other comprehensive (loss) income before reclassifications(8.8)(0.1)(0.1)(36.9)(45.9)
Amounts reclassified out from accumulated other comprehensive (loss) income 7.0 — (1.1)— 5.9 
Other comprehensive (loss) income, net of tax(1.8)(0.1)(1.2)(36.9)(40.0)
Balance, September 30, 2023$(1.6)$1.5 $(10.6)$(212.3)$(223.0)
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications(3.5)(0.2)2.9 (162.5)(163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income0.9 — 13.5 — 14.4 
Other comprehensive (loss) income, net of tax(2.6)(0.2)16.4 (162.5)(148.9)
Balance, September 30, 2022$(3.8)$1.3 $(15.4)$(290.6)$(308.5)
Schedule of Reclassification Out of Accumulated Other Comprehensive Loss
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2023202220232022
Gains (losses) on derivatives:
Foreign currency contracts$(0.2)$0.5 $(1.5)$1.2 Net sales
Foreign currency contracts(1.4)(1.2)(2.0)(2.9)Cost of goods and services sold
Foreign currency contracts(3.4)(0.7)(6.2)1.1 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.2)(0.3)Interest expense
Total before tax(5.1)(1.5)(9.9)(0.9)
Tax benefit (expense)1.6 0.4 2.9 — 
Net of tax$(3.5)$(1.1)$(7.0)$(0.9)
Amortization of defined benefit pension and other postretirement plans:
Actuarial gains$0.3 $1.1 $1.1 $1.1 (a)
Settlements— (27.6)— (28.8)(a)
Other— — 0.4 (0.4)
Total before tax0.3 (26.5)1.5 (28.1)
Tax (expense) benefit(0.1)14.2 (0.4)14.6 
Net of tax$0.2 $(12.3)$1.1 $(13.5)
Total reclassifications for the period, net of tax$(3.3)$(13.4)$(5.9)$(14.4)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Stockholders Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202275.3 $18.8 $232.2 1.2 $(370.9)$2,987.8 $(183.0)$2,684.9 
Net income— — — — — 140.0 — 140.0 
Activity related to stock-based compensation— — (50.8)(0.3)61.8 — — 11.0 
Shares purchased under share repurchase program— — — 0.2 (60.1)— — (60.1)
Dividends declared ($0.19 per share)
— — — — — (14.2)— (14.2)
Other comprehensive income, net of tax— — — — — — 14.6 14.6 
Balance, March 31, 202375.3 $18.8 $181.4 1.1 $(369.2)$3,113.6 $(168.4)$2,776.2 
Net income— — — — — 155.1 — 155.1 
Activity related to stock-based compensation— — (23.2)(0.2)41.2 — — 18.0 
Shares purchased under share repurchase program— — — 0.5 (173.4)— — (173.4)
Dividends declared ($0.19 per share)
— — — — — (14.1)— (14.1)
Other comprehensive loss, net of tax— — — — — — (15.1)(15.1)
Balance, June 30, 202375.3 $18.8 $158.2 1.4 $(501.4)$3,254.6 $(183.5)$2,746.7 
Net income— — — — — 161.3 — 161.3 
Activity related to stock-based compensation— — (35.6)(0.2)63.1 — — 27.5 
Shares purchased under share repurchase program— — — 0.1 (27.8)— — (27.8)
Other comprehensive loss, net of tax— — — — — — (39.5)(39.5)
Balance, September 30, 202375.3 $18.8 $122.6 1.3 $(466.1)$3,415.9 $(223.0)$2,868.2 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net income— — — — — 173.8 — 173.8 
Activity related to stock-based compensation— — (29.1)(0.3)29.2 — — 0.1 
Shares purchased under share repurchase program— — — 0.4 (147.1)— — (147.1)
Dividends declared ($0.18 per share)
— — — — — (13.2)— (13.2)
Other comprehensive loss, net of tax— — — — — — (22.8)(22.8)
Balance, March 31, 202275.3 $18.8 $219.9 1.2 $(347.4)$2,617.3 $(182.4)$2,326.2 
Net income— — — — — 188.5 — 188.5 
Activity related to stock-based compensation— — 5.4 — 9.7 — — 15.1 
Shares purchased under share repurchase program— — — 0.1 (28.6)— — (28.6)
Dividends declared ($0.18 per share)
— — — — — (13.3)— (13.3)
Other comprehensive loss, net of tax— — — — — — (63.5)(63.5)
Balance, June 30, 202275.3 $18.8 $225.3 1.3 $(366.3)$2,792.5 $(245.9)$2,424.4 
Net income— — — — — 120.6 — 120.6 
Activity related to stock-based compensation— — 5.3 (0.1)10.3 — — 15.6 
Shares purchased under share repurchase program— — — 0.1 (27.2)— — (27.2)
Other comprehensive loss, net of tax— — — — — — (62.6)(62.6)
Balance, September 30, 202275.3 $18.8 $230.6 1.3 $(383.2)$2,913.1 $(308.5)$2,470.8 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
Service cost$0.2 $0.3 $— $— $0.2 $0.3 
Interest cost0.6 0.5 0.1 0.1 0.7 0.6 
Expected return on assets(0.4)(0.8)— — (0.4)(0.8)
Recognized actuarial losses (gains)0.2 0.3 (0.5)(0.4)(0.3)(0.1)
Settlements— 49.6 — — — 49.6 
Net periodic benefit cost$0.6 $49.9 $(0.4)$(0.3)$0.2 $49.6 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
U.S. plans$— $49.6 $(0.4)$(0.3)$(0.4)$49.3 
International plans0.6 0.3 — — 0.6 0.3 
Net periodic benefit cost$0.6 $49.9 $(0.4)$(0.3)$0.2 $49.6 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
Service cost$0.8 $1.0 $— $— $0.8 $1.0 
Interest cost1.8 3.7 0.2 0.1 2.0 3.8 
Expected return on assets(1.0)(5.4)— — (1.0)(5.4)
Recognized actuarial losses (gains)0.5 1.0 (1.6)(1.1)(1.1)(0.1)
Settlements— 50.8 — — — 50.8 
Net periodic benefit cost$2.1 $51.1 $(1.4)$(1.0)$0.7 $50.1 
 Pension benefitsOther retirement benefitsTotal
($ in millions)202320222023202220232022
U.S. plans$0.3 $50.3 $(1.4)$(1.0)$(1.1)$49.3 
International plans1.8 0.8 — — 1.8 0.8 
Net periodic benefit cost$2.1 $51.1 $(1.4)$(1.0)$0.7 $50.1 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Other Expense (Income) (Tables)
 9 Months Ended
Sep. 30, 2023
Other Income and Expenses [Abstract]  
Schedule of Other Expense (Income)
Other expense (income) consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Loss on disposal of plant$— $— $11.6 $— 
Asset impairments3.5 1.4 6.9 1.6 
Restructuring and related charges— — (0.8)(1.6)
(Gain) loss on oil hedges(0.5)1.5 0.5 (1.6)
Contingent consideration0.7 1.5 1.5 2.6 
Foreign exchange transaction losses (gains)1.8 (2.2)3.0 (4.6)
Other items0.1 (0.3)(0.2)(0.4)
Total other expense (income)$5.6 $1.9 $22.5 $(4.0)
Schedule of Restructuring Reserve The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:
($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2022$10.1 $15.3 $25.4 
(Credits) Charges(0.8)— (0.8)
Cash payments(3.7)— (3.7)
Non-cash asset write downs— (15.3)(15.3)
Balance, September 30, 2023$5.6 $— $5.6 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Information
The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Net sales:    
Proprietary Products$602.5 $567.0 $1,803.6 $1,822.0 
Contract-Manufactured Products144.9 120.0 414.2 356.5 
Intersegment sales elimination— (0.1)— (0.3)
Consolidated net sales$747.4 $686.9 $2,217.8 $2,178.2 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2023202220232022
Operating profit (loss):
Proprietary Products$181.6 $188.6 $546.5 $615.9 
Contract-Manufactured Products21.0 14.7 53.3 48.0 
Total business segment operating profit$202.6 $203.3 $599.8 $663.9 
Corporate and Unallocated
Stock-based compensation expense$(5.9)$(6.0)$(21.9)$(17.0)
Corporate general costs (1)
(15.9)(10.9)(47.2)(43.6)
Unallocated Items:
Loss on disposal of plant (2)
— — (11.6)— 
Cost investment impairment (3)
(3.3)— (3.3)— 
Restructuring and other charges (4)
— — (0.1)1.6 
Amortization of acquisition-related intangible assets (5)
(0.2)(0.2)(0.6)(0.6)
Total Corporate and Unallocated(25.3)(17.1)(84.7)(59.6)
Total consolidated operating profit$177.3 $186.2 $515.1 $604.3 
Interest (income) expense and other nonoperating (income) expense, net(9.7)50.0 (14.7)53.1 
Income before income taxes and equity in net income of affiliated companies$187.0 $136.2 $529.8 $551.2 
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.

(4) Restructuring and other charges of $0.1 million for the nine months ended September 30, 2023 represents the net impact of an inventory write down of $0.9 million within cost of goods and services sold and a $0.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan. During the nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates.

(5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Revenue Recognition (Details) - Revenue Benchmark
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Customer Concentration Risk | Biologics        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 40.00% 41.00% 37.00% 42.00%
Customer Concentration Risk | Generics        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 19.00% 18.00% 20.00% 18.00%
Customer Concentration Risk | Pharma        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 22.00% 24.00% 24.00% 24.00%
Customer Concentration Risk | Contract-Manufactured Products        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 19.00% 17.00% 19.00% 16.00%
Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Product Concentration Risk | High-Value Product Components        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 50.00% 54.00% 50.00% 56.00%
Product Concentration Risk | High-Value Product Delivery Devices        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 11.00% 6.00% 10.00% 5.00%
Product Concentration Risk | Standard Packaging        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 20.00% 23.00% 21.00% 23.00%
Product Concentration Risk | Contract-Manufactured Products        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 19.00% 17.00% 19.00% 16.00%
Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Geographic Concentration Risk | Americas        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 46.00% 53.00% 45.00% 48.00%
Geographic Concentration Risk | Europe, Middle East, Africa        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 46.00% 38.00% 46.00% 43.00%
Geographic Concentration Risk | Asia Pacific        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 8.00% 9.00% 9.00% 9.00%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Contracts and Liabilities (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Contract With Customer, Asset [Roll Forward]  
Contract assets, December 31, 2022 $ 16.3
Contract assets, September 30, 2023 19.9
Change in contract assets - increase (decrease) 3.6
Contract With Customer, Liability [Roll Forward]  
Deferred income, December 31, 2022 (68.2)
Deferred income, September 30, 2023 (50.0)
Change in deferred income - decrease (increase) $ 18.2
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Jun. 30, 2013
Disaggregation of Revenue [Line Items]      
Revenue recognized that was included in the deferred income balance $ 33.2    
Deferred income 50.0 $ 68.2 $ 20.0
SmartDose      
Disaggregation of Revenue [Line Items]      
Deferred income 2.4    
Deferred income, current 0.9    
Deferred income, noncurrent $ 1.5    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Net Income Per Share - Schedule of Net Income Per Share (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share [Abstract]                
Net income $ 161.3 $ 155.1 $ 140.0 $ 120.6 $ 188.5 $ 173.8 $ 456.4 $ 482.9
Weighted average common shares outstanding (in shares) 74.3     74.4     74.4 74.4
Dilutive effect of equity awards, based on the treasury stock method (in shares) 1.0     1.3     1.1 1.5
Weighted average shares assuming dilution (in shares) 75.3     75.7     75.5 75.9
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Net Income Per Share - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Feb. 28, 2023
Dec. 31, 2021
Earnings Per Share [Abstract]                    
Antidilutive options excluded from computation of diluted net income per share (in shares) 0     200,000     100,000 100,000    
Stock repurchase program, shares authorized (in shares)                 1,000,000,000 650,000
Share purchased under share repurchase program (in shares) 77,329     86,667     753,399 563,334    
Stock purchase program, cost of shares purchased $ 27.8 $ 173.4 $ 60.1 $ 27.2 $ 28.6 $ 147.1 $ 261.3 $ 202.9    
Stock repurchase program, average price per share (in dollars per share) $ 360.25     $ 313.22     $ 346.86 $ 360.03    
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 180.2 $ 170.7
Work in process 93.8 79.0
Finished goods 157.8 165.1
Total inventories $ 431.8 $ 414.8
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Lease Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Leases [Abstract]        
Operating lease cost $ 4.3 $ 3.7 $ 15.0 $ 10.4
Short-term lease cost 1.9 0.3 4.4 1.1
Variable lease cost 1.4 2.3 4.4 4.7
Total lease cost $ 7.6 $ 6.3 $ 23.8 $ 16.2
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows from operating leases $ 4.5 $ 3.7 $ 14.4 $ 10.0
Right-of-use assets obtained in exchange for new operating lease liabilities $ 3.1 $ 14.0 $ 6.6 $ 29.5
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Lease Weighted Average (Details)
Sep. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted average remaining lease term 10 years 1 month 6 days 9 years 3 months 18 days
Weighted average discount rate 3.46% 3.25%
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Remainder of fiscal year $ 4.8  
Year one 19.1 $ 19.0
Year two 17.1 18.1
Year three 14.1 16.0
Year four 9.8 13.4
Year five   9.4
Thereafter 50.6  
Thereafter   50.8
Operating leases liabilities payments due 115.5 126.7
Less: imputed lease interest (16.0) (17.7)
Total lease liabilities $ 99.5 $ 109.0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Affiliated Companies (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]          
Carrying amount, equity-method investments $ 189.7   $ 189.7   $ 197.0
Carrying amount, investments not accounted for under the equity method 5.7   5.7   7.9
Amount due to affiliates 136.5   136.5   183.8
Net sales 747.4 $ 686.9 2,217.8 $ 2,178.2  
Amount receivable from affiliates 122.8   122.8   103.0
Affiliated Entity          
Schedule of Equity Method Investments [Line Items]          
Amount due to affiliates 20.6   20.6   31.2
Net sales 2.5 2.6 8.5 10.2  
Amount receivable from affiliates 1.3   1.3   $ 2.2
Distributorship Agreement          
Schedule of Equity Method Investments [Line Items]          
Related party transaction, purchases from related party $ 34.4 $ 33.6 $ 118.5 $ 131.2  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Long-term debt, gross $ 207.5 $ 209.2
Less: unamortized debt issuance costs 0.2 0.3
Total debt 207.3 208.9
Less: current portion of long-term debt 55.2 2.2
Long-term debt, net $ 152.1 206.7
Term Loan, due December 31, 2024 (6.37%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 6.37%  
Long-term debt, gross $ 81.5 83.2
Series B notes, due July 5, 2024 (3.82%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.82%  
Long-term debt, gross $ 53.0 53.0
Series C notes, due July 5, 2027 (4.02%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 4.02%  
Long-term debt, gross $ 73.0 $ 73.0
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Long-term debt, gross $ 207.5 $ 209.2
Long-term debt 152.1 $ 206.7
Revolving credit facility, Due 2024    
Debt Instrument [Line Items]    
Line of credit facility, current borrowing capacity 500.0  
Line of credit facility, unused commitment level 497.6  
Revolving credit facility, Due 2024 | Letter of Credit    
Debt Instrument [Line Items]    
Long-term line of credit 2.4  
Secured Debt | Term Loan, due December 31, 2024 (6.37%)    
Debt Instrument [Line Items]    
Long-term debt, gross 81.5  
Long-term debt, current 2.2  
Long-term debt $ 79.3  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details)
€ in Millions, ¥ in Millions, $ in Millions, $ in Millions
 9 Months Ended 71 Months Ended
Sep. 30, 2023
SGD ($)
$ / bbl
bbl
Sep. 30, 2023
SGD ($)
$ / bbl
bbl
Sep. 30, 2023
EUR (€)
$ / bbl
Sep. 30, 2023
USD ($)
$ / bbl
Sep. 30, 2023
JPY (¥)
$ / bbl
Dec. 31, 2022
SGD ($)
Dec. 31, 2019
USD ($)
Foreign Exchange Forward              
Derivative [Line Items]              
Derivative contract term 18 months            
Options Held              
Derivative [Line Items]              
Derivative, nonmonetary notional amount, volume | bbl 229,397 975,206          
Derivative, average price risk option strike price | $ / bbl 94.93 94.93 94.93 94.93 94.93    
SGD | Currency Forwards              
Derivative [Line Items]              
Derivative, notional amount $ 601.5 $ 601.5       $ 13.4  
SGD | Currency Forwards | Net Investment Hedges:              
Derivative [Line Items]              
Derivative, notional amount 94.0 94.0          
SGD | Foreign Exchange Forward | Long | Designated as Hedging Instrument              
Derivative [Line Items]              
Derivative, notional amount $ 44.7 $ 44.7          
SGD | Foreign Exchange Forward | Short | Designated as Hedging Instrument              
Derivative [Line Items]              
Derivative, notional amount     € 16.8 $ 15.2      
USD | Cross Currency Interest Rate Contract | Net Investment Hedges:              
Derivative [Line Items]              
Derivative, notional amount       81.5     $ 90.0
EUR | Currency Forwards | Net Investment Hedges:              
Derivative [Line Items]              
Derivative, notional amount | €     278.6        
EUR | Foreign Exchange Forward | Long | Designated as Hedging Instrument              
Derivative [Line Items]              
Derivative, notional amount | €     20.3        
EUR | Foreign Exchange Forward | Short | Designated as Hedging Instrument              
Derivative [Line Items]              
Derivative, notional amount     0.0 22.3      
Yen | Foreign Exchange Forward | Long | Designated as Hedging Instrument              
Derivative [Line Items]              
Derivative, notional amount | ¥         ¥ 5,159.3    
Yen | Foreign Exchange Forward | Short | Designated as Hedging Instrument              
Derivative [Line Items]              
Derivative, notional amount     € 9.0 $ 29.8      
Yen | Cross Currency Interest Rate Contract | Net Investment Hedges:              
Derivative [Line Items]              
Derivative, notional amount | ¥         ¥ 8,900.0    
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]        
Total $ (2.0) $ 2.2 $ (1.7) $ 4.4
Fair Value Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Recognized in earnings, pre-tax, for forward point 0.2 1.1 1.6 2.8
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.3) (0.4) (2.3) 0.3
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 2.3 0.5 4.2 (0.7)
Cash Flow Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI (2.0) (0.8) (6.5) (3.8)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 1.2 0.6 2.8 1.6
Cash Flow Hedges: | Forward treasury locks        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.0 0.0 0.0 0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.1 0.1 0.2
Net Investment Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 2.9 4.3 10.1 13.2
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0 0.0
Other expense (income)        
Derivative Instruments, Gain (Loss) [Line Items]        
Hedged item (intercompany loan) (1.2) (14.1) 8.7 (35.4)
Derivative designated as hedging instrument 0.7 14.1 (10.0) 35.4
Amount excluded from effectiveness testing (1.5) 2.2 (0.4) 4.4
Other expense (income) | Fair Value Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.3) (0.4) (2.3) 0.3
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 2.3 0.5 4.2 (0.7)
Other expense (income) | Net Investment Hedges: | Cross-currency swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 2.9 4.3 10.1 13.2
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0   0.0 0.0
Net sales        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 0.1 (0.5) 1.2 (1.1)
Net sales | Cash Flow Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.5 0.7 (0.4) 1.1
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.1 (0.5) 1.2 (1.1)
Cost of goods and services sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 1.1 1.0 1.5 2.5
Cost of goods and services sold | Cash Flow Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI (2.5) (1.5) (6.1) (4.9)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 1.1 1.0 1.5 2.5
Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax $ 0.0 $ 0.1 $ 0.1 $ 0.2
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on oil hedges $ 0.5 $ (1.5) $ (0.5) $ 1.6
Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on oil hedges 0.5 (1.5) (0.7) 1.6
Commodity call options | Not Designated as Hedging Instrument | Other expense (income)        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on oil hedges 0.5 (1.5) (0.5) 1.6
Currency Forwards | Not Designated as Hedging Instrument | Other expense (income)        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on oil hedges $ 0.0 $ 0.0 $ (0.2) $ 0.0
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Assets:    
Deferred compensation assets $ 9.1 $ 12.5
Commodity call options 1.4 1.2
Total assets at fair value 35.0 32.1
Liabilities:    
Contingent consideration 4.0 4.7
Deferred compensation liabilities 9.3 12.7
Total liabilities at fair value 25.4 18.8
Foreign currency contracts    
Assets:    
Foreign currency contracts 2.4 4.5
Liabilities:    
Foreign currency contracts 12.1 1.4
Cross-currency swap    
Assets:    
Foreign currency contracts 22.1 13.9
Level 1    
Assets:    
Deferred compensation assets 9.1 12.5
Commodity call options 0.0
Total assets at fair value 9.1 12.5
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 9.3 12.7
Total liabilities at fair value 9.3 12.7
Level 1 | Foreign currency contracts    
Assets:    
Foreign currency contracts 0.0 0.0
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 1 | Cross-currency swap    
Assets:    
Foreign currency contracts 0.0 0.0
Level 2    
Assets:    
Deferred compensation assets 0.0 0.0
Commodity call options 1.4 1.2
Total assets at fair value 25.9 19.6
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 12.1 1.4
Level 2 | Foreign currency contracts    
Assets:    
Foreign currency contracts 2.4 4.5
Liabilities:    
Foreign currency contracts 12.1 1.4
Level 2 | Cross-currency swap    
Assets:    
Foreign currency contracts 22.1 13.9
Level 3    
Assets:    
Deferred compensation assets 0.0 0.0
Commodity call options 0.0
Total assets at fair value 0.0 0.0
Liabilities:    
Contingent consideration 4.0 4.7
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 4.0 4.7
Level 3 | Foreign currency contracts    
Assets:    
Foreign currency contracts 0.0 0.0
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 3 | Cross-currency swap    
Assets:    
Foreign currency contracts $ 0.0 $ 0.0
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurement - Other Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Fair Value Disclosures [Abstract]    
Long-term debt, fair value $ 147.2 $ 201.8
Long-term debt $ 152.1 $ 206.7
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance $ 2,746.7 $ 2,776.2 $ 2,684.9 $ 2,424.4 $ 2,326.2 $ 2,335.4 $ 2,684.9 $ 2,335.4
Other comprehensive (loss) income before reclassifications             (45.9) (163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income             5.9 14.4
Other comprehensive (loss) income, net of tax (39.5) (15.1) 14.6 (62.6) (63.5) (22.8) (40.0) (148.9)
Ending balance 2,868.2 2,746.7 2,776.2 2,470.8 2,424.4 2,326.2 2,868.2 2,470.8
(Losses) gains on derivatives                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     0.2     (1.2) 0.2 (1.2)
Other comprehensive (loss) income before reclassifications             (8.8) (3.5)
Amounts reclassified out from accumulated other comprehensive (loss) income             7.0 0.9
Other comprehensive (loss) income, net of tax             (1.8) (2.6)
Ending balance (1.6)     (3.8)     (1.6) (3.8)
Change in equity affiliate investment AOCI                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     1.6     1.5 1.6 1.5
Other comprehensive (loss) income before reclassifications             (0.1) (0.2)
Amounts reclassified out from accumulated other comprehensive (loss) income             0.0 0.0
Other comprehensive (loss) income, net of tax             (0.1) (0.2)
Ending balance 1.5     1.3     1.5 1.3
Defined benefit pension and other postretirement plans                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (9.4)     (31.8) (9.4) (31.8)
Other comprehensive (loss) income before reclassifications             (0.1) 2.9
Amounts reclassified out from accumulated other comprehensive (loss) income             (1.1) 13.5
Other comprehensive (loss) income, net of tax             (1.2) 16.4
Ending balance (10.6)     (15.4)     (10.6) (15.4)
Foreign currency translation                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (175.4)     (128.1) (175.4) (128.1)
Other comprehensive (loss) income before reclassifications             (36.9) (162.5)
Amounts reclassified out from accumulated other comprehensive (loss) income             0.0 0.0
Other comprehensive (loss) income, net of tax             (36.9) (162.5)
Ending balance (212.3)     (290.6)     (212.3) (290.6)
Accumulated other comprehensive loss                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance (183.5) (168.4) (183.0) (245.9) (182.4) (159.6) (183.0) (159.6)
Other comprehensive (loss) income, net of tax (39.5) (15.1) 14.6 (62.6) (63.5) (22.8)    
Ending balance $ (223.0) $ (183.5) $ (168.4) $ (308.5) $ (245.9) $ (182.4) $ (223.0) $ (308.5)
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Cost of goods and services sold $ (459.1)     $ (418.9)     $ (1,366.8) $ (1,304.1)
Interest expense (2.9)     (2.2)     (7.8) (6.2)
Actuarial gains 0.3     0.1     1.1 0.1
Settlements 0.0     (49.6)     0.0 (50.8)
Income before income taxes and equity in net income of affiliated companies 187.0     136.2     529.8 551.2
Tax (expense) benefit (29.4)     (20.4)     (87.8) (85.8)
Net income 161.3 $ 155.1 $ 140.0 120.6 $ 188.5 $ 173.8 456.4 482.9
Reclassification out of Accumulated Other Comprehensive Loss                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net income (3.3)     (13.4)     (5.9) (14.4)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives:                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Income before income taxes and equity in net income of affiliated companies (5.1)     (1.5)     (9.9) (0.9)
Tax (expense) benefit 1.6     0.4     2.9 0.0
Net income (3.5)     (1.1)     (7.0) (0.9)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Foreign currency contracts                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net sales (0.2)     0.5     (1.5) 1.2
Cost of goods and services sold (1.4)     (1.2)     (2.0) (2.9)
Other expense (income) (3.4)     (0.7)     (6.2) 1.1
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Forward treasury locks                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Interest expense (0.1)     (0.1)     (0.2) (0.3)
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans:                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Actuarial gains 0.3     1.1     1.1 1.1
Settlements 0.0     (27.6)     0.0 (28.8)
Other 0.0     0.0     0.4 (0.4)
Income before income taxes and equity in net income of affiliated companies 0.3     (26.5)     1.5 (28.1)
Tax (expense) benefit (0.1)     14.2     (0.4) 14.6
Net income $ 0.2     $ (12.3)     $ 1.1 $ (13.5)
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholder's Equity - Change in Shareholders' Equity (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares)     75,300,000       75,300,000  
Beginning balance $ 2,746.7 $ 2,776.2 $ 2,684.9 $ 2,424.4 $ 2,326.2 $ 2,335.4 $ 2,684.9 $ 2,335.4
Beginning balance (in shares)     1,200,000       1,200,000  
Net income 161.3 155.1 $ 140.0 120.6 188.5 173.8 $ 456.4 $ 482.9
Activity related to stock-based compensation $ 27.5 18.0 11.0 $ 15.6 15.1 0.1    
Share purchased under share repurchase program (in shares) 77,329     86,667     753,399 563,334
Shares purchased under share repurchase program $ (27.8) (173.4) (60.1) $ (27.2) (28.6) (147.1) $ (261.3) $ (202.9)
Dividends declared   (14.1) (14.2)   (13.3) (13.2)    
Other comprehensive income (loss), net of tax $ (39.5) (15.1) 14.6 (62.6) (63.5) (22.8) $ (40.0) (148.9)
Ending balance (in shares) 75,300,000           75,300,000  
Ending balance $ 2,868.2 $ 2,746.7 $ 2,776.2 $ 2,470.8 $ 2,424.4 $ 2,326.2 $ 2,868.2 $ 2,470.8
Ending balance (in shares) 1,300,000           1,300,000  
Common Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Beginning balance $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Ending balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Ending balance $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Capital in Excess of Par Value                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 158.2 181.4 232.2 225.3 219.9 249.0 232.2 249.0
Activity related to stock-based compensation (35.6) (23.2) (50.8) 5.3 5.4 (29.1)    
Ending balance 122.6 158.2 181.4 230.6 225.3 219.9 122.6 230.6
Treasury Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ (501.4) $ (369.2) $ (370.9) $ (366.3) $ (347.4) $ (229.5) $ (370.9) $ (229.5)
Beginning balance (in shares) 1,400,000 1,100,000 1,200,000 1,300,000 1,200,000 1,100,000 1,200,000 1,100,000
Activity related to stock-based compensation $ 63.1 $ 41.2 $ 61.8 $ 10.3 $ 9.7 $ 29.2    
Activity related to stock -based compensation (in shares) (200,000) (200,000) (300,000) (100,000)   (300,000)    
Share purchased under share repurchase program (in shares) 100,000 500,000 200,000 100,000 100,000 400,000    
Shares purchased under share repurchase program $ (27.8) $ (173.4) $ (60.1) $ (27.2) $ (28.6) $ (147.1)    
Ending balance $ (466.1) $ (501.4) $ (369.2) $ (383.2) $ (366.3) $ (347.4) $ (466.1) $ (383.2)
Ending balance (in shares) 1,300,000 1,400,000 1,100,000 1,300,000 1,300,000 1,200,000 1,300,000 1,300,000
Retained earnings                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ 3,254.6 $ 3,113.6 $ 2,987.8 $ 2,792.5 $ 2,617.3 $ 2,456.7 $ 2,987.8 $ 2,456.7
Net income 161.3 155.1 140.0 120.6 188.5 173.8    
Dividends declared   (14.1) (14.2)   (13.3) (13.2)    
Ending balance 3,415.9 3,254.6 3,113.6 2,913.1 2,792.5 2,617.3 3,415.9 2,913.1
Accumulated other comprehensive loss                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (183.5) (168.4) (183.0) (245.9) (182.4) (159.6) (183.0) (159.6)
Other comprehensive income (loss), net of tax (39.5) (15.1) 14.6 (62.6) (63.5) (22.8)    
Ending balance $ (223.0) $ (183.5) $ (168.4) $ (308.5) $ (245.9) $ (182.4) $ (223.0) $ (308.5)
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholder's Equity - Supplemental Equity Information (Details) - $ / shares
 3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Equity [Abstract]        
Dividends declared per share (in dollars per share) $ 0.19 $ 0.19 $ 0.18 $ 0.18
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares available for issuance under the 2016 Plan (in shares) 1,438,454   1,438,454  
Stock options, granted (in shares)     105,640  
Stock options, weighted average exercise price (in dollars per share)     $ 306.92  
Stock options, weighted average grant date fair value (in dollars per share)     $ 108.88  
Risk-free interest rate (in hundredths)     4.10%  
Expected life (in years)     5 years 8 months 12 days  
Stock volatility (in hundredths)     29.80%  
Dividend yield (in hundredths)     0.30%  
Stock-based compensation expense $ 5.9 $ 6.0 $ 21.9 $ 17.0
Performance Share Unit (PSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     37,536  
Grant date fair value (in dollars per share)     $ 306.91  
Performance Share Unit (PSUs) | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target award percentage     0.00%  
Performance Share Unit (PSUs) | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target award percentage     200.00%  
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     4,563  
Grant date fair value (in dollars per share)     $ 310.56  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost $ 0.2 $ 0.3 $ 0.8 $ 1.0
Interest cost 0.7 0.6 2.0 3.8
Expected return on assets (0.4) (0.8) (1.0) (5.4)
Recognized actuarial losses (gains) (0.3) (0.1) (1.1) (0.1)
Settlements 0.0 49.6 0.0 50.8
Net periodic benefit cost 0.2 49.6 0.7 50.1
U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.4) 49.3 (1.1) 49.3
International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.6 0.3 1.8 0.8
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.2 0.3 0.8 1.0
Interest cost 0.6 0.5 1.8 3.7
Expected return on assets (0.4) (0.8) (1.0) (5.4)
Recognized actuarial losses (gains) 0.2 0.3 0.5 1.0
Settlements 0.0 49.6 0.0 50.8
Net periodic benefit cost 0.6 49.9 2.1 51.1
Pension benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.0 49.6 0.3 50.3
Pension benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.6 0.3 1.8 0.8
Other retirement benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.0 0.0 0.0 0.0
Interest cost 0.1 0.1 0.2 0.1
Expected return on assets 0.0 0.0 0.0 0.0
Recognized actuarial losses (gains) (0.5) (0.4) (1.6) (1.1)
Settlements 0.0 0.0 0.0 0.0
Net periodic benefit cost (0.4) (0.3) (1.4) (1.0)
Other retirement benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.4) (0.3) (1.4) (1.0)
Other retirement benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.23.3
Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 0.0 $ 49.6 $ 0.0 $ 50.8
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 0.0 $ 49.6 0.0 $ 50.8
U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Contributions by employer     $ 6.5  
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.23.3
Other Expense (Income) - Summary (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Other Income and Expenses [Abstract]        
Loss on disposal of plant $ 0.0 $ 0.0 $ 11.6 $ 0.0
Asset impairments 3.5 1.4 6.9 1.6
Restructuring and related charges 0.0 0.0 (0.8) (1.6)
(Gain) loss on oil hedges (0.5) 1.5 0.5 (1.6)
Contingent consideration 0.7 1.5 1.5 2.6
Foreign exchange transaction losses (gains) 1.8 (2.2) 3.0 (4.6)
Other items 0.1 (0.3) (0.2) (0.4)
Total other expense (income) $ 5.6 $ 1.9 $ 22.5 $ (4.0)
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Other Expense (Income) - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
facility
Sep. 30, 2022
USD ($)
Restructuring Cost and Reserve [Line Items]          
Loss on disposal of plant   $ 0.0 $ 0.0 $ 11.6 $ 0.0
Number of loss on disposal manufacturing facility | facility       1  
Restructuring and related activities, period of implementation 24 months        
Gain (loss) on oil hedges   $ 0.5 $ (1.5) $ (0.5) $ 1.6
Minimum          
Restructuring Cost and Reserve [Line Items]          
Restructuring and related cost, expected cost $ 25.0        
Effect on future earnings, amount 22.0        
Maximum          
Restructuring Cost and Reserve [Line Items]          
Restructuring and related cost, expected cost 27.0        
Effect on future earnings, amount $ 24.0        
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Other Expense (Income) - Restructuring and Related Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Restructuring Reserve [Roll Forward]        
(Credits) Charges $ 0.0 $ 0.0 $ (0.8) $ (1.6)
2022 Restructuring Plan        
Restructuring Reserve [Roll Forward]        
Balance, December 31, 2022     25.4  
(Credits) Charges     (0.8)  
Cash payments     (3.7)  
Non-cash asset write downs     (15.3)  
Balance, September 30, 2023 5.6   5.6  
Severance and benefits | 2022 Restructuring Plan        
Restructuring Reserve [Roll Forward]        
Balance, December 31, 2022     10.1  
(Credits) Charges     (0.8)  
Cash payments     (3.7)  
Non-cash asset write downs     0.0  
Balance, September 30, 2023 5.6   5.6  
Other charges | 2022 Restructuring Plan        
Restructuring Reserve [Roll Forward]        
Balance, December 31, 2022     15.3  
(Credits) Charges     0.0  
Cash payments     0.0  
Non-cash asset write downs     (15.3)  
Balance, September 30, 2023 $ 0.0   $ 0.0  
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 29.4 $ 20.4 $ 87.8 $ 85.8
Effective income tax rate 15.70% 15.00% 16.60% 15.60%
Tax benefit from termination of pension plans   $ 20.0   $ 20.3
Effective income tax rate reconciliation tax benefit       $ 5.9
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
facility
segment
Sep. 30, 2022
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales $ 747.4 $ 686.9 $ 2,217.8 $ 2,178.2
Operating profit 177.3 186.2 515.1 604.3
Stock-based compensation expense     (21.9) (17.0)
Loss on disposal of plant 0.0 0.0 (11.6) 0.0
Interest (income) expense and other nonoperating (income) expense, net (9.7) 50.0 (14.7) 53.1
Income before income taxes and equity in net income of affiliated companies 187.0 136.2 $ 529.8 551.2
Number of loss on disposal manufacturing facility | facility     1  
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating profit 202.6 203.3 $ 599.8 663.9
Intersegment sales elimination        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 0.0 (0.1) 0.0 (0.3)
Corporate and Unallocated        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating profit (25.3) (17.1) (84.7) (59.6)
Stock-based compensation expense (5.9) (6.0) (21.9) (17.0)
Corporate general costs (15.9) (10.9) (47.2) (43.6)
Loss on disposal of plant 0.0 0.0 (11.6) 0.0
Cost investment impairment (3.3) 0.0 (3.3) 0.0
Amortization of acquisition-related intangible assets (0.2) (0.2) (0.6) (0.6)
Corporate and Unallocated | 2022 Restructuring Plan        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Restructuring and other charges 0.0 0.0 (0.1) 1.6
Inventory write-down     0.9  
Corporate and Unallocated | 2022 Restructuring Plan | Other Operating Income (Expense)        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Benefit within other expense (income) for revised severance estimates     0.8  
Proprietary Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 602.5 567.0 1,803.6 1,822.0
Operating profit 181.6 188.6 546.5 615.9
Contract-Manufactured Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 144.9 120.0 414.2 356.5
Operating profit $ 21.0 $ 14.7 $ 53.3 $ 48.0
XML 82 wst-20230930_htm.xml IDEA: XBRL DOCUMENT 0000105770 2023-01-01 2023-09-30 0000105770 2023-10-16 0000105770 2023-07-01 2023-09-30 0000105770 2022-07-01 2022-09-30 0000105770 2022-01-01 2022-09-30 0000105770 2023-09-30 0000105770 2022-12-31 0000105770 2021-12-31 0000105770 2022-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 2013-06-30 0000105770 wst:SmartDoseMember 2023-09-30 0000105770 2023-02-28 0000105770 wst:DistributorshipAgreementMember 2023-07-01 2023-09-30 0000105770 wst:DistributorshipAgreementMember 2023-01-01 2023-09-30 0000105770 wst:DistributorshipAgreementMember 2022-07-01 2022-09-30 0000105770 wst:DistributorshipAgreementMember 2022-01-01 2022-09-30 0000105770 srt:AffiliatedEntityMember 2023-09-30 0000105770 srt:AffiliatedEntityMember 2022-12-31 0000105770 srt:AffiliatedEntityMember 2023-07-01 2023-09-30 0000105770 srt:AffiliatedEntityMember 2023-01-01 2023-09-30 0000105770 srt:AffiliatedEntityMember 2022-07-01 2022-09-30 0000105770 srt:AffiliatedEntityMember 2022-01-01 2022-09-30 0000105770 wst:TermLoanDue2024Member 2023-09-30 0000105770 wst:TermLoanDue2024Member 2022-12-31 0000105770 wst:SeniorBNotesDue2024Member 2023-09-30 0000105770 wst:SeniorBNotesDue2024Member 2022-12-31 0000105770 wst:SeniorCNotesDue2027Member 2023-09-30 0000105770 wst:SeniorCNotesDue2027Member 2022-12-31 0000105770 wst:Revolvingcreditfacilitydue2024Member 2023-09-30 0000105770 us-gaap:LetterOfCreditMember wst:Revolvingcreditfacilitydue2024Member 2023-09-30 0000105770 wst:TermLoanDue2024Member us-gaap:SecuredDebtMember 2023-09-30 0000105770 currency:SGD us-gaap:ForwardContractsMember 2023-09-30 0000105770 currency:SGD us-gaap:ForwardContractsMember 2022-12-31 0000105770 currency:EUR us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember 2023-09-30 0000105770 currency:SGD us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember 2023-09-30 0000105770 us-gaap:ForeignExchangeForwardMember 2023-01-01 2023-09-30 0000105770 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-09-30 0000105770 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-09-30 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2023-09-30 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2023-09-30 0000105770 us-gaap:OptionMember 2017-11-01 2023-09-30 0000105770 us-gaap:OptionMember 2023-01-01 2023-09-30 0000105770 us-gaap:OptionMember 2023-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:FairValueHedgingMember 2023-07-01 2023-09-30 0000105770 us-gaap:FairValueHedgingMember 2023-01-01 2023-09-30 0000105770 us-gaap:FairValueHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:FairValueHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:CashFlowHedgingMember 2023-07-01 2023-09-30 0000105770 us-gaap:CashFlowHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2023-07-01 2023-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2023-07-01 2023-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0000105770 us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2023-01-01 2023-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2023-01-01 2023-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-09-30 0000105770 wst:NetSalesMember 2023-07-01 2023-09-30 0000105770 wst:NetSalesMember 2022-07-01 2022-09-30 0000105770 wst:NetSalesMember 2023-01-01 2023-09-30 0000105770 wst:NetSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000105770 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000105770 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000105770 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0000105770 us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0000105770 us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0000105770 us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2023-07-01 2023-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2023-01-01 2023-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:NondesignatedMember 2023-07-01 2023-09-30 0000105770 us-gaap:NondesignatedMember 2022-07-01 2022-09-30 0000105770 us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0000105770 us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2023-09-30 0000105770 us-gaap:FairValueInputsLevel2Member 2023-09-30 0000105770 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0000105770 us-gaap:CurrencySwapMember 2023-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000105770 us-gaap:ForeignExchangeContractMember 2022-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000105770 us-gaap:CurrencySwapMember 2022-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2023-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 2023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000105770 us-gaap:CommonStockMember 2022-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-12-31 0000105770 us-gaap:RetainedEarningsMember 2022-12-31 0000105770 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000105770 2023-01-01 2023-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000105770 us-gaap:CommonStockMember 2023-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-03-31 0000105770 us-gaap:RetainedEarningsMember 2023-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000105770 2023-03-31 0000105770 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000105770 2023-04-01 2023-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000105770 us-gaap:CommonStockMember 2023-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-06-30 0000105770 us-gaap:RetainedEarningsMember 2023-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000105770 2023-06-30 0000105770 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000105770 us-gaap:CommonStockMember 2023-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2023-09-30 0000105770 us-gaap:RetainedEarningsMember 2023-09-30 0000105770 us-gaap:CommonStockMember 2021-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2021-12-31 0000105770 us-gaap:RetainedEarningsMember 2021-12-31 0000105770 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000105770 2022-01-01 2022-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000105770 us-gaap:CommonStockMember 2022-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-03-31 0000105770 us-gaap:RetainedEarningsMember 2022-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000105770 2022-03-31 0000105770 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000105770 2022-04-01 2022-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000105770 us-gaap:CommonStockMember 2022-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-06-30 0000105770 us-gaap:RetainedEarningsMember 2022-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000105770 2022-06-30 0000105770 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000105770 us-gaap:CommonStockMember 2022-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-09-30 0000105770 us-gaap:RetainedEarningsMember 2022-09-30 0000105770 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0000105770 srt:MinimumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0000105770 srt:MaximumMember us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0000105770 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 country:US 2023-07-01 2023-09-30 0000105770 country:US 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember 2023-07-01 2023-09-30 0000105770 us-gaap:ForeignPlanMember 2022-07-01 2022-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 country:US 2023-01-01 2023-09-30 0000105770 country:US 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember 2023-01-01 2023-09-30 0000105770 us-gaap:ForeignPlanMember 2022-01-01 2022-09-30 0000105770 2022-12-01 2022-12-31 0000105770 srt:MinimumMember 2022-12-31 0000105770 srt:MaximumMember 2022-12-31 0000105770 srt:MinimumMember 2022-12-01 2022-12-31 0000105770 srt:MaximumMember 2022-12-01 2022-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2022RestructuringPlanMember 2022-12-31 0000105770 us-gaap:OtherRestructuringMember wst:A2022RestructuringPlanMember 2022-12-31 0000105770 wst:A2022RestructuringPlanMember 2022-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0000105770 us-gaap:OtherRestructuringMember wst:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0000105770 wst:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2022RestructuringPlanMember 2023-09-30 0000105770 us-gaap:OtherRestructuringMember wst:A2022RestructuringPlanMember 2023-09-30 0000105770 wst:A2022RestructuringPlanMember 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2023-07-01 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2022-07-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2023-01-01 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2022-01-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2023-07-01 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2022-07-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2023-01-01 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2022-01-01 2022-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2023-07-01 2023-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2022-07-01 2022-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0000105770 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember wst:A2022RestructuringPlanMember 2023-07-01 2023-09-30 0000105770 us-gaap:CorporateNonSegmentMember wst:A2022RestructuringPlanMember 2022-07-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember wst:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0000105770 us-gaap:CorporateNonSegmentMember wst:A2022RestructuringPlanMember 2022-01-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember us-gaap:OtherOperatingIncomeExpenseMember wst:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0000105770 wst:EricMGreenMember 2023-01-01 2023-09-30 0000105770 wst:EricMGreenMember 2023-07-01 2023-09-30 0000105770 wst:EricMGreenMember 2023-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:facility wst:segment 0000105770 --12-31 2023 Q3 false P364D 10-Q true 2023-09-30 false 1-8036 WEST PHARMACEUTICAL SERVICES, INC. PA 23-1210010 530 Herman O. West Drive Exton PA 19341-1147 610 594-2900 Common Stock, par value $0.25 per share WST NYSE Yes Yes Large Accelerated Filer false false false 73989670 747400000 686900000 2217800000 2178200000 459100000 418900000 1366800000 1304100000 288300000 268000000.0 851000000.0 874100000 16400000 13600000 50000000.0 42600000 89000000.0 66300000 263400000 231200000 -5600000 -1900000 -22500000 4000000.0 177300000 186200000 515100000 604300000 2900000 2200000 7800000 6200000 8800000 1500000 18600000 2200000 3800000 -49300000 3900000 -49100000 187000000.0 136200000 529800000 551200000 29400000 20400000 87800000 85800000 3700000 4800000 14400000 17500000 161300000 120600000 456400000 482900000 2.17 1.62 6.13 6.49 2.14 1.59 6.05 6.36 74300000 74400000 74400000 74400000 75300000 75700000 75500000 75900000 161300000 120600000 456400000 482900000 400000 1100000 1900000 3800000 -40900000 -76000000.0 -36900000 -162500000 0.0 14600000 -500000 15500000 -200000 -13600000 1200000 -16400000 0.0 0.0 0.0 0.0 0 -100000 -100000 -200000 800000 0.0 -300000 -800000 1200000 -100000 -1800000 -2600000 -39500000 -62600000 -40000000.0 -148900000 121800000 58000000.0 416400000 334000000.0 898600000 894300000 519100000 507400000 431800000 414800000 122800000 103000000.0 1972300000 1919500000 2607100000 2386600000 1295500000 1228300000 1311600000 1158300000 96800000 104400000 195400000 204900000 106800000 107300000 15700000 18400000 17300000 65600000 38800000 38400000 3754700000 3616800000 55200000 2200000 219800000 215400000 90500000 76800000 15000000.0 24800000 16500000 16000000.0 136500000 183800000 533500000 519000000.0 152100000 206700000 16500000 14300000 28400000 28200000 83000000.0 93000000.0 17900000 19100000 55100000 51600000 886500000 931900000 3000000 3000000 0 0 0 0 0 0 0.25 0.25 200000000 200000000 75300000 75300000 74000000 74100000 18800000 18800000 122600000 232200000 3415900000 2987800000 -223000000.0 -183000000.0 1300000 1200000 466100000 370900000 2868200000 2684900000 3754700000 3616800000 456400000 482900000 99100000 86800000 2300000 2700000 21900000 17000000.0 -11600000 0 6900000 1600000 0 -50800000 13500000 17900000 47300000 130700000 537400000 493200000 253300000 189700000 6600000 3700000 -259900000 -193400000 1700000 43700000 0 1300000 42200000 40000000.0 42600000 17100000 5300000 6100000 261300000 202900000 12800000 19400000 -270100000 -284100000 -3100000 -49300000 4300000 -33600000 894300000 762600000 898600000 729000000.0 Basis of Presentation and Summary of Significant Accounting Policies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023.</span></div> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of September 30, 2023.</span></div> Revenue<div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. </span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, September 30, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, September 30, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2023, $33.2 million of revenue was recognized that was included in deferred income at the beginning of the year. </span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform within a specific therapeutic area. As of September 30, 2023, there was $2.4 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $1.5 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span></div> <div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. </span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div> 0.40 0.41 0.37 0.42 0.19 0.18 0.20 0.18 0.22 0.24 0.24 0.24 0.19 0.17 0.19 0.16 1 1 1 1 0.50 0.54 0.50 0.56 0.11 0.06 0.10 0.05 0.20 0.23 0.21 0.23 0.19 0.17 0.19 0.16 1 1 1 1 0.46 0.53 0.45 0.48 0.46 0.38 0.46 0.43 0.08 0.09 0.09 0.09 1 1 1 1 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, September 30, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, September 30, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 16300000 19900000 3600000 68200000 50000000.0 18200000 33200000 20000000 2400000 900000 1500000 Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023 and 2022, there were 0.0 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.1 million antidilutive shares outstanding during the nine months ended September 30, 2023 and 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. During the three months ended September 30, 2023, we purchased 77,329 shares of our common stock under the program at a cost of $27.8 million, or an average price of $360.25 per share. During the nine months ended September 30, 2023, we purchased 753,399 shares of our common stock under the program at a cost of $261.3 million, or an average price of $346.86 per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions was dependent on a variety of factors, including market conditions. This share repurchase program was completed by December 31, 2022. During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the calendar-year 2022 program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the calendar-year 2022 program at a cost of $202.9 million, or an average price of $360.03 per share.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 161300000 120600000 456400000 482900000 74300000 74400000 74400000 74400000 1000000.0 1300000 1100000 1500000 75300000 75700000 75500000 75900000 0 200000 100000 100000 1000000000 77329 27800000 360.25 753399 261300000 346.86 650000 86667 27200000 313.22 563334 202900000 360.03 Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 180200000 170700000 93800000 79000000.0 157800000 165100000 431800000 414800000 Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the weighted average remaining lease term for operating leases was 10.1 years and 9.3 years, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the weighted average discount rate was 3.46% and 3.25%, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4300000 3700000 15000000.0 10400000 1900000 300000 4400000 1100000 1400000 2300000 4400000 4700000 7600000 6300000 23800000 16200000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4500000 3700000 14400000 10000000.0 3100000 14000000.0 6600000 29500000 P10Y1M6D P9Y3M18D 0.0346 0.0325 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 4800000 19000000.0 19100000 18100000 17100000 16000000.0 14100000 13400000 9800000 9400000 50600000 50800000 115500000 126700000 16000000.0 17700000 99500000 109000000.0 Affiliated Companies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023 and December 31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $189.7 million and $197.0 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $5.7 million and $7.9 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases from, and royalty payments made to, affiliates totaled $34.4 million and $118.5 million for the three and nine months ended September 30, 2023, respectively, as compared to $33.6 million and $131.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the payable balance due to affiliates was $20.6 million and $31.2 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products. </span></div>Sales to affiliates were $2.5 million and $8.5 million, respectively, for the three and nine months ended September 30, 2023, as compared to $2.6 million and $10.2 million, respectively, for the same periods in 2022. As of September 30, 2023 and December 31, 2022, the receivable balance due from affiliates was $1.3 million and $2.2 million, respectively. 189700000 197000000 5700000 7900000 34400000 118500000 33600000 131200000 20600000 31200000 2500000 8500000 2600000 10200000 1300000 2200000 Debt<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (6.37%)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, we had $81.5 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $79.3 million was classified as long-term. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2023, we were in compliance with all of our debt covenants.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (6.37%)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0637 81500000 83200000 0.0382 53000000.0 53000000.0 0.0402 73000000.0 73000000.0 207500000 209200000 200000 300000 207300000 208900000 55200000 2200000 152100000 206700000 500000000 2400000 497600000 81500000 2200000 79300000 Derivative Financial InstrumentsOur ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency interco</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpany loans. As of both September 30, 2023 and December 31, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed in June 2023. As of September 30, 2023, the total amount of these forward exchange contracts was Euro ("EUR") 278.6 million and SGD 94.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:33.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,159.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2023, the notional amount of the cross-currency swap is ¥8.9 billion ($81.5 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From November 2017 through September 2023, we purchased several series of call options for a total of 975,206 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had outstanding contracts to purchase 229,397 barrels of crude oil from September 2023 to March 2025, at a weighted-average strike price of $94.93 per barrel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the balance sheet location and fair values of our derivative instruments as of September 30, 2023 and December 31, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2023 were $0.2 million and $1.6 million, respectively. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 were $1.1 million and $2.8 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Loss) Gain Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency Forwards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023 and 2022, there was no material ineffectiveness related to our hedges.</span></div> 601500000 13400000 278600000 94000000 P18M As of September 30, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:33.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,159.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 20300000 22300000 0 5159300000 29800000 9000000.0 44700000 15200000 16800000 90000000 8900000000 81500000 975206 229397 94.93 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three and nine months ended September 30, 2023 and September 30, 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1200000 14100000 -8700000 35400000 -700000 -14100000 10000000.0 -35400000 1500000 -2200000 400000 -4400000 2000000.0 -2200000 1700000 -4400000 -200000 -1600000 -1100000 -2800000 -300000 -400000 -2300000 -500000 -300000 -400000 -2300000 -500000 500000 700000 -100000 500000 -2500000 -1500000 -1100000 -1000000.0 0 0 0 -100000 -2000000.0 -800000 -1200000 -600000 2900000 4300000 0 0 2900000 4300000 0 0 -2300000 300000 -4200000 700000 -2300000 300000 -4200000 700000 -400000 1100000 -1200000 1100000 -6100000 -4900000 -1500000 -2500000 0 0 -100000 -200000 -6500000 -3800000 -2800000 -1600000 10100000 13200000 0 0 10100000 13200000 0 0 100000 -500000 1200000 -1100000 1100000 1000000.0 1500000 2500000 0 100000 100000 200000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Loss) Gain Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency Forwards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Loss) Gain Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency Forwards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> 500000 -1500000 -500000 1600000 0 0 -200000 0 500000 -1500000 -700000 1600000 Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform (the “SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2023, the estimated fair value of long-term debt was $147.2 million compared to a carrying amount of $152.1 million. At December 31, 2022, the estimated fair value of long-term debt was $201.8 million and the carrying amount was $206.7 million.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9100000 9100000 0 0 2400000 0 2400000 0 22100000 0 22100000 0 1400000 0 1400000 0 35000000.0 9100000 25900000 0 4000000.0 0 0 4000000.0 9300000 9300000 0 0 12100000 0 12100000 0 25400000 9300000 12100000 4000000.0 12500000 12500000 0 0 4500000 0 4500000 0 13900000 0 13900000 0 1200000 1200000 32100000 12500000 19600000 0 4700000 0 0 4700000 12700000 12700000 0 0 1400000 0 1400000 0 18800000 12700000 1400000 4700000 147200000 152100000 201800000 206700000 Accumulated Other Comprehensive Loss<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.269%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 200000 1600000 -9400000 -175400000 -183000000.0 -8800000 -100000 -100000 -36900000 -45900000 -7000000.0 0 1100000 0 -5900000 -1800000 -100000 -1200000 -36900000 -40000000.0 -1600000 1500000 -10600000 -212300000 -223000000.0 -1200000 1500000 -31800000 -128100000 -159600000 -3500000 -200000 2900000 -162500000 -163300000 -900000 0 -13500000 0 -14400000 -2600000 -200000 16400000 -162500000 -148900000 -3800000 1300000 -15400000 -290600000 -308500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.269%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> -200000 500000 -1500000 1200000 1400000 1200000 2000000.0 2900000 -3400000 -700000 -6200000 1100000 100000 100000 200000 300000 -5100000 -1500000 -9900000 -900000 -1600000 -400000 -2900000 0 -3500000 -1100000 -7000000.0 -900000 300000 1100000 1100000 1100000 0 -27600000 0 -28800000 0 0 -400000 400000 300000 -26500000 1500000 -28100000 100000 -14200000 400000 -14600000 200000 -12300000 1100000 -13500000 -3300000 -13400000 -5900000 -14400000 Shareholders<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.431%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.19 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.19 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,254.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,746.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(466.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"></td><td style="width:32.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.473%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.431%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.19 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.19 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,254.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,746.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(466.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"></td><td style="width:32.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.473%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 75300000 18800000 232200000 1200000 -370900000 2987800000 -183000000.0 2684900000 140000000.0 140000000.0 -50800000 -300000 61800000 11000000.0 200000 60100000 60100000 0.19 14200000 14200000 14600000 14600000 75300000 18800000 181400000 1100000 -369200000 3113600000 -168400000 2776200000 155100000 155100000 -23200000 -200000 41200000 18000000.0 500000 173400000 173400000 0.19 14100000 14100000 -15100000 -15100000 75300000 18800000 158200000 1400000 -501400000 3254600000 -183500000 2746700000 161300000 161300000 -35600000 -200000 63100000 27500000 100000 27800000 27800000 -39500000 -39500000 75300000 18800000 122600000 1300000 -466100000 3415900000 -223000000.0 2868200000 75300000 18800000 249000000.0 1100000 -229500000 2456700000 -159600000 2335400000 173800000 173800000 -29100000 -300000 29200000 100000 400000 147100000 147100000 0.18 13200000 13200000 -22800000 -22800000 75300000 18800000 219900000 1200000 -347400000 2617300000 -182400000 2326200000 188500000 188500000 5400000 9700000 15100000 100000 28600000 28600000 0.18 13300000 13300000 -63500000 -63500000 75300000 18800000 225300000 1300000 -366300000 2792500000 -245900000 2424400000 120600000 120600000 5300000 -100000 10300000 15600000 100000 27200000 27200000 -62600000 -62600000 75300000 18800000 230600000 1300000 -383200000 2913100000 -308500000 2470800000 Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2023, there were 1,438,454 shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, we granted 105,640 stock options at a weighted average exercise price of $306.92 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $108.88 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 5.7 years based on prior experience; stock volatility of 29.8% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, we granted 37,536 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $306.91 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, we granted 4,563 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $310.56 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. </span></div>Stock-based compensation expense was $5.9 million and $21.9 million for the three and nine months ended September 30, 2023, respectively. For the three and nine months ended September 30, 2022, stock-based compensation expense was $6.0 million and $17.0 million, respectively. 1438454 105640 306.92 108.88 0.041 P5Y8M12D 0.298 0.003 37536 306.91 0 2 4563 310.56 5900000 21900000 6000000 17000000 Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating (income) expense, which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 200000 300000 0 0 200000 300000 600000 500000 100000 100000 700000 600000 400000 800000 0 0 400000 800000 -200000 -300000 500000 400000 300000 100000 0 -49600000 0 0 0 -49600000 600000 49900000 -400000 -300000 200000 49600000 0 49600000 -400000 -300000 -400000 49300000 600000 300000 0 0 600000 300000 600000 49900000 -400000 -300000 200000 49600000 800000 1000000.0 0 0 800000 1000000.0 1800000 3700000 200000 100000 2000000.0 3800000 1000000.0 5400000 0 0 1000000.0 5400000 -500000 -1000000.0 1600000 1100000 1100000 100000 0 -50800000 0 0 0 -50800000 2100000 51100000 -1400000 -1000000.0 700000 50100000 300000 50300000 -1400000 -1000000.0 -1100000 49300000 1800000 800000 0 0 1800000 800000 2100000 51100000 -1400000 -1000000.0 700000 50100000 6500000 -49600000 -50800000 Other Expense (Income) <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of plant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on oil hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Disposal of Plant</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million, respectively, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $25 million to $27 million, with annualized savings in the range of $22 million to $24 million. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credits) Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash asset write downs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oil Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023, we recorded a gain of $0.5 million and a loss of $0.5 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our hedging activity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents changes in the fair value of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration. Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span>, for additional details. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of plant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on oil hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 -11600000 0 3500000 1400000 6900000 1600000 0 0 -800000 -1600000 500000 -1500000 -500000 1600000 700000 1500000 1500000 2600000 -1800000 2200000 -3000000.0 4600000 -100000 300000 200000 400000 -5600000 -1900000 -22500000 4000000.0 -11600000 1 P24M 25000000 27000000 22000000 24000000 The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credits) Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash asset write downs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 10100000 15300000 25400000 -800000 0 -800000 3700000 0 3700000 0 15300000 15300000 5600000 0 5600000 500000 -500000 -1500000 1600000 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was $29.4 million and $20.4 million for the three months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 15.7% and 15.0%, respectively. The increase in the effective tax rate is primarily due to a t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ax benefit of $20.0 million related to the termination of the U.S. pension plan recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September 30, 2022 that was not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the three months ended September 30, 2023, as compared to the same period in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was $87.8 million and $85.8 million for the nine months ended September 30, 2023 and 2022, respectively, and the effective tax rate was 16.6% and 15.6%, respectively. The increase in the effective tax rate is primarily due to a t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ax benefit of $20.3 million related to the termination of the U.S. pension plan recorded in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022 and a $5.9 million tax benefit recorded as the result of a state tax valuation allowance reversal in the nine months ended September 30, 2022 that were not repeated in the same period in 2023. This was offset by an increase in the tax benefit related to stock-based compensation in the nine months ended September 30, 2023, as compared to the same period in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 29400000 20400000 0.157 0.150 -20000000 87800000 85800000 0.166 0.156 -20300000 5900000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the commitments and contingencies included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> Segment Information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of plant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost investment impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and other charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense and other nonoperating (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other charges of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2023 represents the net impact of an</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inventory write down of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million within cost of goods and services sold and a $0.8 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> benefit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within other expense (income) </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for revised severance estimates in connection with its 2022 restructuring plan. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with its 2020 plan related to revised severance estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#iffef58fe44ff47d88f268776293f7d8b_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Expense (Income)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of these items.</span></div> 2 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of plant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost investment impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and other charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense and other nonoperating (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the nine months ended September 30, 2023, the Company recorded expense of $11.6 million within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During the three and nine months ended September 30, 2023, the Company recorded expense of $3.3 million within other expense (income), as a result of an impairment of one of the Company's cost investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and other charges of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2023 represents the net impact of an</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inventory write down of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million within cost of goods and services sold and a $0.8 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> benefit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within other expense (income) </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for revised severance estimates in connection with its 2022 restructuring plan. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022, the Company recorded a benefit within other expense (income) of $1.6 million for restructuring and severance related costs </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with its 2020 plan related to revised severance estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) During the three and nine months ended September 30, 2023, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div> 602500000 567000000.0 1803600000 1822000000 144900000 120000000.0 414200000 356500000 0 -100000 0 -300000 747400000 686900000 2217800000 2178200000 181600000 188600000 546500000 615900000 21000000.0 14700000 53300000 48000000.0 202600000 203300000 599800000 663900000 5900000 6000000.0 21900000 17000000.0 15900000 10900000 47200000 43600000 0 0 -11600000 0 3300000 0 3300000 0 0 0 100000 -1600000 200000 200000 600000 600000 -25300000 -17100000 -84700000 -59600000 177300000 186200000 515100000 604300000 9700000 -50000000.0 14700000 -53100000 187000000.0 136200000 529800000 551200000 -11600000 1 3300000 100000 900000 800000 -1600000 200000 600000 200000 600000 false false false false Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors, entered into a prearranged stock trading arrangement on May 5, 2023. Mr. Green’s plan provides for the purchase and sale of an aggregate number of 234,864 shares of the Company's common stock (of which Mr. Green will sell 204,864 shares and retain the rest immediately following the exercise) between August 8, 2023 and August 6, 2024. The trading plan was entered into during an open insider trading window and is intended to satisfy Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding insider transactions. Eric M. Green President and Chief Executive Officer, Chair of the Board of Directors May 5, 2023 234864 EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

/I M)P(*"ZD16'W

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 380 297 1 false 79 0 false 11 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.westpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - New Accounting Standards Sheet http://www.westpharma.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Sheet http://www.westpharma.com/role/Revenue Revenue Notes 10 false false R11.htm 0000011 - Disclosure - Net Income Per Share Sheet http://www.westpharma.com/role/NetIncomePerShare Net Income Per Share Notes 11 false false R12.htm 0000012 - Disclosure - Inventories Sheet http://www.westpharma.com/role/Inventories Inventories Notes 12 false false R13.htm 0000013 - Disclosure - Leases Sheet http://www.westpharma.com/role/Leases Leases Notes 13 false false R14.htm 0000014 - Disclosure - Affiliated Companies Sheet http://www.westpharma.com/role/AffiliatedCompanies Affiliated Companies Notes 14 false false R15.htm 0000015 - Disclosure - Debt Sheet http://www.westpharma.com/role/Debt Debt Notes 15 false false R16.htm 0000016 - Disclosure - Derivative Financial Instruments Sheet http://www.westpharma.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 16 false false R17.htm 0000017 - Disclosure - Fair Value Measurements Sheet http://www.westpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 0000018 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 18 false false R19.htm 0000019 - Disclosure - Shareholders' Equity Sheet http://www.westpharma.com/role/ShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 0000020 - Disclosure - Stock-Based Compensation Sheet http://www.westpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 0000021 - Disclosure - Benefit Plans Sheet http://www.westpharma.com/role/BenefitPlans Benefit Plans Notes 21 false false R22.htm 0000022 - Disclosure - Other Expense (Income) Sheet http://www.westpharma.com/role/OtherExpenseIncome Other Expense (Income) Notes 22 false false R23.htm 0000023 - Disclosure - Income Taxes Sheet http://www.westpharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 0000024 - Disclosure - Commitments and Contingencies Sheet http://www.westpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 0000025 - Disclosure - Segment Information Sheet http://www.westpharma.com/role/SegmentInformation Segment Information Notes 25 false false R26.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 28 false false R29.htm 9954472 - Disclosure - Revenue (Tables) Sheet http://www.westpharma.com/role/RevenueTables Revenue (Tables) Tables http://www.westpharma.com/role/Revenue 29 false false R30.htm 9954473 - Disclosure - Net Income Per Share (Tables) Sheet http://www.westpharma.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.westpharma.com/role/NetIncomePerShare 30 false false R31.htm 9954474 - Disclosure - Inventories (Tables) Sheet http://www.westpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.westpharma.com/role/Inventories 31 false false R32.htm 9954475 - Disclosure - Leases (Tables) Sheet http://www.westpharma.com/role/LeasesTables Leases (Tables) Tables http://www.westpharma.com/role/Leases 32 false false R33.htm 9954476 - Disclosure - Debt (Tables) Sheet http://www.westpharma.com/role/DebtTables Debt (Tables) Tables http://www.westpharma.com/role/Debt 33 false false R34.htm 9954477 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.westpharma.com/role/DerivativeFinancialInstruments 34 false false R35.htm 9954478 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.westpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.westpharma.com/role/FairValueMeasurements 35 false false R36.htm 9954479 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss 36 false false R37.htm 9954480 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.westpharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.westpharma.com/role/ShareholdersEquity 37 false false R38.htm 9954481 - Disclosure - Benefit Plans (Tables) Sheet http://www.westpharma.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.westpharma.com/role/BenefitPlans 38 false false R39.htm 9954482 - Disclosure - Other Expense (Income) (Tables) Sheet http://www.westpharma.com/role/OtherExpenseIncomeTables Other Expense (Income) (Tables) Tables http://www.westpharma.com/role/OtherExpenseIncome 39 false false R40.htm 9954483 - Disclosure - Segment Information (Tables) Sheet http://www.westpharma.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.westpharma.com/role/SegmentInformation 40 false false R41.htm 9954484 - Disclosure - Revenue - Revenue Recognition (Details) Sheet http://www.westpharma.com/role/RevenueRevenueRecognitionDetails Revenue - Revenue Recognition (Details) Details 41 false false R42.htm 9954485 - Disclosure - Revenue - Contracts and Liabilities (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails Revenue - Contracts and Liabilities (Details) Details 42 false false R43.htm 9954486 - Disclosure - Revenue - Narrative (Details) Sheet http://www.westpharma.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 43 false false R44.htm 9954487 - Disclosure - Net Income Per Share - Schedule of Net Income Per Share (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails Net Income Per Share - Schedule of Net Income Per Share (Details) Details 44 false false R45.htm 9954488 - Disclosure - Net Income Per Share - Narrative (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails Net Income Per Share - Narrative (Details) Details 45 false false R46.htm 9954489 - Disclosure - Inventories (Details) Sheet http://www.westpharma.com/role/InventoriesDetails Inventories (Details) Details http://www.westpharma.com/role/InventoriesTables 46 false false R47.htm 9954490 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 47 false false R48.htm 9954491 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails Leases - Lease Cash Flow and Supplemental Information (Details) Details 48 false false R49.htm 9954492 - Disclosure - Leases - Lease Weighted Average (Details) Sheet http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails Leases - Lease Weighted Average (Details) Details 49 false false R50.htm 9954493 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) Sheet http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails Leases - Maturities of Operating Lease Liabilities (Details) Details 50 false false R51.htm 9954494 - Disclosure - Affiliated Companies (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesDetails Affiliated Companies (Details) Details http://www.westpharma.com/role/AffiliatedCompanies 51 false false R52.htm 9954495 - Disclosure - Debt - Long-term Debt (Details) Sheet http://www.westpharma.com/role/DebtLongtermDebtDetails Debt - Long-term Debt (Details) Details 52 false false R53.htm 9954496 - Disclosure - Debt - Narrative (Details) Sheet http://www.westpharma.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 53 false false R54.htm 9954497 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) Details 54 false false R55.htm 9954498 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Details 55 false false R56.htm 9954499 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) Details 56 false false R57.htm 9954500 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Details 57 false false R58.htm 9954501 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails Fair Value Measurement - Other Financial Instruments (Details) Details 58 false false R59.htm 9954502 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Details 59 false false R60.htm 9954503 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Details 60 false false R61.htm 9954504 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) Sheet http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails Shareholder's Equity - Change in Shareholders' Equity (Details) Details 61 false false R62.htm 9954505 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) Sheet http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails Shareholder's Equity - Supplemental Equity Information (Details) Details 62 false false R63.htm 9954506 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.westpharma.com/role/StockBasedCompensation 63 false false R64.htm 9954507 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Sheet http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Details 64 false false R65.htm 9954508 - Disclosure - Benefit Plans - Narrative (Details) Sheet http://www.westpharma.com/role/BenefitPlansNarrativeDetails Benefit Plans - Narrative (Details) Details 65 false false R66.htm 9954509 - Disclosure - Other Expense (Income) - Summary (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails Other Expense (Income) - Summary (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 66 false false R67.htm 9954510 - Disclosure - Other Expense (Income) - Narrative (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails Other Expense (Income) - Narrative (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 67 false false R68.htm 9954511 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails Other Expense (Income) - Restructuring and Related Charges (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 68 false false R69.htm 9954512 - Disclosure - Income Taxes (Details) Sheet http://www.westpharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.westpharma.com/role/IncomeTaxes 69 false false R70.htm 9954513 - Disclosure - Segment Information (Details) Sheet http://www.westpharma.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.westpharma.com/role/SegmentInformationTables 70 false false All Reports Book All Reports wst-20230930.htm wst-20230930.xsd wst-20230930_cal.xml wst-20230930_def.xml wst-20230930_lab.xml wst-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 89 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "wst-20230930.htm": { "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20230930", "dts": { "inline": { "local": [ "wst-20230930.htm" ] }, "schema": { "local": [ "wst-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "wst-20230930_cal.xml" ] }, "definitionLink": { "local": [ "wst-20230930_def.xml" ] }, "labelLink": { "local": [ "wst-20230930_lab.xml" ] }, "presentationLink": { "local": [ "wst-20230930_pre.xml" ] } }, "keyStandard": 285, "keyCustom": 12, "axisStandard": 28, "axisCustom": 0, "memberStandard": 59, "memberCustom": 19, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 1 }, "contextCount": 380, "entityCount": 1, "segmentCount": 79, "elementCount": 576, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1195, "http://xbrl.sec.gov/ecd/2023": 10, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.westpharma.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R3": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R4": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R8": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.westpharma.com/role/NewAccountingStandards", "longName": "0000009 - Disclosure - New Accounting Standards", "shortName": "New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.westpharma.com/role/Revenue", "longName": "0000010 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.westpharma.com/role/NetIncomePerShare", "longName": "0000011 - Disclosure - Net Income Per Share", "shortName": "Net Income Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.westpharma.com/role/Inventories", "longName": "0000012 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.westpharma.com/role/Leases", "longName": "0000013 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.westpharma.com/role/AffiliatedCompanies", "longName": "0000014 - Disclosure - Affiliated Companies", "shortName": "Affiliated Companies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.westpharma.com/role/Debt", "longName": "0000015 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "longName": "0000016 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.westpharma.com/role/FairValueMeasurements", "longName": "0000017 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "longName": "0000018 - Disclosure - Accumulated Other Comprehensive Loss", "shortName": "Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.westpharma.com/role/ShareholdersEquity", "longName": "0000019 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.westpharma.com/role/StockBasedCompensation", "longName": "0000020 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.westpharma.com/role/BenefitPlans", "longName": "0000021 - Disclosure - Benefit Plans", "shortName": "Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.westpharma.com/role/OtherExpenseIncome", "longName": "0000022 - Disclosure - Other Expense (Income)", "shortName": "Other Expense (Income)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.westpharma.com/role/IncomeTaxes", "longName": "0000023 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "longName": "0000024 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.westpharma.com/role/SegmentInformation", "longName": "0000025 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.westpharma.com/role/RevenueTables", "longName": "9954472 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "longName": "9954473 - Disclosure - Net Income Per Share (Tables)", "shortName": "Net Income Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.westpharma.com/role/InventoriesTables", "longName": "9954474 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.westpharma.com/role/LeasesTables", "longName": "9954475 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.westpharma.com/role/DebtTables", "longName": "9954476 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "longName": "9954477 - Disclosure - Derivative Financial Instruments (Tables)", "shortName": "Derivative Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "longName": "9954478 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "longName": "9954479 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.westpharma.com/role/ShareholdersEquityTables", "longName": "9954480 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.westpharma.com/role/BenefitPlansTables", "longName": "9954481 - Disclosure - Benefit Plans (Tables)", "shortName": "Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeTables", "longName": "9954482 - Disclosure - Other Expense (Income) (Tables)", "shortName": "Other Expense (Income) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.westpharma.com/role/SegmentInformationTables", "longName": "9954483 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "longName": "9954484 - Disclosure - Revenue - Revenue Recognition (Details)", "shortName": "Revenue - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "longName": "9954485 - Disclosure - Revenue - Contracts and Liabilities (Details)", "shortName": "Revenue - Contracts and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.westpharma.com/role/RevenueNarrativeDetails", "longName": "9954486 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails", "longName": "9954487 - Disclosure - Net Income Per Share - Schedule of Net Income Per Share (Details)", "shortName": "Net Income Per Share - Schedule of Net Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R45": { "role": "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails", "longName": "9954488 - Disclosure - Net Income Per Share - Narrative (Details)", "shortName": "Net Income Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.westpharma.com/role/InventoriesDetails", "longName": "9954489 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails", "longName": "9954490 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails", "longName": "9954491 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)", "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "longName": "9954492 - Disclosure - Leases - Lease Weighted Average (Details)", "shortName": "Leases - Lease Weighted Average (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails", "longName": "9954493 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)", "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "longName": "9954494 - Disclosure - Affiliated Companies (Details)", "shortName": "Affiliated Companies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R52": { "role": "http://www.westpharma.com/role/DebtLongtermDebtDetails", "longName": "9954495 - Disclosure - Debt - Long-term Debt (Details)", "shortName": "Debt - Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R53": { "role": "http://www.westpharma.com/role/DebtNarrativeDetails", "longName": "9954496 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R54": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "longName": "9954497 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details)", "shortName": "Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "longName": "9954498 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "longName": "9954499 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)", "shortName": "Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R57": { "role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "longName": "9954500 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails", "longName": "9954501 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details)", "shortName": "Fair Value Measurement - Other Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954502 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-260", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R60": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "longName": "9954503 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-231", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R61": { "role": "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails", "longName": "9954504 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details)", "shortName": "Shareholder's Equity - Change in Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R62": { "role": "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails", "longName": "9954505 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details)", "shortName": "Shareholder's Equity - Supplemental Equity Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-251", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-251", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.westpharma.com/role/StockBasedCompensationDetails", "longName": "9954506 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R64": { "role": "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails", "longName": "9954507 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "shortName": "Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "longName": "9954508 - Disclosure - Benefit Plans - Narrative (Details)", "shortName": "Benefit Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R66": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails", "longName": "9954509 - Disclosure - Other Expense (Income) - Summary (Details)", "shortName": "Other Expense (Income) - Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R67": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "longName": "9954510 - Disclosure - Other Expense (Income) - Narrative (Details)", "shortName": "Other Expense (Income) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-339", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R68": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "longName": "9954511 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details)", "shortName": "Other Expense (Income) - Restructuring and Related Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-346", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R69": { "role": "http://www.westpharma.com/role/IncomeTaxesDetails", "longName": "9954512 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "unique": true } }, "R70": { "role": "http://www.westpharma.com/role/SegmentInformationDetails", "longName": "9954513 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges:", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r79" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r910" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedges:", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r711", "r715", "r720", "r732", "r736", "r757", "r758", "r759", "r833" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock-based compensation awards", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r16" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r200", "r201", "r588", "r589", "r590", "r591", "r592", "r593" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r577", "r578" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges:", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r78" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r401", "r807", "r808", "r809", "r810", "r811", "r812", "r813" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract Type [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r697", "r699", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r718", "r719", "r720", "r721", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r754", "r756", "r759", "r760", "r831", "r833" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r254", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r286", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r318", "r323", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r795", "r923", "r990" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r81", "r84", "r557" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased for employee tax withholdings", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r208" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r313", "r317", "r728" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r557" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r940" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r15", "r81", "r84" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r15", "r81", "r84", "r87", "r90", "r91", "r557" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r317", "r728" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stockholders Equity", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r14" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r108", "r139", "r648", "r681", "r685", "r691", "r708", "r828" ] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Contract", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r956", "r967" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r599" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r914" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.westpharma.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r21", "r112", "r113", "r114" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r511" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared per share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r139" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r280" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r910" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: unamortized debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_TreasuryLockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryLockMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward treasury locks", "label": "Treasury Lock [Member]", "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r485", "r489", "r517", "r518", "r519", "r825" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense (income)", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r657", "r726", "r762", "r763", "r764" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r166", "r254", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r286", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r318", "r323", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r795", "r923", "r990" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r286", "r920" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r963", "r964" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlements", "negatedLabel": "Settlements", "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement." } } }, "auth_ref": [ "r408", "r450", "r475" ] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring and other charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r319", "r321", "r947" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r881" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative contract term", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r26", "r169", "r214", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r546", "r548", "r549", "r580", "r828", "r951", "r980", "r981" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r258", "r259", "r270", "r275", "r276", "r282", "r284", "r286", "r400", "r401", "r620" ] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit within other expense (income) for revised severance estimates", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r326", "r327", "r328", "r329", "r431", "r483", "r512", "r513", "r514", "r618", "r619", "r677", "r698", "r699", "r747", "r749", "r751", "r752", "r761", "r780", "r781", "r794", "r805", "r824", "r830", "r833", "r946", "r953", "r983", "r984", "r985", "r986", "r987" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r880" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions by employer", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r424", "r434", "r476", "r814", "r815", "r816", "r817" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment sales elimination", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r259", "r270", "r271", "r272", "r273", "r274", "r276", "r280" ] }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in deferred income - decrease (increase)", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied." } } }, "auth_ref": [ "r806" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized that was included in the deferred income balance", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r403" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, December 31, 2022", "periodEndLabel": "Balance, September 30, 2023", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r316", "r320" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r880" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r133", "r171", "r651" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r144", "r558", "r567" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r881" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r641", "r651", "r828" ] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract assets, December 31, 2022", "periodEndLabel": "Contract assets, September\u00a030, 2023", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r389", "r391", "r402" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r516", "r523" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r47", "r49" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r40", "r44", "r93", "r94", "r286", "r686", "r768" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r891" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r409", "r446", "r471", "r816", "r817" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r115", "r205", "r637", "r654" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r40", "r44", "r93", "r94", "r286", "r768" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r847", "r858", "r868", "r893" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r884" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r878" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "verboseLabel": "Amount receivable from affiliates", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r184", "r828" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r884" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r856", "r864", "r874", "r891", "r899", "r903", "r911" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r884" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "negatedTerseLabel": "Tax (expense) benefit", "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r157", "r160", "r232", "r233", "r265", "r528", "r539", "r659" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in net income of affiliated companies", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r117", "r153", "r264", "r290", "r652" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "negatedTerseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r884" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r846", "r857", "r867", "r892" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r151", "r356", "r371", "r801", "r802", "r989" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r35", "r197", "r199", "r206", "r638", "r655" ] }, "currency_JPY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "JPY", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yen", "label": "Japan, Yen" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r139" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r71" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r216", "r344", "r345", "r346", "r347", "r348", "r350", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r595", "r800", "r801", "r802", "r803", "r804", "r934" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r885" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.westpharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r163", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r404" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r409", "r413", "r445", "r470", "r816", "r817" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r238", "r246" ] }, "currency_SGD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "SGD", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SGD", "label": "Singapore, Dollars" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r961" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r887" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r507" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r848", "r859", "r869", "r894" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r886" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r443", "r468", "r816", "r817" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r40", "r44", "r93", "r94", "r286", "r768", "r921" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Currency Contracts", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r15", "r74", "r75", "r76", "r80", "r82", "r84", "r88", "r89" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange transaction losses (gains)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r584", "r585", "r586", "r587", "r738" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r846", "r857", "r867", "r892" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r888" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r237", "r246" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r173", "r303", "r636", "r795", "r828", "r944", "r945" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r889" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r889" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r544", "r932" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r357", "r434", "r435", "r436", "r437", "r438", "r439", "r615", "r616", "r617", "r801", "r802", "r814", "r815", "r816" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r137", "r138", "r139", "r179", "r180", "r181", "r252", "r373", "r374", "r375", "r377", "r380", "r385", "r387", "r687", "r688", "r689", "r690", "r805", "r917", "r933" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r529" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r179", "r180", "r181", "r252", "r373", "r374", "r375", "r377", "r380", "r385", "r387", "r687", "r688", "r689", "r690", "r805", "r917", "r933" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r852", "r863", "r873", "r898" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r849", "r860", "r870", "r895" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (in hundredths)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r513" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock volatility (in hundredths)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r512" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension settlement charge", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r408", "r450", "r475" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r411", "r444", "r469", "r816", "r817" ] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r925" ] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r849", "r860", "r870", "r895" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (in hundredths)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r514" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r344", "r345", "r346", "r347", "r348", "r350", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r595", "r800", "r801", "r802", "r803", "r804", "r934" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r850", "r861", "r871", "r896" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r136", "r213", "r372", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r388", "r568", "r744", "r745", "r766" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r102", "r103", "r149", "r151", "r216", "r344", "r345", "r346", "r347", "r348", "r350", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r595", "r800", "r801", "r802", "r803", "r804", "r934" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan contributions", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r6", "r16" ] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "USD", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "USD", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r61", "r64", "r95", "r96", "r98", "r100", "r137", "r138", "r216", "r344", "r345", "r346", "r347", "r348", "r350", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r595", "r800", "r801", "r802", "r803", "r804", "r934" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r486", "r487", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515" ] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Expense (Income)", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r140", "r142" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/Inventories" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r301" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r486", "r487", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r851", "r862", "r872", "r897" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r504" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r504" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r853", "r864", "r874", "r899" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r891" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r853", "r864", "r874", "r891", "r899" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r207", "r226", "r227", "r228", "r229", "r230", "r239", "r244", "r245", "r246", "r250", "r571", "r572", "r639", "r656", "r791" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and Unallocated", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r17", "r271", "r272", "r273", "r274", "r280", "r941" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r856", "r864", "r874", "r891", "r899", "r903", "r911" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r919", "r930" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r891" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r853", "r864", "r874", "r899" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r107", "r828", "r993" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r891" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r882" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r883" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r884" ] }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Recognized in earnings, pre-tax, for forward point", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method." } } }, "auth_ref": [ "r156", "r965" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r882" ] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term debt", "label": "Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r37" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring and related charges", "terseLabel": "(Credits) Charges", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r315", "r318", "r321", "r323" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r57" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r882" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r613", "r614", "r979" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r882" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r186", "r191", "r550", "r551", "r559" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r883" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r33", "r34", "r116", "r182", "r647", "r682", "r685" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r216", "r259", "r270", "r271", "r272", "r273", "r274", "r276", "r280", "r330", "r331", "r332", "r333", "r335", "r336", "r338", "r340", "r341", "r951", "r952" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r143" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Losses) gains on derivatives", "verboseLabel": "Gains (losses) on derivatives:", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r193", "r201", "r202", "r547", "r790", "r927" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East, Africa", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r997", "r998", "r999", "r1000" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r118", "r129", "r154", "r167", "r195", "r198", "r202", "r214", "r222", "r226", "r227", "r228", "r229", "r232", "r233", "r243", "r257", "r271", "r277", "r280", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r572", "r580", "r653", "r725", "r739", "r740", "r793", "r839", "r951" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r602", "r827" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r883" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r53", "r172", "r650" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit pension and other postretirement plan adjustments, tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r7", "r12", "r143" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r604", "r827" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments Not Designated as Hedges", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r86", "r922" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r216", "r259", "r270", "r271", "r272", "r273", "r274", "r276", "r280", "r330", "r331", "r332", "r333", "r335", "r336", "r338", "r340", "r341", "r951", "r952" ] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForwardContractsMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Forwards", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": [ "r966" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r315", "r316", "r321", "r322" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r603", "r827" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance and benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r215", "r525", "r530", "r531", "r532", "r538", "r540", "r541", "r542", "r692" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, investments not accounted for under the equity method", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r289" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares purchased under share repurchase programs", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r36" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r883" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other postretirement benefits", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r104", "r406", "r407", "r430", "r816" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r605", "r827" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.westpharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r598" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income, net of tax", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r143", "r196", "r199" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r105", "r645", "r828" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r955" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, net of tax of $0.4, $1.1, $1.9 and $3.8, respectively", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r143" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt, fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on derivatives, net of tax of $0.8, $0.0, $(0.3) and $(0.8), respectively", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r187", "r552" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $0.0, $14.6, $(0.5), and $15.5, respectively", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r5", "r12", "r116", "r143" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r883" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r883" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on derivatives, tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r187", "r191", "r194" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r526", "r527", "r643" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r939" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r884" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r845", "r915" ] }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liabilities", "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent", "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r554" ] }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred compensation benefits", "label": "Deferred Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r461", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r958", "r959", "r960" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r321", "r322", "r323" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r106", "r109", "r110", "r131", "r709", "r723", "r742", "r743", "r828", "r840", "r935", "r943", "r970", "r995" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r556" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r831", "r832", "r833", "r835", "r836", "r837", "r838", "r936", "r937", "r969", "r992", "r995" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r401", "r807", "r808", "r809", "r810", "r811", "r812", "r813" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r101", "r524", "r988" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r15" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r884" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3\u00a0million and 75.3 million, respectively; shares outstanding: 74.0\u00a0million and 74.1 million, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r106", "r646", "r828" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r164", "r200", "r201", "r202", "r217", "r218", "r219", "r223", "r231", "r233", "r251", "r297", "r300", "r388", "r520", "r521", "r522", "r533", "r534", "r560", "r561", "r562", "r563", "r564", "r566", "r570", "r588", "r589", "r590", "r591", "r592", "r593", "r611", "r678", "r679", "r680", "r693", "r741" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r106", "r707", "r723", "r995", "r996" ] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target award percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other items", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost, expected cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r315", "r318", "r321", "r323" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareScheduleofNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r240", "r241", "r242", "r246", "r488" ] }, "us-gaap_OtherOperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Income (Expense)", "label": "Other Operating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other operating income (expense)." } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r911" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r609", "r827" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r576" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r975" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year two", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r357", "r434", "r439", "r578", "r616", "r801", "r802", "r814", "r815", "r816" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Income (\"AOCI\") (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r34", "r972", "r973" ] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash asset write downs", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r316", "r322" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, weighted average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r497" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. plans", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r357", "r434", "r439", "r578", "r615", "r814", "r815", "r816" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r148", "r175", "r214", "r257", "r272", "r278", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r545", "r548", "r580", "r642", "r717", "r828", "r840", "r951", "r952", "r980" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r92" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating leases liabilities payments due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r608", "r827" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r105", "r373" ] }, "us-gaap_DefinedBenefitPlanOtherCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanOtherCosts", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Defined Benefit Plan, Other Cost (Credit)", "documentation": "Amount of defined benefit plan cost (credit), classified as other." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r357", "r434", "r435", "r436", "r437", "r438", "r439", "r578", "r617", "r801", "r802", "r814", "r815", "r816" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.westpharma.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Obligations, Net of Unamortized Debt Issuance Costs and Current Maturities", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year one", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year five", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r913" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation tax benefit", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r962" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r105", "r707" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year four", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Unit (PSUs)", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year three", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r610" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of fiscal year", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r976" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r105", "r707", "r723", "r995", "r996" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r526", "r527" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r976" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r97", "r155", "r203", "r261", "r594", "r729", "r839", "r994" ] }, "us-gaap_CommodityOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommodityOptionMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity call options", "label": "Commodity Option [Member]", "documentation": "Option contract in which the underlying asset is a commodity." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r724", "r779", "r834", "r957", "r977", "r978", "r979" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r845", "r915" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in Excess of Par Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r520", "r521", "r522", "r693", "r936", "r937", "r938", "r969", "r995" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r577", "r578", "r579" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r911" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency hedge contracts", "verboseLabel": "Foreign currency contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r789", "r814", "r826" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r321", "r322", "r323" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r130", "r211" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r315", "r316", "r321", "r322" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r18" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r458", "r461", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r481", "r482", "r484", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r202" ] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PositionAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r202" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused commitment level", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r202" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r601", "r606" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on derivative instruments, net, pretax", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r81" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r458", "r461", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r481", "r482", "r484", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AmericasMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Americas", "label": "Americas [Member]" } } }, "auth_ref": [ "r997", "r998", "r999", "r1000" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of each class", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r841" ] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r997", "r998", "r999", "r1000" ] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PositionDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term line of credit", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r20", "r151", "r989" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r910" ] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r202" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount excluded from effectiveness testing", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings." } } }, "auth_ref": [ "r147", "r553" ] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative designated as hedging instrument", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r146" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r842" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]", "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r257", "r269", "r274", "r278", "r279", "r280", "r281", "r282", "r283", "r286" ] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r202" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r843" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reclassification Out of Accumulated Other Comprehensive Loss", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Information", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r45", "r46" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r842" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r911" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r119", "r214", "r257", "r271", "r277", "r280", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r580", "r793", "r951" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "verboseLabel": "Amount due to affiliates", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25", "r828" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r41", "r286" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EUR", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r842" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "lang": { "en-us": { "role": { "verboseLabel": "New Accounting Standards", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r158", "r159", "r161", "r165", "r220", "r221", "r224", "r225", "r234", "r235", "r298", "r299", "r535", "r536", "r537", "r565", "r569", "r573", "r574", "r575", "r581", "r582", "r583", "r596", "r597", "r612", "r621", "r622", "r623", "r681", "r682", "r683", "r684", "r685" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r31", "r164", "r200", "r201", "r202", "r217", "r218", "r219", "r223", "r231", "r233", "r251", "r297", "r300", "r388", "r520", "r521", "r522", "r533", "r534", "r560", "r561", "r562", "r563", "r564", "r566", "r570", "r588", "r589", "r590", "r591", "r592", "r593", "r611", "r678", "r679", "r680", "r693", "r741" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r607", "r827" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r164", "r217", "r218", "r219", "r223", "r231", "r233", "r297", "r300", "r520", "r521", "r522", "r533", "r534", "r560", "r562", "r563", "r566", "r570", "r678", "r680", "r693", "r995" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r910" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit pension and other postretirement plans", "verboseLabel": "Amortization of defined benefit pension and other postretirement plans:", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r13", "r34", "r927", "r928", "r929" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r842" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r13", "r34", "r201", "r202", "r589", "r590", "r591", "r592", "r593", "r927" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r286", "r809", "r955", "r990", "r991" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r174" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in equity affiliate investment AOCI", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r188", "r189", "r190", "r193", "r201", "r202", "r927" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r912" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r45", "r46" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, equity-method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r267", "r290", "r924", "r942" ] }, "us-gaap_ForeignCurrencyGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyGainLossMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense (income)", "label": "Foreign Currency Gain (Loss) [Member]", "documentation": "Primary financial statement caption encompassing foreign currency gain (loss)." } } }, "auth_ref": [ "r968" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r845", "r915" ] }, "us-gaap_DerivativeNonmonetaryNotionalAmountVolume": { "xbrltype": "volumeItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNonmonetaryNotionalAmountVolume", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, nonmonetary notional amount, volume", "label": "Derivative, Nonmonetary Notional Amount, Volume", "documentation": "Nominal volume used to calculate payments on a derivative instrument." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods and services sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Hedged item (intercompany loan)", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r146" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r34", "r561", "r564", "r611", "r678", "r679", "r927", "r928", "r929", "r936", "r937", "r938" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r134", "r324", "r325", "r769", "r948" ] }, "wst_DistributorshipAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "DistributorshipAgreementMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributorship Agreement", "label": "Distributorship Agreement [Member]", "documentation": "Distributorship Agreement" } } }, "auth_ref": [] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r461", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r958", "r959", "r960" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r902" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r122", "r124" ] }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, shares authorized (in shares)", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/Debt" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r135", "r212", "r343", "r349", "r350", "r351", "r352", "r353", "r354", "r359", "r366", "r367", "r369" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r282", "r620", "r671", "r672", "r673", "r674", "r675", "r676", "r782", "r807", "r829", "r923", "r949", "r950", "r955", "r990" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticPlanMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r958", "r959", "r960" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r909" ] }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, average price risk option strike price", "label": "Derivative, Average Price Risk Option Strike Price", "documentation": "The average strike price on the group of price risk option contracts such as put options or call options." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r126" ] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignPlanMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International plans", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r958", "r959", "r960" ] }, "wst_PackagingSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "PackagingSystemsMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proprietary Products", "label": "Packaging Systems [Member]", "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash items, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r129" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r904" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r906" ] }, "wst_DeliveryDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "DeliveryDevicesMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Packaging", "label": "Delivery Devices [Member]", "documentation": "Delivery Devices [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r903" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Activity related to stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r72", "r105", "r106", "r139" ] }, "wst_SeniorCNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "SeniorCNotesDue2027Member", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series C notes, due July 5, 2027 (4.02%)", "label": "Senior C Notes Due 2027 [Member]", "documentation": "Senior C Notes Due 2027 [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r40", "r44", "r93", "r94", "r286", "r768" ] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in affiliated companies", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": [ "r926" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r168", "r185", "r214", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r545", "r548", "r580", "r828", "r951", "r952", "r980" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r284", "r285", "r694", "r695", "r696", "r748", "r750", "r753", "r765", "r767", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r783", "r808", "r833", "r955", "r990" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r577", "r578", "r579" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r200", "r201", "r588", "r589", "r590", "r591", "r592", "r593" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r188", "r189", "r191" ] }, "wst_DeliverySystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "DeliverySystemsMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "label": "Delivery Systems [Member]", "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r905" ] }, "wst_NumberOfManufacturingFacilitiesSold": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "NumberOfManufacturingFacilitiesSold", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loss on disposal manufacturing facility", "label": "Number of Manufacturing Facilities Sold", "documentation": "Number of Manufacturing Facilities Sold" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r458", "r613", "r614", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r700", "r701", "r702", "r703", "r704", "r722", "r724", "r746", "r979" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "wst_Revolvingcreditfacilitydue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "Revolvingcreditfacilitydue2024Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility, Due 2024", "label": "Revolving credit facility, due 2024 [Member]", "documentation": "Revolving credit facility, due 2024 [Member]" } } }, "auth_ref": [] }, "wst_ContractWithCustomerLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ContractWithCustomerLiabilityRollForward", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Liability [Roll Forward]", "label": "Contract With Customer, Liability [Roll Forward]", "documentation": "Contract With Customer, Liability [Roll Forward]" } } }, "auth_ref": [] }, "wst_TermLoanDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "TermLoanDue2024Member", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan, due December 31, 2024 (6.37%)", "label": "Term Loan Due 2024 [Member]", "documentation": "Term Loan Due 2024" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r879" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r907" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r908" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r316", "r931" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r176" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r209" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss on equity affiliate accumulated other comprehensive income, tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r188", "r189", "r192" ] }, "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Expense (Income)", "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]", "documentation": "Schedule Of Other Income And Expense, By Component" } } }, "auth_ref": [] }, "wst_HighValueComponentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "HighValueComponentsMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "High-Value Product Components", "label": "High-Value Components [Member]", "documentation": "High-Value Components [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r209" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r909" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r127", "r128", "r129" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r389", "r390", "r402" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Activity related to stock -based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r14", "r105", "r106", "r139" ] }, "wst_A2022RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "A2022RestructuringPlanMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Restructuring Plan", "label": "2022 Restructuring Plan [Member]", "documentation": "2022 Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income, noncurrent", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r389", "r390", "r402" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r24", "r214", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r546", "r548", "r549", "r580", "r705", "r792", "r840", "r951", "r980", "r981" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Deferred income, December 31, 2022", "negatedPeriodEndLabel": "Deferred income, September\u00a030, 2023", "terseLabel": "Deferred income", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r389", "r390", "r402" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r284", "r285", "r694", "r695", "r696", "r748", "r750", "r753", "r765", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r783", "r808", "r833", "r955", "r990" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r0", "r73", "r543" ] }, "wst_SeniorBNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "SeniorBNotesDue2024Member", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B notes, due July 5, 2024 (3.82%)", "label": "Senior B Notes Due 2024 [Member]", "documentation": "Senior B Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r909" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r844" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r20", "r151", "r370" ] }, "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]", "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities" } } }, "auth_ref": [] }, "wst_CostInvestmentImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "CostInvestmentImpairment", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost investment impairment", "label": "Cost Investment Impairment", "documentation": "Cost Investment Impairment" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShare" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Income Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r236", "r247", "r248", "r249" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r177" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r178" ] }, "wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases", "label": "Lessee, Lease Cash Flow And Supplemental Information [Table Text Block]", "documentation": "Lessee, Lease Cash Flow And Supplemental Information" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r877" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r106" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, average price per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r65" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r111", "r152", "r649", "r828", "r935", "r943", "r970" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net Periodic Benefit Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r81", "r83", "r84", "r87", "r697", "r699", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r718", "r719", "r720", "r721", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r754", "r756", "r759", "r760", "r789", "r831", "r833" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r106", "r707" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r282", "r620", "r671", "r672", "r673", "r674", "r675", "r676", "r782", "r807", "r829", "r923", "r949", "r950", "r955", "r990" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share purchased under share repurchase program (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r14", "r106", "r139" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on oil hedges", "negatedTerseLabel": "(Gain) loss on oil hedges", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r86", "r922" ] }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period." } } }, "auth_ref": [ "r85" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividend payments", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r36" ] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompanies" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Companies", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r162", "r293", "r296", "r918" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Corporate general costs", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r121", "r727" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r121" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r910" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r916" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains", "negatedTerseLabel": "Recognized actuarial losses (gains)", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r415" ] }, "wst_PharmaCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "PharmaCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharma", "label": "Pharma Customers [Member]", "documentation": "Pharma Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r567" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r65" ] }, "wst_EricMGreenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "EricMGreenMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Eric M. Green [Member]", "documentation": "Eric M. Green" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r286", "r809", "r955", "r990", "r991" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r15", "r74", "r75", "r76", "r80", "r82", "r84", "r88", "r89", "r91", "r567" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r65" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost (1.3\u00a0million and 1.2 million shares, respectively)", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32", "r65", "r66" ] }, "wst_GenericsCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "GenericsCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Generics", "label": "Generics Customers [Member]", "documentation": "Generics Customers [Member]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r842" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans." } } }, "auth_ref": [ "r11", "r67", "r68", "r69", "r70" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net sales", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r40", "r44", "r93", "r94", "r286" ] }, "wst_ContractWithCustomerAssetRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ContractWithCustomerAssetRollForward", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Asset [Roll Forward]", "label": "Contract With Customer, Asset [Roll Forward]", "documentation": "Contract With Customer, Asset [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r132", "r786" ] }, "wst_ContractManufacturedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ContractManufacturedProductsMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "label": "Contract Manufactured Products [Member]", "documentation": "Contract Manufactured Products [Member]" } } }, "auth_ref": [] }, "wst_EffectiveIncomeTaxRateReconciliationTerminationOfPensionPlanAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "EffectiveIncomeTaxRateReconciliationTerminationOfPensionPlanAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit from termination of pension plans", "label": "Effective Income Tax Rate Reconciliation Termination Of Pension Plan Amount", "documentation": "Effective Income Tax Rate Reconciliation Termination Of Pension Plan Amount" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r132", "r787" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r43", "r768" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r23" ] }, "wst_OtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "OtherIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 }, "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense (income) (Note 15)", "negatedTotalLabel": "Total other expense (income)", "label": "Other Income (Expense)", "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r51" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r357", "r434", "r435", "r436", "r437", "r438", "r439", "r578", "r615", "r616", "r617", "r801", "r802", "r814", "r815", "r816" ] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r132", "r788" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [ "r974" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeSummaryDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of plant", "terseLabel": "Loss on disposal of plant", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r9" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r600" ] }, "wst_SmartDoseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "SmartDoseMember", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SmartDose", "label": "SmartDose [Member]", "documentation": "SmartDose [Member]" } } }, "auth_ref": [] }, "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": { "xbrltype": "durationItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related activities, period of implementation", "label": "Restructuring and Related Activities, Period of Implementation", "documentation": "Restructuring and Related Activities, Period of Implementation" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r207", "r226", "r227", "r228", "r229", "r230", "r237", "r239", "r244", "r245", "r246", "r250", "r571", "r572", "r639", "r656", "r791" ] }, "wst_AccruedSalariesWagesAndBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "AccruedSalariesWagesAndBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries, wages and benefits", "label": "Accrued Salaries, Wages, and Benefits, Current", "documentation": "Accrued Salaries, Wages, and Benefits, Current" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net sales", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r204", "r214", "r258", "r259", "r270", "r275", "r276", "r282", "r284", "r286", "r295", "r330", "r331", "r333", "r334", "r335", "r337", "r339", "r341", "r342", "r580", "r640", "r951" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r842" ] }, "wst_ContractManufacturedCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ContractManufacturedCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "label": "Contract-Manufactured Customers [Member]", "documentation": "Contract-Manufactured Customers [Member]" } } }, "auth_ref": [] }, "wst_ContractWithCustomerAssetIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "ContractWithCustomerAssetIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract assets - increase (decrease)", "label": "Contract With Customer, Asset, Increase (Decrease)", "documentation": "Contract With Customer, Asset, Increase (Decrease)" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating profit", "terseLabel": "Operating profit", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r257", "r271", "r277", "r280", "r793" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r9", "r50" ] }, "wst_StandardPackagingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "StandardPackagingMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "High-Value Product Delivery Devices", "label": "Standard Packaging [Member]", "documentation": "Standard Packaging [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r600" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.westpharma.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r183", "r785", "r828" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension benefits", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r458", "r461", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r481", "r484", "r816", "r817", "r821", "r822", "r823" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed lease interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r106" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r247" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r287", "r288" ] }, "wst_BiologicsCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "BiologicsCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biologics", "label": "Biologics Customers [Member]", "documentation": "Biologics Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r600" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlans" ], "lang": { "en-us": { "role": { "verboseLabel": "Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r405", "r431", "r433", "r439", "r457", "r459", "r460", "r461", "r462", "r463", "r478", "r479", "r480", "r816" ] }, "wst_NotesPayableAndOtherDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "NotesPayableAndOtherDebtCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes payable and other current debt", "label": "Notes Payable and Other Debt, Current", "documentation": "Notes Payable and Other Debt, Current" } } }, "auth_ref": [] }, "wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Held", "label": "Options Held [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": [ "r145", "r713", "r718", "r730", "r734", "r754", "r755", "r756", "r831", "r832" ] }, "wst_NetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20230930", "localname": "NetSalesMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Net Sales [Member]", "documentation": "Net sales member" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r842" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income per share:", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectOnFutureEarningsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOnFutureEarningsAmount", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect on future earnings, amount", "label": "Effect on Future Earnings, Amount", "documentation": "The quantified amount of the future effect on earnings." } } }, "auth_ref": [ "r55" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r853", "r864", "r874", "r899" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 17)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r30", "r99", "r644", "r706" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r854", "r865", "r875", "r900" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r326", "r327", "r328", "r329", "r483", "r619", "r677", "r698", "r699", "r747", "r749", "r751", "r752", "r761", "r780", "r781", "r794", "r805", "r824", "r830", "r953", "r982", "r983", "r984", "r985", "r986", "r987" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other charges", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r796", "r797", "r798", "r799" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r903" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r103", "r150" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r954" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r458", "r613", "r614", "r700", "r701", "r702", "r703", "r704", "r722", "r724", "r746" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r326", "r327", "r328", "r329", "r431", "r483", "r512", "r513", "r514", "r618", "r619", "r677", "r698", "r699", "r747", "r749", "r751", "r752", "r761", "r780", "r781", "r794", "r805", "r824", "r830", "r833", "r946", "r953", "r983", "r984", "r985", "r986", "r987" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r902" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r854", "r865", "r875", "r900" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r853", "r864", "r874", "r899" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r326", "r327", "r328", "r329", "r483", "r619", "r677", "r698", "r699", "r747", "r749", "r751", "r752", "r761", "r780", "r781", "r794", "r805", "r824", "r830", "r953", "r982", "r983", "r984", "r985", "r986", "r987" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r853", "r864", "r874", "r899" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest (income) expense and other nonoperating (income) expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r123" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r15", "r557" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock purchase program, cost of shares purchased", "negatedTerseLabel": "Shares purchased under share repurchase program", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r14", "r65", "r139" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r912" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Cost of goods and services sold", "negatedTerseLabel": "Cost of goods and services sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r120", "r620" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r855", "r866", "r876", "r901" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22", "r828" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r52" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r39", "r170", "r784" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r19", "r34" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-down", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r302" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of acquisition-related intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r48", "r50" ] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, purchases from related party", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified out from accumulated other comprehensive (loss) income", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r19", "r34" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Reserve", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r54", "r56" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r902" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r127" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r902" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r971" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r167", "r214", "r291", "r292", "r294", "r295", "r580" ] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/SegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes and equity in net income of affiliated companies", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r257", "r271", "r277", "r280", "r658", "r793" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, including cash equivalents at beginning of period", "periodEndLabel": "Cash, including cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r127", "r210" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r902" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214", "r291", "r292", "r294", "r295", "r580" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r15" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r902" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r345" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r902" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Other nonoperating (income) expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r125" ] }, "us-gaap_OtherAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity call options", "label": "Other Assets, Fair Value Disclosure", "documentation": "Fair value portion of other assets." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other retirement benefits", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r406", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r458", "r461", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r481", "r482", "r816", "r817", "r818", "r819", "r820" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org//323/tableOfContent" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r917": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r918": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "323", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 90 0000105770-23-000068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-23-000068-xbrl.zip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ɑ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ƴ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